TW378207B - Benzylidene derivatives - Google Patents

Benzylidene derivatives Download PDF

Info

Publication number
TW378207B
TW378207B TW082108811A TW82108811A TW378207B TW 378207 B TW378207 B TW 378207B TW 082108811 A TW082108811 A TW 082108811A TW 82108811 A TW82108811 A TW 82108811A TW 378207 B TW378207 B TW 378207B
Authority
TW
Taiwan
Prior art keywords
group
compound
cha
ministry
please read
Prior art date
Application number
TW082108811A
Other languages
Chinese (zh)
Inventor
Saichi Matsumoto
Tatsuo Tsuri
Masanao Inagaki
Hirokuni Jyoyama
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of TW378207B publication Critical patent/TW378207B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D291/00Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/46Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
    • C07D333/48Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Benzylidene derivatives having anti-inflammatory activities, which is shown by the following formula I: (I) wherein A is íVCH2- or íVCH2CH2; B is a bond or íVCH2-, -CHOH-, -CO-, -O-, or A and B may taken together form íVCH-CH-; D is >N- or >CH-; R1 and R2 each independently is hydrogen, C1-C5 alkyl or C1-C3 alkoxy; R3 is hydrogen, C1-C5 alkyl, cycloalkyl, C1-C3 alkoxy, arylalkyloxy, heteroarylalkyloxy, C1-C3 alkylcarbonyl, arylcarbonyl, substituted or unsubstituted carbamoyl, or a group of the formula: -(CH2)n-R4 wherein R4 is hydrogen, hydroxy, substituted or unsubstituted amino, aryl, heteroaryl, hydroxycarbonyl, or C1-C3 alkyloxycarbonyl; n is an integer of 0-3.

Description

修王 年月日 ,、 88. 8. 25 補充 Α7 Β7 五、發明説明(24 )Revised Date, 88. 8. 25 Supplement Α7 Β7 V. Description of the Invention (24)

MOMOMOMO

t-Bu 6 + ,n-r341 Ονο :驗t-Bu 6 +, n-r341 Ονο: check

7171

=\B 3a= \ B 3a

(E-異構物) (Z-異«ί物I) 8 . 3 經濟部中央橾準局貞工消費合作社印製 啻俐 1 ( Ra = Et) 某-s- ds-二•隹=-丁甚-4-揮甚 > gg y 甚-1 .卜 里瞜盹啶-1 . 1 -二氳化物(8an?茸(7)-思縑物fQa) 於二異丙胺(15.5*1» 110.6··ο1 )内經歷20分鐘時 間藉》拌於冰水浴中逐滴加入正丁鋰於己烷(1·6Μ» 69.5 ·1,111β·ο1)。添加完成後又持繙攪拌15分鐘且反應混 合物冷卻至-78t:接著加入ΤΗΡ(1〇〇·1) »於反應混合物 内經歴15分鐘時間接著逐滴加入Ν-乙基-1,2-異睡唑啶-1, 卜二氧化物 4a (15g,100.5ββο1) ,3,5-二-第三丁基-4- 甲氧基甲氧苯甲醛6(25g,90·5lίol)及HMPA(30Bl)於 THF (70β1 )之溶液。反應混合物於同溫又攪拌30分鐘, 溫熱至室溫,倒入冷2Ν-ΗΠ(1〇〇·1)内及K乙酸乙酯抽 取(2Χ 250·1)。乙酸乙_相以碘酸氫納稀水溶液(300 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) _ _ ---II-------裝------訂------線— (請先閱讀背面之注意事項再填寫才頁) A7 B7(E-isomer) (Z- 异 «ί 物 I) 8. 3 Printed by Zhengong Consumer Cooperative of the Central Bureau of Quasi-Ministry of Economic Affairs 1 (Ra = Et) --s- ds- 二 • 隹 =- Ding Qi-4-Wuqian > gg y QI-1. Brillidin-1. 1-dihydrazone (8an? (7) -threate fQa) in diisopropylamine (15.5 * 1 » 110.6 ·· ο1) After 20 minutes, add n-butyllithium to hexane (1.6M »69.5 · 1, 111β · ο1) dropwise in an ice-water bath. After the addition was complete, the mixture was stirred for 15 minutes and the reaction mixture was cooled to -78t: TTP (100 · 1) was then added. »In the reaction mixture, N-ethyl-1,2-iso was added dropwise over a period of 15 minutes. Doxazolyl-1, dioxane 4a (15g, 100.5ββο1), 3,5-di-tert-butyl-4-methoxymethoxybenzaldehyde 6 (25g, 90 · 5lίol) and HMPA (30Bl ) In THF (70β1). The reaction mixture was stirred for another 30 minutes at the same temperature, warmed to room temperature, poured into cold 2N-ΗΠ (100 · 1) and extracted with K ethyl acetate (2 × 250 · 1). Ethyl acetate _ phase is diluted with aqueous hydrogen iodate solution (300 paper sizes are applicable to Chinese National Standard (CNS) A4 specifications (210 × 297 mm) _ _ --- II ------- packing ------ Order ------ line-(Please read the notes on the back before filling out the page) A7 B7

五、發明説明(1 發明铕Μ 本發明係有關具有抗發炎活性之新穎亞苄基衍生物。 發明背醤 非類固醇消炎藥如溶菌酶氯等可有效改善風濕症的最 初症狀與急性發炎,但無法改善帶有骨頭破壊的慢性風濕 症的漸進病情或治療骨鼷節炎等。又復,習知蕖物由於作 用強故可能引起胃潰瘍。 近來,已明顯了解白三烯類αυ,待別ltb4等(其爲 花生四烯酸與5-脂氧化酶之代謝徑路中的代謝產物)乃發 炎反應的主要媒介物。也提示細胞激動素中之一型介白素 -1 (IL-1)與發炎有關,特別與慢性風濕症有極大關係。 於前述條件下,考廉可抑制LTB·及IL-1二者的產生的化合 物皆有作為抗發炎藥物的展望。此等化合物比較習知非類 固醇消炎藥更爲有用,歸因於預期其不僅可有效用於急性 發炎同時也可用於慢性發炎如慢性風濕症等。 可用作消炎藥之多種化合物曾經揭示於曰本特許公開 案第(KOKAI) Nos. 79944/1983, 257967/1986, 42977/ 1987, 305028/1989, 4729/1990, 256645/1990, 270865/ 1990號,日本專利案第W0 89/503782號等。欲獲得可有效 治療慢性發炎同時具有較低副作用如胃障礙之化合物,持 續需要開發可有效阻止發炎之媒介物如前列腺素Ea(PGEa) ,LTB«,IL-1等之產生之化合物。 發明人發現某棰亞苄基衍生物可顯著抑制PGE2及細胞 激動素如LTB4,IL-1等的產生,因而完成本發明。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -------„--^--‘一-1 装------訂------泉一I (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 3 五、發明説明(38 A7 B7 7.2卜7.25(411,靈,2\芳香-11,2/?丫-1〇,7.42(111,1:,<1 = 2.2 Hz,CH)I8.50-8.58(2H,«,Py-H). 兀素分析(CaaHaeNaOaS) 計算值:C,66.63;H,7.29;N,6.76;S,7.73 賁測值:C,66.46;H,7.18;N,6.66;S,7.49. m〇m〇( t-Bu、/t-BuV. Description of the Invention (1) The invention relates to novel benzylidene derivatives with anti-inflammatory activity. Invention of non-steroidal anti-inflammatory drugs such as lysozyme chloride can effectively improve the initial symptoms and acute inflammation of rheumatism, but It is not possible to improve the progressive condition of chronic rheumatism with bone fractures or to treat osteoarthritis, etc. It is also known that it is possible to cause gastric ulcers due to strong effects of urinary substances. Recently, leukotriene αυ has been clearly understood, wait for ltb4, etc. ( It is a metabolite in the metabolic pathway of arachidonic acid and 5-lipoxygenase) is the main mediator of the inflammatory response. It also suggests that interleukin-1 (IL-1) and inflammation in cytokinin In particular, it has a great relationship with chronic rheumatism. Under the aforementioned conditions, compounds that can inhibit the production of both LTB · and IL-1 by Corian are expected to be anti-inflammatory drugs. These compounds are more known to be non-steroidal anti-inflammatory The drug is more useful due to its anticipation that it is effective not only for acute inflammation but also for chronic inflammation such as chronic rheumatism, etc. Many compounds that can be used as anti-inflammatory drugs have been disclosed KOKAI No. 79944/1983, 257967/1986, 42977/1987, 305028/1989, 4729/1990, 256645/1990, 270865/1990, Japanese Patent No. WO 89/503782, etc. To obtain compounds that can effectively treat chronic inflammation and have lower side effects such as gastric disorders, there is a continuing need to develop compounds that can effectively prevent inflammation such as prostaglandin Ea (PGEa), LTB «, IL-1, etc. The inventors have discovered A certain benzylidene derivative can significantly inhibit the production of PGE2 and cytokinins such as LTB4, IL-1, etc., thus completing the present invention. The paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) --- ---- „-^ --'- 1 installed ------ ordered ------ Quan Yi I (Please read the precautions on the back before filling this page) Staff of the Central Standards Bureau of the Ministry of Economic Affairs Printed by the Consumer Cooperatives 3 V. Description of the invention (38 A7 B7 7.2, Bu 7.25 (411, Ling, 2 \ Aroma-11, 2 /? -1-10, 7.42 (111,1 :, < 1 = 2.2 Hz, CH ) I8.50-8.58 (2H, «, Py-H). CaaHaeNaOaS Calculated value: C, 66.63; H, 7.29; N, 6.76; S, 7.73 Test value: C, 66.46; H, 7.18; N, 6.66; S, 7.49. M〇m〇 (t-Bu, / t-Bu

,0 S: 'N、〇 I Y0 S: 'N, 〇 I Y

77

(E/Z混合物) 脫去保iii (丫=脫去保瑰 基) I 11 I n I n 訂 線 (請先聞讀背面之注意事項再填穿,r頁) 經濟部中央樣準局負工消費合作社印製(E / Z mixture) Take off guarantee iii (Ya = take off Bao Jiji) I 11 I n I n Thread (please read the precautions on the back before filling in, page r) Printed by Industrial and Consumer Cooperatives

(E-異構物) 10a(E-isomer) 10a

(Z-異搰物) 10b (R3= Η) (Υ= C0.C(CH3),) (Κ)-Η- ( 二-笛三丁某-4-筠V西午某.2-里臃ΡΦ腚 1 .1-二氬仆.物now 本紙張尺度通用中國國家標準(CNS ) A4規格(210X297公釐) -40 - 五、發明説明((Z-isocyanate) 10b (R3 = Η) (Υ = C0.C (CH3),) (Κ) -Η- (Di-Di San Ding Mou-4- 筠 V Xiwu Mou. 2-Li 臃ΡΦ 腚 1.1-Diargon servant. 物 now This paper size is in accordance with the Chinese National Standard (CNS) A4 specification (210X297 mm) -40-5. Description of the invention (

A7 B7 務昍說明 如此,本發明提供一種式I化合物*·A7 B7 Task Description Thus, the present invention provides a compound of formula I * ·

式中 A 為-CHa-或-CHsCHa-; B 為一鍵或-CHa-, -CHOH-, -CO-,-0-,或者A與B可共同結合生成-CH = CH-; D爲 >N- _>CH- ; R1及R»各自獨立為氫,低碘烷基或低磺烷氧 基;R3為氫,低碩烷基,環烷基,低磺烷氧基,芳基烷基 氧基,雜芳基烷基氧基,低磺烷基羰基,芳基羰基,取代 或無取代之胺甲醢基,或如下式之基: -(CHs)n-R4 式中R4為氫,羥基,取代或無取代胺基,芳基,雜芳基, 羥羰基或低碳烷基氧羰基;η為〇至3之整數。 典型式I化合物包含其中式I中之含硫雜環族環係由 下列各式代表者。 --------ΊΙ^--.—'— 裝------訂------懷 - - (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 D-Where A is -CHa- or -CHsCHa-; B is a bond or -CHa-, -CHOH-, -CO-, -0, or A and B can be combined to form -CH = CH-; D is > N- _ >CH-; R1 and R »are each independently hydrogen, low iodoalkyl or low sulfoalkoxy; R3 is hydrogen, low alkyl, cycloalkyl, low sulfoalkoxy, arylalkane Aryloxy, heteroarylalkyloxy, low sulfoalkylcarbonyl, arylcarbonyl, substituted or unsubstituted carbamoyl, or a group of the formula:-(CHs) n-R4 where R4 is hydrogen Hydroxy, substituted or unsubstituted amine, aryl, heteroaryl, hydroxycarbonyl or lower alkyloxycarbonyl; n is an integer from 0 to 3. Typical compounds of formula I include compounds in which the sulfur-containing heterocyclic ring system of formula I is represented by the following formulae. -------- ΊΙ ^ --.—'— Install ------ Order ------ Huai--(Please read the notes on the back before filling this page) Central Standards of the Ministry of Economic Affairs Printed by Bureau of Consumer Cooperatives D-

Qk yp •S'Qk yp • S '

D- ⑻ (b) 4 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 瞻補,::.' 斗月曰Ί >88. 8. 25 補无1 A7 B7D- ⑻ (b) 4 This paper size is applicable to Chinese National Standard (CNS) A4 (210X297 mm) Zhan Yue, ::. 'Douyue Yue gt > 88. 8. 25 No 1 A7 B7

CHO 〇、々〇 + ^N-EtCHO 〇, 々〇 + ^ N-Et

OHOH

五、發明説明(52 啻俐29 (|^-9-7.甚-5-(3.5--二異丙基--4-瘅)亞¥某-1.2-里噱睥 if -1 . 1 -二氩化物(87) 4a. p-TsOH ^ ——Μ-----裝— (請先閲讀背面之注意事項再填^4苋)V. Description of the invention (52 啻 29 (| ^ -9-7. Even-5- (3.5--diisopropyl--4- 瘅)) ¥ -1.2-Li 噱 睥 if -1. 1- Diargon (87) 4a. P-TsOH ^ ——M ----- pack— (Please read the precautions on the back before filling ^ 4 苋)

線 經濟部中央橾準局貝工消费合作社印装 根據實例1之類似方法,使用N-乙基-1,2-異唾唑啶-1,1-二氧化物(4a) (4.9g,32·8·βο1)及 3,5-二異丙基-4-甲氧甲氧苯甲醛<6c) (7.51g,30aa〇l )進行_醇反應 而得6.07g (50.6%)加成化合物(7r)呈白色粉末。於_ 辞加成化合物7r(5.0g,2〇M〇l-)於甲苯(lOOul)之溶 液内加入對-甲苯磺酸水合物( 200ng)。混合物加熱至回 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) -5 4 - A7 B7 五、發明説明(3' ) °Λ /Ρ D- 〇wP D- I 〇Printed by Shellfish Consumer Cooperative of Central Bureau of Quasi-Economics of the Ministry of Online Economics According to a similar method as in Example 1, N-ethyl-1,2-isosiazolidine-1,1-dioxide (4a) (4.9g, 32 8.β? 1) and 3,5-diisopropyl-4-methoxymethoxybenzaldehyde < 6c) (7.51g, 30aaOl) were subjected to an alcohol reaction to obtain 6.07g (50.6%) of an addition compound (7r) White powder. To a solution of the addition compound 7r (5.0 g, 200 mol-) in toluene (100 ul) was added p-toluenesulfonic acid hydrate (200 ng). The mixture is heated to the back. The paper size is in accordance with Chinese National Standard (CNS) A4 (210 X 297 mm) -5 4-A7 B7. 5. Description of the invention (3 ') ° Λ / Ρ D- 〇wP D- I 〇

⑹ (d) 〇wP D-⑹ (d) 〇wP D-

〇s /〇 :s./ \〇s / 〇: s. / \

D- (e) (f) (請先閲讀背面之注意事項再填寫本頁) -裝· 式中D為>N-或>CH-。 較佳式I化合物包含其中式I中之含硫雜環族環係由 如下式所代表者。D- (e) (f) (Please read the precautions on the back before filling out this page) -In the installation, D is > N- or > CH-. Preferred compounds of formula I include those in which the sulfur-containing heterocyclic ring system in formula I is represented by the following formula.

、1T •N- (a-1) q s /〇 :s( N- V3 CH- (a—2) 線 經濟部中央標準局員工消費合作社印製 (b-1) qx /〇 ‘ 〇1T • N- (a-1) q s / 〇: s (N- V3 CH- (a-2) line Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (b-1) qx / 〇 ‘〇

N- (θ—1) qs /p 'O*N- (θ-1) qs / p 'O *

N- I 0 (d-1) ϋΐ 5 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 經濟部中央標準局員工消費合作社印製 A7 B7 五·、發明説明(4 ) 由上式顯然易見化合物I可Μ (E)型及(Z)型兩棰立體 結構式存在。如此除非另行註明,否則本說明書中描逑之 化合物I應包含(Ε)及(Ζ)異構物。 供如文所揭示及申請專利之本發明之目的之用,下列 術語之定義如下。 “低磺烷基”一詞代表直鍵或分支鰱C^Ce烷基,包 含甲基,乙基,正丙基,異丙基,正丁基,異丁基,第二 丁基,第三丁基,正戊基,異戊基,新戊基,第二戊基, 第三戊基,正己基,新己基,異己基,第二己基,第三己 基,庚基及辛基。較佳低磺烷基為直薄或分支鐽ChC*烷 基,而最佳者為甲基或乙基。 “低碩烷氧基”一詞代表直鐽或分支鍵G-Cb烷氧基 ,包含甲烷基,乙氧基,正丙氧基,異丙氧基,正丁氧基 ,異丁氧基,第二丁氧基,第三丁氧基,正戊氧基,異戊 氧基,新戊氧基,第二戊氧基,第三戊氧基,正己氧基, 新己氧基,異己氧基,第二己氧基及第三己氧基。較佳低 硝烷氧基爲G-C3烷氧基,而最佳者爲甲氧基。 “環烷基”一詞代表C3-C7環烷基且包含環丙基,環 丁基,環戊基,環己基及環庚基。以C3-Ce環烷基為特佳 〇 “芳基”一詞代表取代或無取代苯基或萘基。芳基可 由選自鹵原子,低碳烷氧基,低碳烷基及硝基中之一或多 個取代基取代。芳基之範例包含苯基,4-氯苯基,4-甲氧 苯基,4-硝基苯基,3,4-二氣苯基,3,4-二甲氧苯基,3, 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 6 - * I - —^ϋ - - 1- 1 · ·ί· m HI I (請先閲讀背面之注意事項再填寫本頁) ,ιτ 線 Α7 Β7 經濟部中央標準局員工消費合作社印製 ^、發明説明(5 ) 4-二硝基苯基,卜萘基及2-萘基。 “芳基烷氧基”一詞代表於如上所定義之烷氧基上取 代一艏芳基所生成之基。芳基烷基氧基之範例包含苄基氧 基,4-氯苄基氧基,4-甲氧基苄基氧基,3,4-二氯苄基氧 基,3,4-二甲氧基苄基氧基,4-硝基苄基氧基,2-苯基乙 基氧基,2-(4-氣苯基)乙基氧基,2-(4-甲氧基苯基) 乙基氧基,卜萘基甲基氧基及2-萘基甲基氧基。最佳者為 苄基氧基。 “雜芳基” 一詞代表含有1-4雜原子之環形基。其範 例包含吡啶基,睡唑基,異噻唑基,瞜唑基,異噚唑基, 眯唑基,三唑基及四唑基。供本發明之用Μ吡啶基,噻唑 基*噚唑基及眯唑基爲佳,而Μ吡啶基為最佳。 “雜芳基烷基氧基”一詞代表經由取代一値雜芳基至 如上所定義之烷氧基上所生成之基。範例包含2-吡啶基甲 基氧基,3-吡啶基甲基氧基,4-吡啶基甲基氧基,2-眯唑 基甲基氧基,4-眯唑基甲基氧基,2-睡唑基甲基氣基及4-噻唑基甲基氧基。 “低礦烷基羰基”之範例包含乙醢基,丙酿基,丁醯 基,戊醢基,己醢基,庚醢基及辛酿基。 “芳基羰基”之範例包含苯甲醯基,4-氣苯甲醢基, 4-甲氧基苯甲醯基,4-硝基苯甲醢基,3,4-二氯苯甲醯基 ,3,4-二甲氧基苯甲酿基,3,4-二硝基苯甲酿基,卜萘甲 醯基及2-萘甲醯基。 “取代或無取代胺甲醞基”一詞代表於氮原子上由選 本纸張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) .裝- 訂 線 A7 B7 經濟部中央標隼局員工消費合作社印製 五、發明説明( 自下列之一或多取代基視需要而任意取代之胺甲醯基:低 碳烷基,低硝烷氧基,羥基,瓖烷基,芳基烷基,烷氧基 烷基,烷基羰基,芳基羰基,環烷基氧基及芳基烷基氧基 。較佳取代基為低硪烷基,低磺烷氧基及羥基。取代胺甲 酿基之範例包含N-甲基胺甲醯基,Ν,Ν-二甲基胺甲酿基, Ν-羥基胺甲醯基,Ν-甲基-Ν-羥基胺甲酿基,Ν-甲氧基胺 甲醯基,Ν-甲氧基-Ν-甲基胺甲酿基,Ν-乙基胺甲醚基, Ν,Ν-二乙基胺甲醢基,Ν-乙基-Ν-羥基胺甲酿基,Ν-丙基 胺甲醸基,Ν,Ν-二丙基胺甲酿基及Ν-丙基-Ν-羥基胺甲醢 基° “鹵原子”一詞代表氟,氯,溴及碘。 “低硪烷基氧羰基”之範例包含甲氧羰基,乙氧羰基 ,丙氧羰基,異丙氧羰基,丁氧羰基,異丙氧羰基及第三 丁氧羰基。 “取代胺基” 一詞代表一-或二-取代胺基而取代基係 由如上所定義之低碳烷基及芳基烷基中選出。 本發明化合物bb較Ε5110及8¾哚美沙辛(indomethacin) (於下列實驗例中用作對照化合物)對於抑制PGE8,LTB4 及I L-1之生產上顯示卓越的試管試驗活性。又復於活體試 驗中證實化合物I可抑制水腫而對胃黏膜僅造成少許傷害 ,證實其爲卓越的非類固醇消炎劑。 本發明之亞苄基衍生物為新穎且例如可藉如下(1>至 (4>所述方法製備。但本發明絕非僅限於此等方法所製備 之化合物而包含所有藉任何其它已知方法所製備之化合物 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 8 —.----;-^--.1 ——裝------訂------線一-- - 1 (請先閲讀背面之注意事項再填寫本頁) A7 B7 五、發明説明( (1) 0Rb R1、丄^R2N- I 0 (d-1) ϋΐ 5 This paper size applies to Chinese National Standard (CNS) A4 (210 × 297 mm) A7 B7 printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (4) It is obvious that the formula I can exist in the two (3) stereostructures of the form (E) and (Z). As such, unless otherwise noted, Compound I described in this specification should include (E) and (Z) isomers. For the purposes of the present invention as disclosed and patented, the following terms are defined below. The term "low sulfoalkyl" represents a straight or branched 鲢 C ^ Ce alkyl group including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, second butyl, third Butyl, n-pentyl, isopentyl, neopentyl, second pentyl, third pentyl, n-hexyl, neohexyl, isohexyl, second hexyl, third hexyl, heptyl and octyl. Preferably, the low sulfoalkyl group is a straight or branched fluorene ChC * alkyl group, and the most preferred is methyl or ethyl. The term "low alkoxy" represents a straight or branched G-Cb alkoxy group, including methyl, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, Second butoxy, third butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, second pentoxy, third pentoxy, n-hexyloxy, neohexyloxy, isohexyloxy Group, a second hexyloxy group and a third hexyloxy group. The preferred low nitrate alkoxy group is G-C3 alkoxy group, and the most preferred is methoxy group. The term "cycloalkyl" stands for C3-C7 cycloalkyl and includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. C3-Ce cycloalkyl is particularly preferred. The term "aryl" stands for substituted or unsubstituted phenyl or naphthyl. The aryl group may be substituted with one or more substituents selected from a halogen atom, a lower alkoxy group, a lower alkyl group and a nitro group. Examples of aryl include phenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-nitrophenyl, 3,4-diphenylphenyl, 3,4-dimethoxyphenyl, Paper size applies Chinese National Standard (CNS) Α4 specification (210 × 297 mm) 6-* I-— ^ ϋ--1- 1 · · · m HI I (Please read the precautions on the back before filling this page), ιτ Line Α7 Β7 Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs ^, Description of the invention (5) 4-Dinitrophenyl, phenaphthyl and 2-naphthyl. The term "arylalkoxy" represents a group formed by substituting an aryl group on an alkoxy group as defined above. Examples of arylalkyloxy include benzyloxy, 4-chlorobenzyloxy, 4-methoxybenzyloxy, 3,4-dichlorobenzyloxy, 3,4-dimethoxy Benzyloxy, 4-nitrobenzyloxy, 2-phenylethyloxy, 2- (4-fluorophenyl) ethyloxy, 2- (4-methoxyphenyl) ethyl Ethoxy, p-naphthylmethyloxy and 2-naphthylmethyloxy. The most preferred is benzyloxy. The term "heteroaryl" represents a cyclic radical containing 1-4 heteroatoms. Examples include pyridyl, doxazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxazolyl, triazolyl and tetrazolyl. M pyridyl, thiazolyl * oxazolyl and oxazolyl are preferred for use in the present invention, and Mpyridyl is most preferred. The term "heteroarylalkyloxy" refers to a group formed by substituting a heteroaryl group to an alkoxy group as defined above. Examples include 2-pyridylmethyloxy, 3-pyridylmethyloxy, 4-pyridylmethyloxy, 2-oxazolylmethyloxy, 4-oxazolylmethyloxy, 2 -Doxazolylmethylamino and 4-thiazolylmethyloxy. Examples of "low ore alkylcarbonyl" include ethenyl, propionyl, butyryl, pentamyl, hexyl, heptyl and octyl. Examples of "arylcarbonyl" include benzamyl, 4-aminobenzyl, 4-methoxybenzyl, 4-nitrobenzyl, 3,4-dichlorobenzyl , 3,4-dimethoxybenzyl, 3,4-dinitrobenzyl, benzonaphthyl and 2-naphthylmethyl. The term "substituted or unsubstituted amine methylamine" represents the nitrogen atom selected by the paper size to apply Chinese National Standard (CNS) A4 specifications (210X297 mm) (Please read the precautions on the back before filling this page) . Installation-Line A7 B7 Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs. 5. Description of the invention (Aminomethylamino, optionally substituted from one or more of the following substituents as needed: lower alkyl, lower nitrane Oxy, hydroxy, fluorenyl, arylalkyl, alkoxyalkyl, alkylcarbonyl, arylcarbonyl, cycloalkyloxy and arylalkyloxy. Preferred substituents are oligoalkyl , Sulfoalkoxy and hydroxyl. Examples of substituted aminomethyl groups include N-methylaminomethylmethyl, N, N-dimethylaminomethylmethyl, N-hydroxyaminomethylmethyl, N-methyl -N-hydroxylaminomethyl, N-methoxyaminomethyl, N-methoxy-N-methylaminomethyl, N-ethylaminomethyl ether, Ν, N-diethyl Carbaminyl, N-ethyl-N-hydroxylaminomethyl, N-propylaminomethyl, N, N-dipropylaminomethyl, and N-propyl-N-hydroxylaminomethyl Radical ° pronoun "halogen" Fluorine, chlorine, bromine, and iodine. Examples of "lower alkyloxycarbonyl" include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isopropoxycarbonyl, and tertiary butoxycarbonyl The term "substituted amine group" represents a mono- or di-substituted amine group and the substituents are selected from the lower alkyl and arylalkyl groups as defined above. The compound bb of the present invention is better than E5110 and 8¾ inmethacetin ( indomethacin) (used as a control compound in the following experimental examples) shows excellent in vitro test activity in inhibiting the production of PGE8, LTB4, and IL-1. It was also confirmed in vivo that compound I can inhibit edema and only affect gastric mucosa. It caused a little damage and proved to be an excellent non-steroidal anti-inflammatory agent. The benzylidene derivative of the present invention is novel and can be prepared, for example, by the methods described in (1 > to (4 >) below. However, the present invention is by no means limited to these The compounds prepared by the method include all compounds prepared by any other known method. The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) 8 —.----;-^-. 1 — --Install ------ order ------ line - - 1 (Please read the notes on the back of this page and then fill in) A7 B7 V. invention is described in ((1) 0Rb R1, Shang ^ R2

CHO 6 B-d °〇 R3 4CHO 6 B-d ° 〇 R3 4

acid

9 (請先閲讀背面之注意事項再填寫本頁) .裝. 訂 經濟部中央標隼局員工消費合作社印製 式中A,B,D,R1,Ra及!13之定義如上,而Re為氫或 羥保護基。 起始化合物之一,含硫化合物1例如可依據如下反應 式製備。 r3nh2 2 q驗⑻ cr ^ 'S02CI —CI^^^SOpNHR3 鹼 ㈧ r3nh ,0 S; -N 〇 R3 4' 2 鹼 式中R3之定義如上。 9 本纸張尺度適用中國國家標準(CNS ) Λ4規格(210X297公釐) A7 B7 五、 經濟部中央標準局員工消費合作社印製 發明説明(8 ) 3-氯丙基磺醢氯L1與胺2_反應而得磺醯胺中間物3_1。 反應係於齡(A)存在下進行,若有所需,可於溶劑内 進行,溶劑係灌自醚,氯仿,亞甲基氯,二氯甲烷*二氯 乙烷,四氫呋喃,二甲氧乙烷,二乙氧乙烷,苯,甲苯, 二甲苯,乙酸乙酯,乙酸甲酯等,溶劑可含有水。胺(R3NHa> 可為鹽酸鹽。 若有所需,使用齡(A>包含齡金颶鹼如氫氧化鋰,氫 氧化納,氫氧化鉀,磺酸納,碳酸鉀,碩酸氫鈉及硪酸氫 鉀等;及有機齡如吡啶,4-Ν,Ν-二甲基胺基eft啶(DMAP), 三乙胺,二異丁基乙基胺,1,8-二吖二環[5,4,0]十一硪 -7-烯〇81]),1,4-二吖二環[2,2,2]辛烷(0六8(:0)等。當使 用鹼金羼驗時,若有所需較好加入相轉移催化劑。較佳相 轉移催化劑之範例有第四銨鹽如N-苄基三甲基銨鹽*四丁 基銨鹽等。 磺醢胺中間物轉成含碕化合物il之反醮可於驗(B) 存在下於由前述者中選出的溶剤内進行。無水溶劑如二甲 亞礙,二甲基甲醯胺等爲佳。除前述者外,可使用氫化納 及氫化鋰作鹼(B)。 另外,可由化合物L1中一次製備含碕化合物而無需 分離磺醯胺中間物3_L。此種情況下,化合物L1與胺1之反 應係於適當溶劑内於2當量_存在下進行。溶劑及鹸可由 如上舉例者中選出,但特好者使用氫化納作齡及二甲基甲 酿胺作溶劑。 本紙張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐) ---1-------L I 裝------訂------涞 - - (請先閱讀背面之注意事項再填寫本頁) 10 五、 發明説明( A7 B7 s; 1)R3NH2 '〇 '° 2)POCI3 -νΛ〇 R3 5: 4: 經濟部中央標準局員工消費合作社印製 另外,期望的含硫化合物也可得自市面上可得之7 -®5l!(參見參考例)。換言之,令化合物5_L與胺(R3NH,〉 反應及Μ脫水劑處理所得產物。反應可於無溶劑之下進行 ,但若有所需可於前述溶劑下進行。有用的脫水剤範例包 含常用者,如磷醯氯,亞碓酿氯,五氯化磷,五氧化磷等 ,而Μ磷酿氣爲佳。 化合物中之Re代表氫或羥基保護基。羥基保護基包 含甲氧甲基,甲氧乙氧甲基,三甲基矽烷基及第三丁基二 甲基矽烷基。較好RB為羥基保護基,特別甲氧甲基。 如上所得化合物匕與i間之醛醇反應係於_<C)存在 下於適當溶劑内進行。蠔(C)之範例包含有機鋰鹽,如正 丁基鋰,第二丁基鋰,第三丁基鋰,苯基鋰,鋰二異丙醢 胺,鋰二乙醢胺,鋰六甲基二矽胺烷等;及鹸金颶驗如氫 化納及第三丁氧化鋰等。特別以鋰二異丙醢胺或鋰六甲基 二矽胺烷為佳。 反應溶劑之範例包含醚溶劑,如二乙醚,四氫呋喃, 二甲氧乙烷,二乙氧乙烷等;或烴溶劑如正己烷,環己烷 等。若有所需,反應較好於作為鋰金屬配合基之化學劑存 在下進行,此等化學劑例如四甲基伸乙基二胺,六甲基磷 醢胺等。 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 11 (請先閲讀背面之注意事項再填寫本頁) -裝- 五 發明説明(ίο蓄;'趟 Α7 Β7 反應係於由-80Ό至+50TC之溫度範圍内進行,偏好使 用較低溫之範圍。 醛醇加成化合物:L於酸存在下轉成化合物8_及0_之混 合物。酸之範例包含有機酸如三氟乙酸,對-甲苯磺酸, 棒腦磺酸等;及無機酸如硫酸,鹽酸等。又復可使用尋常 脫水劑如亞磺醢氯,甲烷磺醢氯,氯化鋁,磷醢氣,五氯 化磷等。較好反應係藉加熱於下列溶劑内進行:芳香族烴 如苯,甲苯,二甲苯等;鹵化垤如氯仿,二氯甲烷,二氯 乙烷等;或醚溶劑如四氫呋喃,二甲氧乙垸,二乙氧乙烷 等。9 (Please read the precautions on the back before filling out this page). Assemble. Order A, B, D, R1, Ra, and! 13 in the printed format of the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs as above, and Re is Hydrogen or hydroxyl protecting group. One of the starting compounds, the sulfur-containing compound 1 can be prepared according to the following reaction formula, for example. r3nh2 2 q ⑻ cr ^ 'S02CI —CI ^^^ SOpNHR3 base ㈧ r3nh, 0 S; -N 〇 R3 4' 2 base R3 is as defined above. 9 This paper size applies to Chinese National Standards (CNS) Λ4 specifications (210X297 mm) A7 B7 V. Statement of invention printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (8) 3-chloropropylsulfonyl chloride L1 and amine 2 _ Reaction to obtain sulfamidamide intermediate 3_1. The reaction is carried out in the presence of age (A). If necessary, it can be carried out in a solvent. The solvent is poured from ether, chloroform, methylene chloride, methylene chloride * dichloroethane, tetrahydrofuran, and dimethoxyethyl. Alkane, diethoxyethane, benzene, toluene, xylene, ethyl acetate, methyl acetate, etc. The solvent may contain water. The amine (R3NHa) may be a hydrochloride salt. If necessary, the age of use (A) contains aging alkali such as lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium sulfonate, potassium carbonate, sodium bisulfate and Potassium hydrogen acetate, etc .; and organic ages such as pyridine, 4-N, N-dimethylamino eftidine (DMAP), triethylamine, diisobutylethylamine, 1,8-diazinebicycle [ 5,4,0] Undecylen-7-ene 〇81]), 1,4-diazinebicyclo [2,2,2] octane (0 6 8 (: 0), etc. When using alkali gold fluorene During the test, if necessary, it is better to add a phase transfer catalyst. Examples of preferred phase transfer catalysts are fourth ammonium salts such as N-benzyltrimethylammonium salt * tetrabutylammonium salt, etc. The reaction with the fluorene-containing compound il can be performed in the presence of the test (B) in a solvent selected from the foregoing. An anhydrous solvent such as dimethylamine, dimethylformamide, etc. is preferred. In addition to the foregoing, Sodium hydride and lithium hydride can be used as the base (B). In addition, the fluorene-containing compound can be prepared from compound L1 at one time without isolation of the sulfonamide intermediate 3-L. In this case, the reaction between compound L1 and amine 1 is in a suitable solvent Within 2 equivalents Solvents and solvents can be selected from the above examples, but the most preferred ones use sodium hydride as the age and dimethyl methylamine as the solvent. This paper size applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm)- -1 ------- LI installation ------ order ------ 涞--(Please read the notes on the back before filling out this page) 10 V. Description of the invention (A7 B7 s; 1) R3NH2 '〇' ° 2) POCI3-νΛ〇R3 5: 4: Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs In addition, the expected sulfur compounds can also be obtained from commercially available 7-5l! (See the reference example). In other words, the compound 5_L is reacted with an amine (R3NH,> and treated with a dehydrating agent. The reaction can be performed without a solvent, but if necessary, it can be performed under the aforementioned solvent. Useful dehydration Examples include those commonly used, such as phosphonium chloride, sulfonium chloride, phosphorus pentachloride, phosphorus pentoxide, etc. M phosphorus gas is preferred. Re in the compound represents hydrogen or a hydroxyl protecting group. The hydroxyl protecting group contains methoxy Methyl, methoxyethoxymethyl, trimethylsilyl and tert-butyldimethylsilyl. Preferred RB is a hydroxyl protecting group , Especially methoxymethyl. The aldol reaction between the compound obtained above and i is performed in a suitable solvent in the presence of < C). Examples of oysters (C) include organic lithium salts, such as n-butyllithium, Second butyllithium, third butyllithium, phenyllithium, lithium diisopropylamidamine, lithium diethylamidamine, lithium hexamethyldisilazane, etc .; and gold tests such as sodium hydride and third Lithium butoxide, etc. Especially preferred is lithium diisopropylamidide or lithium hexamethyldisilazane. Examples of the reaction solvent include ether solvents such as diethyl ether, tetrahydrofuran, dimethoxyethane, and diethoxyethane Etc .; or hydrocarbon solvents such as n-hexane, cyclohexane and the like. If necessary, the reaction is preferably performed in the presence of a chemical agent as a lithium metal complex, such as tetramethylethylenediamine, hexamethylphosphoniumamine and the like. This paper size applies the Chinese National Standard (CNS) A4 specification (210 × 297 mm) 11 (Please read the precautions on the back before filling out this page)-Pack-Five Invention Instructions (ίο 蓄; '' Α7 Β7 The reaction is based on- The temperature range is from 80 ° C to + 50TC, and the lower temperature range is preferred. Aldol addition compound: L is converted into a mixture of compounds 8_ and 0_ in the presence of an acid. Examples of acids include organic acids such as trifluoroacetic acid, P-toluenesulfonic acid, clavulanic acid, etc .; and inorganic acids such as sulfuric acid, hydrochloric acid, etc. Ordinary dehydrating agents such as sulfenyl chloride, methanesulfonyl chloride, aluminum chloride, phosphine gas, pentachloride can be used. Phosphorus, etc. The preferred reaction is performed by heating in the following solvents: aromatic hydrocarbons such as benzene, toluene, xylene, etc .; halogenated halides such as chloroform, methylene chloride, dichloroethane, etc .; or ether solvents such as tetrahydrofuran, dimethyl Oxyacetam, diethoxyethane, etc.

(Ε/Ζ混合物) 8 1 (請先閱讀背面之注意事項再填寫本頁) 裝(E / Z mixture) 8 1 (Please read the precautions on the back before filling this page)

'II 經濟部中央標隼局員工消費合作社印製 脫去保謀 (γ=保誰基)'II Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs

準 標 家 國 國 中 用 適 度 尺 張 紙 本Appropriate rule paper for quasi-standard countries

Ns 釐 公 A7 B7 五、發明説明(1 上式中之驗(C>之定義如上。Υ代表Ν保護基如第三 丁氧羰基,苄氧羰基,苄基,4-甲氧苄基,3,4-二甲氧苄 基,4-硝基苄基等。醛醇反應之反應條件類似如上反應圖 1所述者。醛醇加成化合物L轉成化合物i〇a與m之混合 物之轉化反應中使用的脫水劑及脫保護劑包含對甲苯磺酸 及三氟乙酸,氣化鋁,四氯化鈦等。如反應溶劑,溫度等 條件皆與反應圖1所述者類似。(E)-及(Z)-異構物之混合 物脫去保護而得式I化合物iiM m (式中D為>N-而R3 為H)。 (3)Ns centimeter A7 B7 V. Description of the invention (1 The test in the above formula (C > is as defined above. Υ represents an N protecting group such as a third butoxycarbonyl group, a benzyloxycarbonyl group, a benzyl group, a 4-methoxybenzyl group, 3 , 4-dimethoxybenzyl, 4-nitrobenzyl, etc. The reaction conditions for aldol reaction are similar to those described in the above reaction Figure 1. Conversion of aldol addition compound L to a mixture of compounds i0a and m The dehydrating agent and deprotecting agent used in the reaction include p-toluenesulfonic acid and trifluoroacetic acid, aluminum gasification, titanium tetrachloride, etc. The conditions such as the reaction solvent, temperature and the like are similar to those described in the reaction figure 1. (E) Deprotection of the mixture of-and (Z) -isomers gives the compound iiM m of formula I (where D is > N- and R3 is H). (3)

(請先聞讀背面之注意事項再填寫本頁) 裝.(Please read the notes on the back before filling this page).

10 r3-x m (D) 烷基化 睦基化 胺甲醯基化 烷氧羰基化10 r3-x m (D) Alkylation Methylation Carboxylation Alkoxycarbonylation

,ιτ 泉 經濟部中央標準局員工消費合作社印製 此反應中期望的取代基R3加入如式I的本發明化合物 (式中D為>^而R3為H)而得各棰衍生物。當R3-X為烷化 劑時,所用鹺(D)包含鹾金屬鹺如氫氧化鈉,氫氧化鉀, 碳酸納,碳酸鉀,碩酸氫鈉,碳酸氫鉀,氫氧化鋰等;或 有機驗如Pft啶,三乙胺,二異丙基乙基胺等。烷化反應較 好使用氫氧化鈉或碳酸鉀於合宜的第四銨鹽作相轉移催化 劑存在下進行。 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 13 '~~~五、發明説明( A7 B7 若R3X爲酿化劑,則較好使用有機齡(如吡啶,4-二 甲胺基吡啶,三乙胺,二異丙基乙基胺等)作齡(〇)。 當R3X為胺甲醯化剤或烷氧羰化劑時,較好使用有機 鋰鹼(如正丁鋰,鋰六甲基二矽胺烷,鋰二異丙基醯胺) 作驗(D)。本發明非僅限於此等驗也可使用有機鹼如毗啶 ,三乙胺,二異丙基乙基胺等或前逑驗金羼鹼。 (4)Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. The desired substituent R3 in this reaction is added to the compound of the present invention such as Formula I (where D is > ^ and R3 is H) to obtain each pyrene derivative. When R3-X is an alkylating agent, the rhenium (D) used includes rhenium metals such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bisulfate, potassium bicarbonate, lithium hydroxide, etc .; or organic Tests such as Pftidine, triethylamine, diisopropylethylamine and so on. The alkylation reaction is preferably carried out using sodium hydroxide or potassium carbonate in the presence of a suitable fourth ammonium salt as a phase transfer catalyst. This paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) 13 '~~~ V. Description of the invention (A7 B7 If R3X is a brewing agent, it is better to use organic age (such as pyridine, 4-dimethyl Aminopyridine, triethylamine, diisopropylethylamine, etc.) are used as the age (0). When R3X is a carbamidine or an alkoxycarbonylating agent, an organic lithium base (such as n-butyllithium) is preferably used. , Lithium hexamethyldisilazane, lithium diisopropylamidamine) as test (D). The present invention is not limited to these tests. Organic bases such as pyridine, triethylamine, diisopropylethyl can also be used. Amines, etc. or pre-tested chrysophylline (4)

8J 脫去保護8J off protection

11a 11b (請先閱讀背面之注意事項再填寫本頁) -裝i 經濟部中央標準局員工消費合作社印製 式I化合物112_及11]2_ (式中D爲〉N-而R3為OH)係經 由去苄基化合物8_及1使用脫去保護劑進行而得。脫去保 護之進行方式係經由於耙/碩或氧化鉑存在下氫化進行, 或使用路易士酸如氣化鋰,四氯化钛等,若有所需連同茴 香醚,2,6-二-第三丁基酚等進行。 除鹵化烴如二氯甲烷,氣仿,二氯乙烷等外,也可使 用硝基甲烷,苯,甲苯,二甲苯等作反應溶劑。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 14 五、 發明説明(l311a 11b (Please read the precautions on the back before filling out this page)-Install i Printed compound I of formula I 112_ and 11] 2_ (where D is> N- and R3 is OH) It is obtained through debenzyl compounds 8_ and 1 using a deprotecting agent. Deprotection is carried out by hydrogenation in the presence of a rake / steel or platinum oxide, or using a Lewis acid such as lithium gasification, titanium tetrachloride, etc., if necessary, together with anisole, 2,6-di- Third butylphenol and the like are carried out. In addition to halogenated hydrocarbons such as dichloromethane, gas-form, dichloroethane, etc., nitromethane, benzene, toluene, xylene, etc. can be used as a reaction solvent. This paper size is applicable to China National Standard (CNS) A4 specification (210X297 mm) 14 V. Description of the invention (l3

A7 B7 如上(1),(2),(3)及(4>所列舉之方法概略可應用 於本發明之生產式I化合物,且特定說明於如下實施例1-35 ° 本發明化合物I也可藉下述方法生成:經由使用氣碩 酸乙酯等於習知脫水劑如三乙胺存在下處理如下式新穎化 合物:A7 B7 The methods listed in (1), (2), (3), and (4> above can be roughly applied to the production of the compound of formula I in the present invention, and are specifically illustrated in the following Examples 1-35 ° The compound I of the present invention is also It can be generated by treating a novel compound of the following formula by using ethyl geranate equal to a conventional dehydrating agent such as triethylamine:

而割裂環,獲得如下式化合物 (請先聞讀背面之注意事項再填寫本頁) -裝.And split the ring to obtain the compound of the following formula (please read the precautions on the back before filling this page) -pack.

訂 經濟部中央標牟局員工消費合作社印製 脫水劑之範例包含氯甲酸乙酯,三乙胺,磷醢氯,亞 磺醯氯,DCC (二環己基甲二醸亞肢)等。此方法概略可 應用於經由選擇適當的起姶化合物及反應條件而製備本發 明之式I化合物。 本發明之化合物I可經口或經腸道外投藥作抗炎劑。 Μ經口投藥為例,本發明化合物可調配成固體形式之尋常 調配劑,例如錠劑,散劑,粒劑,膠囊劑等;溶液劑;油 懸浮液;液體調配劑如糖漿劑,酏劑等。Μ經腸道外投藥 為例,本發明化合物可調配成水或油性注射懸浮液或外用 本紙張尺度適用中國國家樣準(CNS ) Α4規格(210Χ 297公釐) 15 線—--I . 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(14·ϋ 製劑。於調配劑之製備中,可使用習知賦形劑,黏結劑, 潤滑劑,水溶劑,油溶劑,乳化劑,懸浮爾等;也可包含 其它添加劑如保藏劑,安定劑等。 雖然本發明化合物之合宜每日劑量依據投藥途徑,病 人年齡、體重及情況,及治療的疾病種類而異,但以成年 病人爲例,經口投藥概略介於10-500 ag,較好50-100 mg ,而經腸道投藥槪略介於卜250 mg,較好5-10 mg,平分 成1至5次投藥。 提供下列實例進一步舉例說明本發明而絕非限制其範 圍。 實例中使用之縮寫定義如下:LDA =鋰二異丙基酿胺 ;Μ0Μ=甲氧基甲基;P_TsOH=對-甲苯磺酸;THF=四氬 呋喃;DMF= Ν,Ν-二甲基甲酿胺;HMPA=六甲基磷醯胺; 1^心05=鋰六甲基二矽胺烷;081)=1,8-二吖二環[5,4,0] 十一磺-7-烯;及DIBAL=氫化二異丁鋁。Examples of dehydrating agents printed by the Employees' Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs include ethyl chloroformate, triethylamine, phosphonium chloride, sulfenyl chloride, DCC (dicyclohexyl formamidine sublime) and the like. This method is roughly applicable to the preparation of the compound of formula I of the present invention by selecting an appropriate starting compound and reaction conditions. The compound I of the present invention can be administered orally or parenterally as an anti-inflammatory agent. As an example, M is administered orally. The compounds of the present invention can be formulated into solid formulations such as lozenges, powders, granules, capsules, etc .; solutions; oil suspensions; liquid formulations such as syrups, elixirs, etc. . For example, the parenteral administration of MU can be formulated into water or oily injection suspensions or for external use. The paper size is applicable to China National Standard (CNS) A4 specification (210 × 297 mm) 15 lines --- I. Ministry of Economic Affairs Printed by A7 B7, Consumer Cooperatives of the Central Bureau of Standards 5. Description of the invention (14 · ϋ Preparations. In the preparation of formulations, conventional excipients, binders, lubricants, water solvents, oil solvents, emulsifiers, suspensions, etc. can be used. Other additives such as preservatives, stabilizers, etc. may also be included. Although the appropriate daily doses of the compounds of the present invention will vary depending on the route of administration, the age, weight and condition of the patient, and the type of disease being treated, taking adult patients as an example, Oral administration is roughly between 10-500 ag, preferably 50-100 mg, while enteral administration is slightly between 250 mg, preferably 5-10 mg, divided equally into 1 to 5 administrations. The following examples are provided to further The present invention is exemplified without limiting its scope in any way. The abbreviations used in the examples are defined as follows: LDA = lithium diisopropyl amine; MOM = methoxymethyl; P_TsOH = p-toluenesulfonic acid; THF = tetrahydrofuran ; DMF = Ν, -Dimethyl methylamine; HMPA = hexamethylphosphamide; 1 ^ heart 05 = lithium hexamethyl disilazane; 081) = 1,8-diazodicyclo [5,4,0] ten Monosulfo-7-ene; and DIBAL = diisobutylaluminum hydride.

於3-氯丙基磺酿氣1 (6.1g,34_5mmol)於越(25ml 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 16 --------L I 裝-----^ I 訂------線 i (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標隼局員工消費合作社印製 A7 B7 五、發明説明(15 )之溶液內,藉攪拌於加冰冷卻下以15分鐘時間逐滴加入 乙胺(70%水溶液,4.4g,68.3mmol)。所得混合物於室 溫攪拌1小時及於真空濃縮。苯(l〇〇al)加入殘渣内及 真空蒸皤去除溶劑。於殘渣內加醚(15〇Β1)及過濾去除 不溶性物料。濾液經真空蒸皤而去除醚,獲得6.96g (產 率約100%)粗N-乙基-3-氯丙基磺醢胺(中間物3a)呈無 色結晶(ηι·ρ· = 30-32υ)。於此中間物 3a(6.96g,34.5 1111〇1)於1'1^(5〇1«1)之溶液内藉攪拌於加冰冷卻下以15 分鐘時間緩慢加入氫化納(60%於油,1.52g,38.0mmol )。反應混合物於室溫又攪拌30分鐘。加入醚(50ml)後 ,混合物經過濾而去除不溶性物料及濾液經真空蒸餾去除 溶劑而得4. 93g( 96%)目榧化合物^呈淡黃色油。 IR(CHCl3)cm-1 : 3018,2976,2868,1452,1306,1220,1179, 1129,1015. NMR(CDC13)S : 1.24(3H,t,J=7.4Hz,CH3),2.28-2.42 (2H, m,CHs),3.10(2H,q,J=7.4Hz,CHa),3.15(2H,t,J=7.6Hz,CHa), 3.22-3.29(2H,m,CHa). 剪備例2 ( R3 = Me) N-申某-1 .2-里噱邮啶-1 .1 -二氛化物Uh) 3-氣丙基磺醯氯1 (6.8g,94.9mmol),甲胺HC1( 13.5g,200mmol)及碩酸鉀(27.6g,200mmol)依次加入 乙酸乙酯( 500ml)内。加入氣化N-苄基三甲基銨(約200 »g)後,所得混合物於室溫攪拌2小時及於無水硫酸鈉上 脫水。混合物通過小量氧化矽凝膠過濾及濾液於真空濃縮 本紙張尺度適用中國國家標準(CNS )八4規格(210X 297公釐) _ _ (請先閲讀背面之注意事項再填寫本頁) 裝· A7 B7For 3-chloropropyl sulfonic acid fermentation gas 1 (6.1g, 34_5mmol) Yuyue (25ml This paper size applies to China National Standard (CNS) A4 specifications (210 X 297 mm) 16 -------- LI Pack ----- ^ Order I ------ line i (Please read the notes on the back before filling this page) Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs A7 B7 V. Description of Invention (15) In the solution, ethylamine (70% aqueous solution, 4.4 g, 68.3 mmol) was added dropwise over 15 minutes with stirring under ice cooling. The resulting mixture was stirred at room temperature for 1 hour and concentrated in vacuo. Benzene (100al ) Added to the residue and removed the solvent by vacuum distillation. Ether (150B1) was added to the residue and the insoluble materials were removed by filtration. The ether was removed by vacuum distillation of the filtrate to obtain 6.96 g (yield 100%) of crude N-ethyl. 3-Methyl-3-chloropropylsulfonamide (intermediate 3a) is colorless crystals (η · ρ · = 30-32υ). The intermediate 3a (6.96g, 34.5 1111〇1) is at 1'1 ^ (5 〇1 «1) was slowly added sodium hydride (60% in oil, 1.52g, 38.0mmol) over 15 minutes with stirring under ice cooling. The reaction mixture was stirred at room temperature for another 30 minutes. Ether (50ml) was added. )Rear The mixture was filtered to remove insoluble materials and the filtrate was vacuum distilled to remove the solvent to obtain 4.93g (96%) of the mesh compound ^ as a pale yellow oil. IR (CHCl3) cm-1: 3018,2976,2868,1452,1306 , 1220,1179, 1129,1015. NMR (CDC13) S: 1.24 (3H, t, J = 7.4Hz, CH3), 2.28-2.42 (2H, m, CHs), 3.10 (2H, q, J = 7.4Hz , CHa), 3.15 (2H, t, J = 7.6Hz, CHa), 3.22-3.29 (2H, m, CHa). Preparation Example 2 (R3 = Me) N-Shenmou-1. 2-Li Post Pyridine-1. 1 -diammonium compound Uh) 3-Gaspropylsulfonyl chloride 1 (6.8g, 94.9mmol), methylamine HC1 (13.5g, 200mmol) and potassium succinate (27.6g, 200mmol) were added in order Ethyl acetate (500ml). After adding vaporized N-benzyltrimethylammonium (about 200 »g), the resulting mixture was stirred at room temperature for 2 hours and dehydrated over anhydrous sodium sulfate. The mixture is filtered through a small amount of silica gel and the filtrate is concentrated in a vacuum. The paper size is applicable to the Chinese National Standard (CNS) 8-4 specifications (210X 297 mm) _ _ (Please read the precautions on the back before filling this page). A7 B7

五、發明説明(16 而得12g (74%)粗N-甲基-3-氯丙基磺醢胺(中間物3b) 呈淡黃色油。 於中間物 3b ( 11.79g,68.69mmol)於苯(300ml)之 溶液內加入DBU( 10.79ml,72. 12 mmol),及所得混合物於 室溫攪拌24小時並通過小量氧化矽凝膠過濾。濾液當真空 蒸脯去除溶薄(時,獲得7_0g (75%)目榛化合物4b無色固 體(m_ ρ· = 36-40t )。 IR(CHCl3)cm-1 : 3016,1451,1307,1218,1187,1127. NMR(CDC13)S : 2.27-2.42(2H,m,CHa),2.69(3H,s,CH3), 3.U-3.20(2H,m,CHa>,3.22(2H,t,J = 6.8Hz,CHa). 製備例 3 ( R3 = CHaCH(CH3) a) N-里丁甚-1.2-里皤唑Qg-〗.〗-二着.仆.物(4d 3-氯丙基磺醢氣1 (7.08g,40mraol),異丁基胺( 7.3g,lOOmmol)及礦酸氫納(3.36g,40mmol)依次加入 乙酸乙酯( 200ml)與水(20ml)之混合物內。於此混合 物內加入氯化N-苄基三甲基銨(約100mg)。所得混合物 於室溫攪拌3小時,然後Μ類似製備例2所述之方式處理 而得8.19g (96%)粗Ν-異丁基-3-氣丙基磺酿胺(中間物 3c)呈無色結晶(m.p. = 68-6910 )。 於中間物3c (4.27g,20mmol )於苯(60ml)之溶液 内加入DBU (3.3ml,22®m〇l)及反應混合物以類似製備例 2所述之方式處理而得3.37g (95%)目檷化合物4c呈無 色油。 IR(CHCl3)cm-1 : 3016,2956,1465,1304,1226,1131,1024. 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) ------------LI裝------訂------線 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標隼局員工消費合作社印製 18 B7 B7 五、 經濟部中央標準局員工消費合作社印製 發明説明(17_ NMR(CDC13)§ : 〇.95(6H,d,J=6.6Hz,(CH3)*),1.75-1.96 (1H,m,CH),2.27-2.42(2H,m,CHa),2.80(2H,d,J=7.4Hz> (請先閲讀背面之注意事項再填寫本頁) CH2) ,3. 10-3. 19(2H,iB,CHa) ,3.24(2H(t, J = 6.8Hz,CHa). 勉備例4 ( R3=環丙基) N-璀芮某-U-里瞌映ng-1.1-二氣化物(4d) 3-氯丙基磺酿氯1 (7.08g,40mmol),瓖丙胺(6.0g ,105aB〇l)及磺酸氫納(3.7g,44mmol)加入醚( 200ml >與水(lOal)之混合物內。所生成之混合物以類似製備 例3所述之方式處理而得8.〇g (約100% )粗N-環丙基-3-氯丙基磺酿胺(中間物3d)呈結晶(101. = 48-49.51¾)。 所述中間物 3d (l_98g,lOamol)與 DBU (1.65ml,11 mnol)於苯(30·1)内反應,當以類似製備例2所述之方 式反應時,反應混合物獲得1.40g(87%)目檷化合物4d 呈淡黃色油。 IR(CHC13)cm-1 : 3016,1309,1221,1140,1026. NMR(CDC13)S : 0.60-0.85(4Η,ι»,環丙基 >,2·20-2·40( 3Η, m, CH» + CH),3.15-3.25(2H,m,CHa),3.32(2H,t,J = 6.6Hz, CHa). 勒備俐 R ( R3 = -CHaCH.CHa) N-TF 丙某二氤化物(4e) 3-氯丙基磺酿氣1 (7.08g,40iiiB〇l),正丙胺(5.90g ,lOOnmol ),磺酸鉀(5_52g,40mmol)及小量氯化 N-苄基三甲基銨(約lOOmg)於_ ( 200ml)與水(20·1)之 混合物内攪拌3小時。反應混合物Μ類似製備例2所述之 19 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) A7 B7 五、發明説明 經濟部中央橾準局員工消費合作社印製 方式處理而得8.Og (約100%)粗N-正丙基-3-氯丙基磺酿 胺(中間物3e)呈結晶(^^ = 47.5-4810)。 所述中間物 3e ( 2.0g,lOmmol)與 DBU ( 1.65ml , 11 mmol)於苯(30ml) Μ製備例2所述之類似方式反應而得 1.41g(86%)目檫化合物4e呈淡黃色至無色油。 IR(CHCl3)ca-1 : 3018,2962,2868,1304,1224,1130,1019. NMR(CDC19)5 : 0.96(3H,t, J = 7Hz,CH3 ) , 1.52-1.72(2H,a, CH«),2.28-2.42(2H,m,CHa),2.94-3.04(2H,b,CH,),3.10-3.20(2H,b.CH8),3.25(2H,t,J=6.7Hz,CHe). 剪備例 6 (R3=0CH,) N-田氤某-1.2-畕臃睥啶-1 .1-二氬仆.物UH 3-氣丙基磺醢氯1 (7.08g,4〇BB〇l ) ,0-甲基羥胺 HC1 (3.76g,40mmol )與碳酸鉀(5_80g,42mmol) Μ 類 似製備例5所述之方式反應而得7.02g (94%)粗Ν-甲氧 基-3-氯丙基磺醢胺(中間物3f)呈無色至淡黃色油。 中間物3f (6.25g,33_3mmol )與氫化鈉(60%於油 ,1.47s,36.7mmol )以類似製備例1所述方式反應而得 3.70g(73%)目棲化合物4f呈無色油。 IR(CHCl3)cm-1 : 3022,1355,1249,1222,1165,1138,1035,1011. NMR(CDC13)5 : 2.37-2.50(2H,m,CHe) ,3.20-3. 14(2H,m, CHa),3.50(2H,t,J = 7.0Hz,CHa),3.81(3Ht s,0CHa). 剪備例 7 ( R3 = 0CH*C6Hb) 氤某-1.2-里嗛二氩仆.物(4g) (請先閲讀背面之注意事項再填寫本頁) 裝·V. Description of the invention (16 to give 12 g (74%) of crude N-methyl-3-chloropropylsulfonamide (intermediate 3b) as a pale yellow oil. In intermediate 3b (11.79g, 68.69mmol) in benzene (300 ml) was added to DBU (10.79 ml, 72.12 mmol), and the resulting mixture was stirred at room temperature for 24 hours and filtered through a small amount of silica gel. The filtrate was thinned when the preserved food was removed in vacuo (7_0 g was obtained) (75%) mesh hazel compound 4b colorless solid (m_ρ · = 36-40t). IR (CHCl3) cm-1: 3016,1451,1307,1218,1187,1127. NMR (CDC13) S: 2.27-2.42 ( 2H, m, CHa), 2.69 (3H, s, CH3), 3.U-3.20 (2H, m, CHa >, 3.22 (2H, t, J = 6.8Hz, CHa). Preparation Example 3 (R3 = CHaCH (CH3) a) N-ridine even-1.2-rixazole Qg-〗.〗-Two. Serum (4d 3-chloropropylsulfonium 1 (7.08g, 40mraol), isobutylamine (7.3g, 100mmol) and sodium hydrogen mineral acid (3.36g, 40mmol) were sequentially added to a mixture of ethyl acetate (200ml) and water (20ml). To this mixture was added N-benzyltrimethylammonium chloride ( About 100 mg). The resulting mixture was stirred at room temperature for 3 hours, and then treated in a manner similar to that described in Preparation Example 2 to obtain 8.19 g (96%) of crude N-iso 3-Gaspropylsulfonamide (intermediate 3c) showed colorless crystals (mp = 68-6910). To a solution of intermediate 3c (4.27g, 20mmol) in benzene (60ml) was added DBU (3.3ml, 22®mol) and the reaction mixture were treated in a manner similar to that described in Preparation Example 2 to obtain 3.37 g (95%) of the head compound 4c as a colorless oil. IR (CHCl3) cm-1: 3016, 2956, 1465, 1304 , 1226,1131,1024. This paper size is applicable to China National Standard (CNS) A4 specification (210X 297mm) ------------ LI installed -------- Order ---- --Line (Please read the notes on the back before filling out this page) Printed by the Consumers 'Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs 18 B7 B7 V. Printed Invention Notes by the Consumers' Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (17_ NMR (CDC13) §: 0.95 (6H, d, J = 6.6Hz, (CH3) *), 1.75-1.96 (1H, m, CH), 2.27-2.42 (2H, m, CHa), 2.80 (2H, d, J = 7.4Hz > (Please read the precautions on the back before filling this page) CH2), 3. 10-3. 19 (2H, iB, CHa), 3.24 (2H (t, J = 6.8Hz, CHa). Mian Preparation Example 4 (R3 = cyclopropyl) N-Clui-U-Li Yingying ng-1.1-digas (4d) 3-chloropropylsulfonyl chloride 1 (7.08g, 40mmol), propylpropylamine ( 6.0g, 105aB0l) Acid hydrogen sodium (3.7g, 44mmol) was added ether (200ml > the mixture with water (LoAL) of. The resulting mixture was treated in a manner similar to that described in Preparation Example 3 to obtain 8.0 g (about 100%) of crude N-cyclopropyl-3-chloropropylsulfonamide (intermediate 3d) as a crystal (101. = 48-49.51¾). The intermediate 3d (l-98g, 10amol) was reacted with DBU (1.65ml, 11 mnol) in benzene (30 · 1). When reacted in a manner similar to that described in Preparation Example 2, the reaction mixture obtained 1.40g (87% ) Compound 4d was a pale yellow oil. IR (CHC13) cm-1: 3016,1309,1221,1140,1026. NMR (CDC13) S: 0.60-0.85 (4Η, ι », cyclopropyl >, 2.20-2 · 40 (3Η, m , CH »+ CH), 3.15-3.25 (2H, m, CHa), 3.32 (2H, t, J = 6.6Hz, CHa). Le Bei Li R (R3 = -CHaCH.CHa) N-TF Halide (4e) 3-chloropropylsulfuric acid 1 (7.08g, 40iiiB0l), n-propylamine (5.90g, 100nmol), potassium sulfonate (5-52g, 40mmol) and a small amount of N-benzyl chloride Methyl ammonium (about 100 mg) was stirred in a mixture of _ (200ml) and water (20 · 1) for 3 hours. The reaction mixture M was similar to that described in Preparation Example 2 19 This paper is in accordance with the Chinese National Standard (CNS) A4 specification ( 210X297 mm) A7 B7 V. Description of the invention 8. 8.Og (about 100%) crude N-n-propyl-3-chloropropylsulfonamide (middle) Compound 3e) is crystalline (^^ = 47.5-4810). The intermediate 3e (2.0 g, 10 mmol) is reacted with DBU (1.65 ml, 11 mmol) in benzene (30 ml) in a similar manner as described in Preparation 2 and 1.41 g (86%) of compound 4e was obtained as a pale yellow to colorless oil. IR (CHCl3) ca-1: 3018,2962,2868,1304,1224,1130,1019. NMR (C DC19) 5: 0.96 (3H, t, J = 7Hz, CH3), 1.52-1.72 (2H, a, CH «), 2.28-2.42 (2H, m, CHa), 2.94-3.04 (2H, b, CH, ), 3.10-3.20 (2H, b.CH8), 3.25 (2H, t, J = 6.7Hz, CHe). Shearing example 6 (R3 = 0CH,) N- 田 氤 某 -1.2-piperidine- 1.1.1-Diargon hydride UH 3-Gaspropylsulfonyl chloride 1 (7.08g, 4BBl), 0-methylhydroxylamine HC1 (3.76g, 40mmol) and potassium carbonate (5-80g, 42mmol) Μ Reaction in a manner similar to that described in Preparation Example 5 gave 7.02 g (94%) of crude N-methoxy-3-chloropropylsulfonamide (intermediate 3f) as a colorless to pale yellow oil. Intermediate 3f (6.25 g, 33-3 mmol) and sodium hydride (60% in oil, 1.47s, 36.7 mmol) were reacted in a manner similar to that described in Preparation Example 1 to obtain 3.70 g (73%) of the eye-dwelling compound 4f as a colorless oil. IR (CHCl3) cm-1: 3022,1355,1249,1222,1165,1138,1035,1011. NMR (CDC13) 5: 2.37-2.50 (2H, m, CHe), 3.20-3. 14 (2H, m , CHa), 3.50 (2H, t, J = 7.0Hz, CHa), 3.81 (3Ht s, 0CHa). Preparation example 7 (R3 = 0CH * C6Hb) 4g) (Please read the notes on the back before filling this page)

、1T 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 20、 1T This paper size is applicable to China National Standard (CNS) Α4 specification (210X297 mm) 20

A 7 i '發明説明(igfSIl 3-氣丙基磺醯氣1 ( 30.28g,0.17mmol) ,0-苄基羥 胺 HC1 (27.3g,0.17β·ο1 ),磺酸鉀(50g,0·36ι»βο1) 及硫化四丁銨(約500»g)於ft與水(1 : 1) (100ml)之 混合物内於室溫彼此反應24小時及反應混合物Μ乙酸乙酯 抽取。抽取物於氧化矽凝膠上接受柱式層析。使用乙酸乙 酯/正己烷(1:4)混合物溶離*所得溶離分中獲得18.4g (41%)粗N-苄氧基-3-氣丙基磺酿氯(中間物3g)呈淡 黃色油。 於如上中間物 3g (18.4g,69.9mmol)於 THF (150ml) 之溶液内加入氫化納(60%於油,2.94g,73.4nnnol), 及Μ類似製備例1所述方式進行反應。產物於氧化矽凝膠 上接受柱式層析。由使用乙酸乙酯/正己烷(1:5)之混 合物所得溶離分中獲得l〇.75g (68%)目榛化合物4g呈無 色結晶。 m. p . = 52-54¾ IR(CHCl3)cm-1 : 3022,2956,1453,1354,1165,1140,1081, 1000. NMR(CDC13)5 : 2.30-2.48 (2H,m,CH2),3.04-3.14(2H,ni, CH8),3.45(2H,t,J=6.9Hz,CHa),5.00(2H>s,0CH8),7.30-7.45(5H,ip, C6H,). 剪備例8 ( R3= 4-甲氧苄基) 田氬苄某)-1 .2-里臃_啶-1 . 1 -二氬仆物(4h) 3-氣丙基磺醢氯1 (17_7g,0.1mmol ),對-甲氧苄 基胺(15.0g,0.11minol)及碳酸氫鈉(8_4g,0.1i〇in〇U 於乙酸乙酯( 400ml )及水(40ml)之混合物内以類似製 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -2 1 _ ---------:----L — 裝------訂------線 ; 一 (請先閲讀背面之注意事項再填寫本頁) 經濟部中夬標準局員工消費合作社印製 五、 發明説明(20 Μ A7 B7 經濟部中央標率局員工消費合作社印製 尨珀舢I 備例3所述之方式反應而得19.1g (69%)粗Ν- (4-甲氧 基苄基)-3-氣丙基磺醢胺(中間物3h)呈無色結晶( m.p. = 78-80*0 )。 於上中間物3h ( ll.llg,40bbo1)與DBU (6·6·1,40 »·〇1)於苯(150ml)内反應。所得混合物以類似製備例 2所述方式處理而得8.89g (92% )目檷化合物4h呈結晶 (Β·P.= 48-51Ό)。 IR(CHC13)ci·- 1 : 3016.1612,1511,1304,1245.1136,1034, NMR(CDCU)5 : 2.20-2.38(2H.a,CHe),3.09(2H,t,J = 6.8Hz,CHa),3·14-3.24(2H,m,CHa),3.81(3H,s,0CH3),4.12 (2H,s,CHa) ,6.84-6.94 (2H,iB,CHa) ,7.22-7.32(4H,in,4x 芳香-H>. 製備例9 (R3=3,4-二甲氧苄基) ( 3·4-二甲氲¥甚)-1.2-惠睐_啶-1.1-二氩化物(4;) 3-氯丙基磺醢氯1 (8.85g,50m«ol ) ,3,4_二甲氧 苄基胺(9.0ml,60mmol)及碳酸鉀(4.13g,30mmol)以 類似製備例2所述之方式反應而得14· 5g (94%)粗N-( 3,4-二甲氧基苄基)-3-氣丙基磺醢胺(中間物3ί)。 中間物3i當Μ類似製備例1方式處理時獲得目檫化合物4i (產率:69% )。 IR(CHC13)cm-1 : 3018,1516,1307,1262,1225,1155,1138, 1027. NMR(CDC1S)5 : 2.22-2.38 (2H, m, CH〇 , 3. 11 (2H, t, J = 6. 7 Hz.CH»),3.16-3.25(2H,m,CHa),3.88(3H,s,0CH3),3.89( 本紙張尺度適用中國國家橾準(CNS )八4規格(210Χ297公釐) 22 (請先閲讀背面之注意事項再填寫本頁) -裝. 、?τ A7 B7 五 、發明説明(21 3H,s,CH3〉,4. 12(2H,s,CHa) ,6·79-6·91<3Η,κ,3Χ 芳香-H) 製備例 10 ( R3= CgH.) H-茱某-1.2-里瞎脞啶-1.1-二氦仆.物U.i) 3-氣丙基磺醣氯1 ( 1.456g,8.23BB〇l)M約5分鐘 時間伴Μ冷郤至-20至-3010而逐滴加入苯胺(0.5·1, 8·23ϋ·〇1)於吡啶(5ml)之溶液。添加完成後,反應混 合物又於室溫攪拌45分鐘。反應混合物經真空濃縮及殘渣 於氧化矽凝膠上接受柱式層析。使用乙酸乙酯/正己烷( 1:2)之混合物所得溶離分中獲得1.683g(88%) N-苯基 -3-氯丙基磺醢胺(中間物3g)呈黃色油,其Μ類似製備 例1所述方式處理時獲得化合物4j呈淡黃色固艟(產率57 96)。 IR(CHC13)cm-1 : 3020,1598,1495,1315,1139. NMR(CDCU)5 : 2.46-2.60 (2H, m, CHa) , 3.34 (3.42(2H, m, CHa),3.78(2H,t,J=6.6Hz,CH8),7.10-7.40(5H,m,CeHe). 製備例11 ( R3 = 4-氣苯基) N- f 4-氣荣某)-1 .2-基臃脾啶-1 .1 -二氬化物(4k) 根據製備例10所述之類似方法,3-氯丙基磺醯氯與4-氣苯胺於吡啶反應而得N- (4-氣苯基> -3-氣丙基磺醢胺 (中間物3k)(產率93%)。中間物3kM類似製備例2所 述之方式使用DBU處理而得目檷化合物4k (產率68%)呈 無色結晶(m_P. = 110. 5-111. 5C )。 IRiKBrJcm-1 : 3010,2960,1595,1493,1300,1267,1131. NMR(CDC13)5 : 2.47-2.61(2H,m,CHa)(3.35-3.43(2H,m, ---------Ί—--.LI 裝-----I 訂------泉 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) -23 - 23 A7 B7 經濟部中央標隼局員工消費合作社印製 五、發明説明(22 ) CHS) ,3.76<2H,t, J = 6.4Hz,CHa> ,7. 16-7.36(4H,m,4x 芳香 -Η). 剪備例1 2 ( R3 = 2-Btt啶基) M- f 2-nH··啶基)-1.2-里睐睐啶-1 .1 -二g化物un 根據製備例10所述之類似方法,3-氯丙基磺酿氣與2-胺基吡啶反應而得N- (2-Btfc啶基)_3_氯丙基磺醯胺(中 間物31)呈淡黃色固體(產率54%)。於此中間物31 ( 2.138g,9.11 mmol )於DMF (30 ml)之溶液內於加冰冷 卻下加入氯化鈉(60%於油,401 mg,10 mmol )。所得 混合物於851攪拌30分鐘及真空蒸皤去除溶劑。殘渣於氧 化矽凝膠上接受柱式層析。由使用乙酸乙酯/正己烷(1 :1 )之混合物溶離得之溶離分中獲得1.806g(100%)目 檷化合物41呈黃色固體。 IR(CHC13)cid-1 : 3022,1592,1473,1434,1 139. NMR(CDC13)5 : 2.47-2.60(2H,m,CHa),3.43(2H,t,J=7.5 Hz,CHa),4.05(2H,t.J=6.6Hz,CHa),6.88-7.02(lH,m,CH) ,7.26-7.35(lH,m,CH),7.58-7.70(lH,iH,CH),8.33(lH,d> J = 4.4Hz,CH). 製JLMll (R3 = 3-吡啶基) N- 啶某)-1 . 2-里膝邮啶-1 . 1 -二羞化物(4m) 依據製備例10所述之類似方式,3-氯丙基磺酿氯( 17.28g,41.1mmol)與 3-肢基吡啶(4.6g,49.3mmol)於 吡啶(15ml)内反應而得4. 50g (46%)粗N- (3-Bit啶基 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0X297公釐) IJ----1---丨裝------訂------泉 (請先閱讀背面之注意事項再填寫本頁) 24 A7 B7 五、 經濟、邓中央標準局員工消費合作社印製 發明説明(23 ) )-3-氯丙基磺酿胺(中間物3ra)呈無色固體。 中間物3m ( 232mg,0.988mmol) Μ類似製備例12所述 之方式使用氫化鈉(60%於油,43_5mg,1.09mmol)於DMF (5ml〉處理而得190mg (97%)目檷化合物4m呈無色固體。 IR(CHC13)cib-1 : 3022,2960,1590,1484,1428,1319,1142. NMR(CDCla)5 : 2.53-2.67(2H,m,CHa),3.38-3.45(2H,m, CHa) , 3.83(2H,t,J = 6.6Hz,CHa),7.28-7.36 (1H,m,CH),7.73 -7.79(1H, m, CH),8.41(1H,d,J = 4.6Hz,CH),8.46(lH,d,J = 2.4Hz,CH). 剪備例1 4 (R3= 4-吡啶基) N- ( 4-PH:啶某)-1 .2-里睐 _ 啶-1 . 1 -二氬仆,物(4n) 於3-氯丙基磺酿氯(3ml,24.7mmol)及4-胺基吡啶 (2.32g,24.7mo1)於 DMF (25ml)之溶液 K5 分鐘時間 藉攪拌於加冰冷郤下緩慢加入氫化納(60%於油,2. 17g ,54.3min〇l)。於501又持續攪拌30分鐘後,反應混合物 於氧化矽凝膠上接受柱式層析。由使用二氯甲烷/甲醇( 10: 1 )之混合物所得溶離分中獲得l_294g (27%)目檫 化合物4η呈黃色固體。 IRiCHCUJcm-1 : 3024,2956,1597,1504,1320,1143. NMR(CDC13)5 : 2.53-2.67(2H,m,CHa),3.43(2H>t,J=7.6 Hz,CHa),3.81(2H,t,J=6.6Hz,CH.),7.08(2H,d,J=5.4Hz, CH),8.49(2H,d,J=5.4Hz,CH). 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) I------;----L.I 裝------訂------泉 (請先閱讀背面之注意事項再填寫本頁) 25 修王 年月日 ,、 88. 8. 25 補充 Α7 Β7 五、發明説明(24 )A 7 i 'Explanation of the invention (igfSIl 3-Gaspropylsulfonium gas 1 (30.28g, 0.17mmol), 0-benzylhydroxylamine HC1 (27.3g, 0.17β · ο1), potassium sulfonate (50g, 0.36m) »Βο1) and tetrabutylammonium sulfide (about 500» g) were reacted with each other in a mixture of ft and water (1: 1) (100ml) at room temperature for 24 hours and the reaction mixture was extracted with ethyl acetate. The extract was extracted in silica Column chromatography was performed on the gel. Ethyl acetate / n-hexane (1: 4) mixture was used to dissolve the obtained fraction. 18.4 g (41%) of crude N-benzyloxy-3-aminopropylsulfonyl chloride was obtained. (Intermediate 3g) was a pale yellow oil. To a solution of the intermediate 3g (18.4g, 69.9mmol) in THF (150ml) as above was added sodium hydride (60% in oil, 2.94g, 73.4nnnol), and similar preparation The reaction was carried out in the manner described in Example 1. The product was subjected to column chromatography on a silica gel. 10.75 g (68%) mesh was obtained from the fractions obtained using a mixture of ethyl acetate / n-hexane (1: 5). 4g of hazel compound is colorless crystal. M.p. = 52-54¾ IR (CHCl3) cm-1: 3022, 2956, 1453, 1354, 1165, 1140, 1081, 1000. NMR (CDC13) 5: 2.30-2.48 (2H , m, CH2), 3.04-3.14 (2H, ni, CH8), 3.45 (2H, t, J = 6.9 Hz, CHa), 5.00 (2H > s, 0CH8), 7.30-7.45 (5H, ip, C6H,). Preparation example 8 (R3 = 4-methoxybenzyl) argon benzyl)-1.2- Lipyridine-1. 1 -Diargon servant (4h) 3-Gaspropylsulfonyl chloride 1 (17_7g, 0.1mmol), p-methoxybenzylamine (15.0g, 0.11minol) and sodium bicarbonate (8_4g, 0.1i0in〇U in a mixture of ethyl acetate (400ml) and water (40ml) at a similar paper size to the Chinese National Standard (CNS) A4 specification (210X297 mm) -2 1 _- -------: ---- L — install ------ order ------ line; one (please read the notes on the back before filling this page) Ministry of Economic Affairs Zhongli Standard Bureau Printed by the Employee Consumption Cooperative V. Description of the invention (20 Μ A7 B7 Printed by the Employees' Cooperative Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. Printed by I. The method described in Example 3 was used to obtain 19.1g (69%) of crude N- (4 -Methoxybenzyl) -3-propanylsulfonamide (intermediate 3h) showed colorless crystals (mp = 78-80 * 0). The intermediate was reacted for 3 h (ll.llg, 40bbo1) with DBU (6.6 · 1,40 »· 〇1) in benzene (150ml). The resulting mixture was treated in a manner similar to that described in Preparation Example 2 to obtain 8.89 g (92%) of the mesh hydrazone compound as crystals in 4h (B · P. = 48-51%). IR (CHC13) ci · -1: 3016.1612, 1511, 1304, 1245.1136, 1034, NMR (CDCU) 5: 2.20-2.38 (2H.a, CHe), 3.09 (2H, t, J = 6.8Hz, CHa), 3.14-3.24 (2H, m, CHa), 3.81 (3H, s, 0CH3), 4.12 (2H, s, CHa), 6.84-6.94 (2H, iB, CHa), 7.22-7.32 (4H, in, 4x Aromatic-H >. Preparation Example 9 (R3 = 3,4-dimethoxybenzyl) (3.4-dimethylformamide ¥ even) -1.2-Preferred_pyridine-1.1-diargonide (4;) 3-chloropropylsulfonyl chloride 1 (8.85g, 50m «ol), 3,4-dimethoxybenzylamine (9.0ml, 60mmol) and potassium carbonate (4.13g, 30mmol) were similar to those described in Preparation Example 2 The reaction was carried out to obtain 14.5g (94%) of crude N- (3,4-dimethoxybenzyl) -3-aminopropylsulfonamide (intermediate 3). The intermediate 3i was similar to the preparation example. Obtained compound 4i (yield: 69%) when treated in the first method. IR (CHC13) cm-1: 3018, 1516, 1307, 1262, 1225, 1155, 1138, 1027. NMR (CDC1S) 5: 2.22-2.38 (2H, m, CH〇, 3. 11 (2H, t, J = 6.7 Hz. CH »), 3.16-3.25 (2H, m, CHa), 3.88 (3H, s, 0CH3), 3.89 (this Paper size applies to China National Standards (CNS) 8 4 specifications (210 × 297 mm) 22 (Please read the precautions on the back before filling out this page)-Packing,? Τ A7 B7 5 Description of the invention (21 3H, s, CH3>, 4. 12 (2H, s, CHa), 6.79-6 · 91 < 3Η, κ, 3 × aromatic-H) Preparation Example 10 (R3 = CgH.) H -Jumou-1.2-Lipipyridine-1.1-Dihelium. Ui) 3-Gasylsulfonyl chloride 1 (1.456g, 8.23BB0l) M Cools to -20 with M for about 5 minutes To -3010, a solution of aniline (0.5 · 1, 8 · 23ϋ · 01) in pyridine (5 ml) was added dropwise. After the addition was complete, the reaction mixture was stirred at room temperature for 45 minutes. The reaction mixture was concentrated in vacuo and the residue was Column chromatography was performed on a silica gel. Using a mixture of ethyl acetate / n-hexane (1: 2), 1.683 g (88%) of N-phenyl-3-chloropropylsulfonamide ( Intermediate 3g) was a yellow oil, and M was obtained in a similar manner to that described in Preparation Example 1 to obtain compound 4j as a pale yellow solid (yield 57 96). IR (CHC13) cm-1: 3020,1598,1495,1315,1139. NMR (CDCU) 5: 2.46-2.60 (2H, m, CHa), 3.34 (3.42 (2H, m, CHa), 3.78 (2H, t, J = 6.6Hz, CH8), 7.10-7.40 (5H, m, CeHe). Preparation Example 11 (R3 = 4-Gaphenyl) N-f 4-Garong)-1.2-based spleen Pyridine-1. 1 -diargonide (4k) According to a similar method described in Preparation Example 10, 3-chloropropylsulfonyl chloride was reacted with 4-aeroaniline in pyridine to obtain N- (4-aerophenyl). -3-Gaspropylsulfonamide (intermediate 3k) (yield 93%). Intermediate 3kM was treated in a similar manner to that described in Preparation Example 2 using DBU to obtain the compound 4k (68% yield) as colorless crystals. (M_P. = 110. 5-111. 5C). IRiKBrJcm-1: 3010, 2960, 1595, 1493, 1300, 1267, 1131. NMR (CDC13) 5: 2.47-2.61 (2H, m, CHa) (3.35- 3.43 (2H, m, --------- Ί ---. LI installation ----- I order ----- quan (Please read the precautions on the back before filling this page) Economy Printed by the Consumer Standards Cooperative of the Ministry of Standards of the People's Republic of China Standards for this paper are applicable to Chinese National Standards (CNS) A4 (210 X 297 mm) -23-23 A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 22) CHS), 3.76 < 2H, t, J = 6 .4 Hz, CH >, 7. 16-7.36 (4H, m, 4x aromatic-fluorene). Clipping Example 1 2 (R3 = 2-Bttpyridyl) M- f 2-nH ·· pyridyl) -1.2- In a similar manner, pyridine-1. 1-diglyphin is unreacted. According to a similar method as described in Preparation Example 10, 3-chloropropylsulfonic acid is reacted with 2-aminopyridine to obtain N- (2-Btfc pyridyl) _3. _Chloropropylsulfonamide (Intermediate 31) is a pale yellow solid (yield 54%). The intermediate 31 (2.138 g, 9.11 mmol) was added to a solution of DMF (30 ml) under ice-cooling. Sodium chloride (60% in oil, 401 mg, 10 mmol). The resulting mixture was stirred at 851 for 30 minutes and the solvent was removed by vacuum evaporation. The residue was subjected to column chromatography on a silica gel. Ethyl acetate / hexane was used. In a fraction obtained by dissolving a mixture of alkanes (1: 1), 1.806 g (100%) of mesh 檷 compound 41 was obtained as a yellow solid. IR (CHC13) cid-1: 3022,1592,1473,1434,1 139. NMR ( CDC13) 5: 2.47-2.60 (2H, m, CHa), 3.43 (2H, t, J = 7.5 Hz, CHa), 4.05 (2H, tJ = 6.6Hz, CHa), 6.88-7.02 (lH, m, CH ), 7.26-7.35 (lH, m, CH), 7.58-7.70 (lH, iH, CH), 8.33 (lH, d > J = 4.4Hz, CH). JLMll (R3 = 3-pyridyl) N- (Pyrimidine)-1.2-2 knee knees-1. 1-two shame (4m) In a similar manner as described in Preparation 10, 3-chloropropylsulfonyl chloride (17.28 g, 41.1 mmol) and 3-limylpyridine (4.6 g, 49.3 mmol) were reacted in pyridine (15 ml) to 4.50g (46%) coarse N- (3-Bitpyridine basic paper size applies to Chinese National Standard (CNS) A4 specification (2 丨 0X297mm) IJ ---- 1 --- 丨 installation ---- --Order ------ Quan (Please read the precautions on the back before filling this page) 24 A7 B7 V. Economic and Deng Central Standards Bureau Staff Consumer Cooperatives Printed Invention Description (23)) 3-chloropropane Sulfamethoxamine (intermediate 3ra) was a colorless solid. Intermediate 3m (232mg, 0.988mmol) Μ treated in the same manner as described in Preparation Example 12 using sodium hydride (60% in oil, 43-5mg, 1.09mmol) in DMF (5ml> to give 190mg (97%) mesh compound 4m Colorless solid IR (CHC13) cib-1: 3022,2960,1590,1484,1428,1319,1142. NMR (CDCla) 5: 2.53-2.67 (2H, m, CHa), 3.38-3.45 (2H, m, CHa), 3.83 (2H, t, J = 6.6Hz, CHa), 7.28-7.36 (1H, m, CH), 7.73 -7.79 (1H, m, CH), 8.41 (1H, d, J = 4.6Hz, CH), 8.46 (lH, d, J = 2.4Hz, CH). Preparation example 1 4 (R3 = 4-pyridyl) N- (4-PH: pyrimidine)-1.2-Li favor _ pyridine- 1.1-Diarginine (4n) in 3-chloropropylsulfonyl chloride (3ml, 24.7mmol) and 4-aminopyridine (2.32g, 24.7mo1) in DMF (25ml) in K5 minutes Sodium hydride (60% in oil, 2.17g, 54.3min) was added slowly with stirring under ice cooling. After stirring for another 30 minutes at 501, the reaction mixture was subjected to column chromatography on silica gel. From the eluate obtained using a mixture of dichloromethane / methanol (10: 1), l-294g (27%) of the mesh compound 4η was obtained as a yellow solid. IRiCHCUJcm-1: 3024, 2956, 1597, 1504, 1320, 1143. NMR ( CDC 13) 5: 2.53-2.67 (2H, m, CHa), 3.43 (2H &t; t, J = 7.6 Hz, CHa), 3.81 (2H, t, J = 6.6Hz, CH.), 7.08 (2H, d, J = 5.4Hz, CH), 8.49 (2H, d, J = 5.4Hz, CH). This paper size is applicable to China National Standard (CNS) A4 specification (210X297 mm) I ------;- --LI Pack ------ Order ------ Quan (Please read the notes on the back before filling in this page) 25 Month, Month, 88. 8. 25 Supplement Α7 Β7 V. Invention Instructions (24)

MOMOMOMO

t-Bu 6 + ,n-r341 Ονο :驗t-Bu 6 +, n-r341 Ονο: check

7171

=\B 3a= \ B 3a

(E-異構物) (Z-異«ί物I) 8 . 3 經濟部中央橾準局貞工消費合作社印製 啻俐 1 ( Ra = Et) 某-s- ds-二•隹=-丁甚-4-揮甚 > gg y 甚-1 .卜 里瞜盹啶-1 . 1 -二氳化物(8an?茸(7)-思縑物fQa) 於二異丙胺(15.5*1» 110.6··ο1 )内經歷20分鐘時 間藉》拌於冰水浴中逐滴加入正丁鋰於己烷(1·6Μ» 69.5 ·1,111β·ο1)。添加完成後又持繙攪拌15分鐘且反應混 合物冷卻至-78t:接著加入ΤΗΡ(1〇〇·1) »於反應混合物 内經歴15分鐘時間接著逐滴加入Ν-乙基-1,2-異睡唑啶-1, 卜二氧化物 4a (15g,100.5ββο1) ,3,5-二-第三丁基-4- 甲氧基甲氧苯甲醛6(25g,90·5lίol)及HMPA(30Bl)於 THF (70β1 )之溶液。反應混合物於同溫又攪拌30分鐘, 溫熱至室溫,倒入冷2Ν-ΗΠ(1〇〇·1)内及K乙酸乙酯抽 取(2Χ 250·1)。乙酸乙_相以碘酸氫納稀水溶液(300 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) _ _ ---II-------裝------訂------線— (請先閱讀背面之注意事項再填寫才頁) 五 '發明説明(25 A7 B7 經濟部中央標準局員工消費合作社印製 ml)及飽和鹽水( 300ml)洗滌,Μ無水硫酸納乾燥及真 空蒸皤而去除溶劑。殘渣於氧化矽凝膠上柱式層析純化, 使用正己烷/乙酸乙酯(4 : 1至1 : 1)溶離而得21.3g ( 55%)醛醇加成化合物7a呈無色固體。 於加成化合物7a (8.5g,19·9μο1)於甲苯(150ml )之溶液内加入對-甲苯磺酸水合物(2.49g,13inmol)。 所得混合物加熱至回流歴30分鐘然後倒入磺酸氫鈉稀水溶 液(150·1)內及Μ乙酸乙酯抽取(150mlx2 )。有機層 Μ水(150»1)及飽和鹽水(150al)洗滌,Μ無水硪酸納 乾燥及真空蒸發而去除溶劑。殘渣於氧化矽凝膠上接受柱 式層析。由使用正己烷/乙酸乙酯(3:1)溶離之溶離分 中依次獲得目様化合物9a ( 376mg,70%)及8a (2.59g, 36% ) ° 化合物 8a : m. p. = 135-1371 . IRiKBrJcm-1 : 3610,3440,2970,2880,1645,1597,1430, 1290,1173,1151,1139. NMR(CDC13)S : 1.29(3H,t,J = 7.2Hz,CH3), 1.45(18H,s,2 XBut),3.07-B.19(4H>m,CH2)>3.28(2H,q(J = 7.2Hz>CHil), 5. 50(1H, s, OH),7.24-7· 26(3H, m, 2X 芳香 H, CH). 元素分析(CaDH31N03S〉 計算值:C,65.71;H,8.55;N,3.83;S,8.77 實測值:C,65· 65; H,8.43; N,3.85; S,8. 78. 化合物 9a : m. p. = 137-138¾ . IRiKBricm-1 : 3560,2975,1637,1600,1431,1289,1275, (請先閲讀背面之注意事項再填寫本頁) -裝. ,ιτ 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ 297公釐) 27 五、 發明説明(26 ) A7 B7 經濟部中央標準局員工消費合作社印製 1168,1150, 1111. NMR(CDC13)5 ; 1.26(3H,t,J=7.2Hz,CH3),1.45(18H.s, 2X Bu*),3.00(2H,dt,J=2.0,6.0Hz,CH«),3.15(2H,q,J=7.2 Hz,CHa),3.25(2H,t,J=6.0Hz,CHa),5.47(lH,s,OH),6.73( 1ΗΛ, J = 2.0Hz,CH) ,7.52(2H,s,2x 芳香-H) · 兀素分析(CaDH3iN〇3S) 計算值:C,65.71;H,8.55;N,3.83;S,8.77 實测值:C,65.68;H,8·43;N,3.61;S,8.66 ¾J@L2_ (R3 = CHa) (£)-2-甲某-5-(3.5-二-笛三丁某-4-锊)亞;某-1.?-里 1¾ _啶-1 .1 -二氣仆.物(8h)苻其(Z)-里嫌物(Qh) 依據實例1之類似方式,使用化合物6 (3.34g,12 mmol)及N-甲基-1,2-異睡唑啶-1,1-二氧化物4b (1.35g ,IOmoI)進行醛醇反應而得1.65g (40%)加成化合物 7b。於加成化合物7b (1.60g,3.87mmol)於甲苯(30b1 )之溶液内加入對甲苯磺酸水合物(160mg),及所得混 合物加熱至回流經歷30分鐘。反應產物於氧化矽凝膠上接 受柱式層析。由使用正己烷/乙酸乙酯(3:7)之混合物 溶離之溶離分中獲得目榡化合物8b ( 580mg> 43%)及9b (200mg,15% )。 化合物 8b: β.ρ.= 168-170Ό. IR(CHC13)cm-1 : 3620,2956,1435,1292,1218,1149. NMR(CDC13)5 : 1.45(18H,s,2x BuM ,2.76(3H,s,NCH3), 3.07-3.18(2H,ffl,CHi),3.20-3.32(2H>iB,CH8),5.51(lH,s, 本紙張尺度適用中國國家標隼(CNS ) Α4規格(210X 297公釐) 28 (請先閲讀背面之注意事項再填寫本頁) •案· 、τ Γ 經濟部中央標隼局員工消費合作社印掣 A7 B7 五、發明説明(27 ) 〇H),7.23-7.29 (3H,m,2x 芳香-H,CH)_ 元素分析(C13HssN03S> 計算值:C,64.92;H,8.32;N,3.98;S,9.12 賁測值:C,64.62;H,8.31;N,3.95;S,9_14· 化合物9b:ln.p.=152-163¾. IR(CHCl3)cm-1 : 3622,2956,1433,1293,1241,1160,1010. NMR(CDCU)S : 1.45(18H,s,2XBu”,2.75(3H,s,NCH3), 2.95-3.05(2H,mF CH3),3.16-3.26(2H,m,CHa),5.49(1H,s, OH〉,6.75(lH,t, J = 2.2Hz,CH) ,7.58(2H,s,2x 芳香-H) 元素分析(Ci 3H»sN〇3S) 計算值:C,64.92;H,8.32;N,3.98;S,9.12 實测值:C,64.61;H,8.29;N,3.95;S,9.07. 竇例 3 ( R3= CH,CH(CH3)2) (E)-2-M 丁某-S- (3.5-二-笛三丁甚-4-掷)西苄某-1 .2-異睥啶-1 .1-二氬仆.物 依據實例1之類似方式,使用化合物6 (2.78g,19 miB〇l)及N-異丁基-1,2-異睡唑啶-1,卜二氧化物4c (1.95g ,llmmol )進行醛醇反應獲得3.67g (81%)加成化合物 7〇 ° 此加成化合物7c (3_60g,7.9®mol)於甲苯(50重1) Μ類似實例1之方式使用對-甲苯磺酸水合物(360ng)處 理。產物於氧化矽凝膠上接受柱式層析及由使用正己烷― 乙酸乙酯(1:3)之混合物溶離之溶離分中獲得目標化合 物 8c ( 1· 30g,42% )。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 29 丨~„---^----ϊ—装-----^丨訂------線 (請先閱讀背面之注意事項再填寫本頁) 五、發明説明(28 ) A7 B7 經濟部中央標隼局員工消費合作社印製 m.p.= 167-170¾ . IR(CHCl3)cnr1 : 3620,2956, 1646, 1435, 1289, 1240, 1148, 1081. NMR(CDC13)S : 0.97(6H,d, J = 6.4Hz) , (CH3)a) , 1.45(18H, s,2x BuM,1.81-2.02(1H,b,CH),2.87(2H,d,J = 7.4Hz,CH8), 3.06-3.18(2H,m,CHa),3.22-3.33(2H,b,CHa),5.50(lH,s, 0H),7.23-7.27<3H,m,2x 芳香-H,CH). 兀素分析(CgaHaeNOaS) 計算值:C,67.14;H,8.96;N,3.56;S,8_15 實測值:C,66.85;H,8.99;N,3.58;S,8.11. 窨例4 (R3=環丙基) (E)-2-頊丙某-5- ( 3.5-二-笛二丁甚-4-锊)亞苄某-1 .2-里睐_ -1 . 1 -二筮仆.物(8H) 依據實例1之類似方式,使用化合物6 (2_67g,9.6 ββοΙ)及N-環丙基-1,2-異睡唑啶-1,1-二氧化物4d (1.29g ,8·0β·〇1)進行醛醇反應,獲得3.09g (88%)加成化合 物7d。加成化合物7d (3.0g,7«〇1)於甲苯(50ml)共 同使用對-甲笨磺酸水合物( 300mg)處理。反應產物Μ實 例3之類似方式純化而得1 · 03g ( 40% )目橒化合物8d。 a. P. = 202-204V . IRiCHClaJcm1 : 3620,2956,1434,1297,1237,1145. NMR(CDC13)5 : 0.68-0.90(4H,m,2X CHe), 1.44(18H,s,2x Bu*)2.28-2.40(1H,m,CH),3.08(2H,dt,J=2.6,6.7Hz,CH.), 3.36(2H,t,J = 6.7Hz,CHS),5.51(lH,s,OH),7.2〇-7.25 (3H, (請先閲讀背面之注意事項再填寫本頁) .裝. 訂 康彳. 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 30 經濟部中央標準局員工消費合作社印製 A7 _____________ B7 五、發明説明(29 ) m,2x 芳香-H,CH) · 元素分析(CaiH31N〇3S) 計算值:C,66.81;H,8.28;N,3.71;S,8.49 實測值:C,66.67;H,8.29;N,3.71;S,8.38. 奮例 5 ( R3 = CH2CH2CH3) (E)-2-TF·丙某-5- ( 3.5-二-笛三丁某-4-揮)昍竽某-1 .2-異瞌_啶-1 .1 -二氬化物(8e) »其(7J -里嫌物 依據實例1之類似方式,使用化合物6 (2.78g, 10 BBol)及N-正丙基-1,2-異睡唑啶-1,1-二氣化物4e (1.35g ,8.27ϋ·ο1)進行醛醇反應而得1.5g(41%)加成化合物 7e。加成化合物7e使用對-甲苯磺酸水合物( 400*g) Μ實 例1所述之類似方式處理。反應產物於氧化矽凝膠上接受 柱式層析及由使用正己烷-乙酸乙酯(1: 4 )之混合物溶 離之溶離分中獲得目標化合物8e (810mg,26%)及9e ( 120mg *3.8%) 〇 化合物 8e : m. ρ· = 181-183ΐ!. IR(CHCl3)cm-1 : 3616,2954,1435,1289,1146. NMR(CDC13) δ : 0.98(3H,t,J=7.4Hz,CH3),1.45(18H,s, 2x BuM,1.57-1.78(2H,b,CHs),2.98-3.20(4H,b,2x CHa), 3.22-3.34 (2H,m,2x CHa ) , 5 . 50 (1H , s , OH) , 7.23-7.27 (3H , m, 2x 芳香-H, CH). 元素分析(CalH33N03S) * 計算值:C,66_45;H,8_76;N,3.69;S,8.45 實測值:C,66.25;H,8.74;N,3.70;S,8.33. 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -31 - 1^---^------l· —裝-----.丨訂------線 1 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標隼局員工消費合作社印聚 Μ Β7 五、發明説明(3〇 ) 化合物 9e : m· p. = 123-124. 5^0 . IRiCHClaJcm-1 : 3622,2958,1433,1289,1164. NMR(CDCla)5 : 0.96(3H, t, J-7.4Hz,CH3),1.45{18H,s,2 x BuM, 1.55-1.72(2H,m> CHa),2.95-3.08 (4H,m(2x CHa), 3.20-3.29(2H,m,2x CHa),5.47(lH,s,OH),6.74(lH,t,J= 2.1Hz,CH),7.57(2H,s,2x 芳香-H). 窨例 6 ( R3 = 0CHa) (E)-2-甲氩-5- m-二-笛三丁甚-4-筠)凸苄某-1 .2-異 睡唑啶-1 .1-二氤>f卜.物(8Π^其(7J-里縑物(9f) 依據實例1之類似方法,使用化合物6 (5. 56g,20 Bmol)及N-甲氧-1,2-異睡唑啶-1,1-二氧化物4f (3.32g ,22mmol )進行醛醇反應而得6.89g (80%)加成化合物 。加成化合物7f ( 6.89g,16mmol)於甲苯(100ml)係 Μ實例1所述之類似方式使用對-甲笨磺酸水合物(lg) 處理。反應產物於氧化矽凝膠上接受柱式層析及由正己烷 -乙酸乙酯(6: 1)之混合物溶離之溶離分中獲得目榡化 合物 8f (2.40g,41%)及 9f ( 500mg,8.5%)。 化合物 8f : m.p. = 166-168^ . IRiCHClaJcm-1 : 3616,2952,1639,1436,1340,1240,1158, 1002. NMR(CDC13)5 : 1.45(18H,s,2x BuM ,3. ll(2H,dt, J = 2.8, 7.0Hz, CHS) , 3.66(2H,t,J = 7Hz,CHa),3.81(3H,s,0CH3),5.55 (lH,s,0H〉,7.25-7.35 (3H,m,2x 芳香-H,CH). 元素分析(C19HasN〇4S) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -32 _ ^ ^ _Γ 裝 ^--訂------^ —1 (請先閱讀背面之注意事項再填寫本頁) A7 B7 經濟部中央標隼局員工消費合作社印製 五、發明説明(31 ) 計算值:C,62.10;H,7.95;N,3.81;S, 8.72 實測值:C,61.90;H,7.88;N, 3.91;S, 8.67. 化合物9f : m.p. = 173-176Ϊ:. IR(CHCla)cn-1 : 3616,2950,1431,1341,1240,1155,1010. NMR(CDC13)5 : 1.45(18H,s,2x BuM,3. 12(2H,dt,J = 2.2, 6.8Hz,CH2),3.61(2H,t>J=6.8Hz,CHa),3.61(3H,s,0CHa), 5.49(1H,s,0H),7.01(1H,t,J = 2.2Hz,CH),7.49(2H,s, 2x 芳香-H). 元素分析(ClsHasNCUSX 〇.4HS0) 計算值:C,60.90;H,8.02;N,3.74;S,8.56 實測值:C,61.08;H,7.76;N,3.75;S,8.61. 奮例 7 ( R3= 0CHaC6He) (R)-2-苄氤甚-fi- ( 3.5-二-笛三丁某-4-辉)亞苄基-1.2-里暄_啶-1 .1 -二Μ化物(8g) 依據實例1之類似方法,使用化合物6 (15g,54 mmol)及N-苄氧-1,2-異睡唑啶-1,卜二氧化物4g (10.23g ,45iamol)進行醛醇反應而得15.5U (68%)加成化合物 7g。加成化合物 7g ( 10.21g,20_ 2mnol)於甲苯(150ml) Μ實例1所述之類似方式使用對-甲苯磺酸水合物(lg)處 理。反應產物通過小量氧化矽凝膠過濾,濾液經真空濃縮 而得 5.32g(59%)目標化合物 8g(B.P.= 134-135t:)。 IR(CHCl3>Cffl* : 3620,2956,1639,1436,1339,1241,1159· NMR(CDC13)5 : 1.44(18H,s,2X BuM,3.〇9(2H,dt,J=2.6, 6.8Hz,CH.),3.58(2H,t,J = 6.8Hz,CHil),5.02(2H,s>0CHa)> 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 33 I-^---Λ--l-L —裝-----——訂------線 1 (請先閲讀背面之注意事項再填寫本頁) 五、 A7 B7 發明説明(32 ) 5. 53(1 H,s,OH) ,7.25-7.45 (8H,m,7x 芳香-H.CH) 元素分析(CaeH33N〇4S> 計算值:C,67.69;H,7.50;N,3_16;S,7.23 實測值:C,67.52;H,7·59;N,3.18;S,7·16 實J@LS_ (R3 = 4-甲氧苄基) -笛二丁某-4-辉)亞 苄甚-1.2-里__腚-1.1-二氬化物(8h)苻其(Ζ)-異構物 (9h) 依據實例1之類似方法,使用化合物6 (9g,32M〇l )及N- (4-甲氧苄基-1,2-異睡唑啶-1,卜二氧化物4h( 7.24g,30miB〇l)進行醛醇反應而得13.61g (84%>加成 化合物7h。加成化合物7h ( 12.6g,24.2β·ο1)於甲苯( 150ml) Μ實例1之類似方式使用對-甲苯磺酸水合物( 1.3g)處理而得8.83g目檫化合物8h及9h之混合物。(E-isomer) (Z- 异 «ί 物 I) 8. 3 Printed by Zhengong Consumer Cooperative of the Central Bureau of Quasi-Ministry of Economic Affairs 1 (Ra = Et) --s- ds- 二 • 隹 =- Ding Qi-4-Wuqian > gg y QI-1. Brillidin-1. 1-dihydrazone (8an? (7) -threate fQa) in diisopropylamine (15.5 * 1 » 110.6 ·· ο1) After 20 minutes, add n-butyllithium to hexane (1.6M »69.5 · 1, 111β · ο1) dropwise in an ice-water bath. After the addition was complete, the mixture was stirred for 15 minutes and the reaction mixture was cooled to -78t: TTP (100 · 1) was then added. »In the reaction mixture, N-ethyl-1,2-iso was added dropwise over a period of 15 minutes. Doxazolyl-1, dioxane 4a (15g, 100.5ββο1), 3,5-di-tert-butyl-4-methoxymethoxybenzaldehyde 6 (25g, 90 · 5lίol) and HMPA (30Bl ) In THF (70β1). The reaction mixture was stirred for another 30 minutes at the same temperature, warmed to room temperature, poured into cold 2N-ΗΠ (100 · 1) and extracted with K ethyl acetate (2 × 250 · 1). Ethyl acetate _ phase is diluted with aqueous hydrogen iodate solution (300 paper sizes are applicable to Chinese National Standard (CNS) A4 specifications (210 × 297 mm) _ _ --- II ------- packing ------ Order ------ line-(Please read the notes on the back before filling in the page) 5 'Invention description (25 A7 B7 printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs, printed by ml) and saturated saline (300ml) washed, Μ anhydrous sodium sulfate was dried and evaporated under vacuum to remove the solvent. The residue was purified by column chromatography on silica gel using n-hexane / ethyl acetate (4: 1 to 1: 1) to obtain 21.3g (55% ) Aldol addition compound 7a is a colorless solid. To a solution of addition compound 7a (8.5 g, 19.9 μ1) in toluene (150 ml) was added p-toluenesulfonic acid hydrate (2.49 g, 13 inmol). The resulting mixture was heated The mixture was refluxed for 30 minutes, then poured into a dilute aqueous solution of sodium hydrogen sulfonate (150 · 1) and extracted with ethyl acetate (150 ml x 2). The organic layer was washed with water (150 »1) and saturated brine (150al), and dried without water. The solvent was removed by sodium sulfate drying and vacuum evaporation. The residue was subjected to column chromatography on silica gel. By using n-hexane / ethyl acetate (3: 1) In the dissociation fraction, the compound 9a (376mg, 70%) and 8a (2.59g, 36%) were sequentially obtained. Compound 8a: mp = 135-1371. IRiKBrJcm-1: 3610, 3440, 2970 , 2880,1645,1597,1430, 1290,1173,1151,1139. NMR (CDC13) S: 1.29 (3H, t, J = 7.2Hz, CH3), 1.45 (18H, s, 2 XBut), 3.07-B .19 (4H > m, CH2) > 3.28 (2H, q (J = 7.2Hz > CHil), 5.50 (1H, s, OH), 7.24-7 · 26 (3H, m, 2X aromatic H, CH). Elemental analysis (CaDH31N03S> Calculated: C, 65.71; H, 8.55; N, 3.83; S, 8.77 Found: C, 65 · 65; H, 8.43; N, 3.85; S, 8. 78. Compound 9a: mp = 137-138¾. IRiKBricm-1: 3560,2975,1637,1600,1431,1289,1275, (Please read the precautions on the back before filling this page) -Packing. Standard (CNS) A4 specification (210 × 297 mm) 27 V. Invention description (26) A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 1168,1150, 1111. NMR (CDC13) 5; 1.26 (3H, t, J = 7.2Hz, CH3), 1.45 (18H.s, 2X Bu *), 3.00 (2H, dt, J = 2.0,6.0Hz, CH «), 3.15 (2H, q, J = 7.2 Hz, CHa), 3.25 (2H, t, J = 6.0Hz, CHa), 5.47 (lH, s, OH), 6.73 (1Η , J = 2.0Hz, CH), 7.52 (2H, s, 2x aromatic-H) · Wood element analysis (CaDH3iN〇3S) Calculated value: C, 65.71; H, 8.55; N, 3.83; S, 8.77 found : C, 65.68; H, 8.43; N, 3.61; S, 8.66 ¾J @ L2_ (R3 = CHa) (£) -2- 甲某 -5- (3.5- 二-笛 三 丁某 -4- 锊) Ya; -1.?-Li 1¾ _pyridine-1. 1-Diqifu. (8h) 苻 (Z) -Li suspect (Qh) In a similar manner as in Example 1, compound 6 (3.34 g, 12 mmol) and N-methyl-1,2-isopropazolidine-1,1-dioxide 4b (1.35 g, 10 moI) were subjected to aldol reaction to obtain 1.65 g (40%) of addition compound 7b . To a solution of the addition compound 7b (1.60 g, 3.87 mmol) in toluene (30b1) was added p-toluenesulfonic acid hydrate (160 mg), and the resulting mixture was heated to reflux for 30 minutes. The reaction products were subjected to column chromatography on a silica gel. From the fractions eluted with a mixture of n-hexane / ethyl acetate (3: 7), mesh 8b (580 mg > 43%) and 9b (200 mg, 15%) were obtained. Compound 8b: β.ρ. = 168-170Ό. IR (CHC13) cm-1: 3620, 2956, 1435, 1292, 1218, 1149. NMR (CDC13) 5: 1.45 (18H, s, 2x BuM, 2.76 (3H , s, NCH3), 3.07-3.18 (2H, ffl, CHi), 3.20-3.32 (2H > iB, CH8), 5.51 (lH, s, This paper size applies to China National Standard (CNS) Α4 size (210X 297 (Mm) 28 (please read the notes on the back before filling this page) • Case · τ Γ Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs A7 B7 V. Invention Description (27) 〇H), 7.23-7.29 (3H, m, 2x aromatic-H, CH) _ Elemental analysis (C13HssN03S > Calculated value: C, 64.92; H, 8.32; N, 3.98; S, 9.12 贲 Estimated value: C, 64.62; H, 8.31; N, 3.95; S, 9-14. Compound 9b: ln.p. = 152-163¾. IR (CHCl3) cm-1: 3622,2956,1433,1293,1241,1160,1010. NMR (CDCU) S: 1.45 (18H, s, 2XBu ", 2.75 (3H, s, NCH3), 2.95-3.05 (2H, mF CH3), 3.16-3.26 (2H, m, CHa), 5.49 (1H, s, OH>, 6.75 (lH, t, J = 2.2Hz, CH), 7.58 (2H, s, 2x aromatic-H) Elemental analysis (Ci 3H »sN〇3S) Calculated value: C, 64.92; H, 8.32; N, 3.98; S, 9.12 Measured value : C, 64.61; H, 8.29; N, 3.95; S, 9.07. Sinus Example 3 (R3 = CH, CH (CH3) 2) (E) -2-M Ding -S- (3.5-di-ditributane-4-throw) cebenzyl-1. 2-isopyridine-1.1-diargon. In a similar manner as in Example 1, compound 6 (2.78 g, 19 miB0l) and N-isobutyl-1,2-isopropazolidine-1, dioxane 4c (1.95 g, 11 mmol) were subjected to aldol reaction to obtain 3.67 g (81%) of an addition compound 70 ° This addition compound 7c (3-60 g, 7.9 mol) was treated with toluene (50 weight 1) in a manner similar to Example 1 using p-toluenesulfonic acid hydrate (360ng). The product was subjected to a column on a silica gel The target compound 8c (1.30 g, 42%) was obtained from the fractions obtained by the chromatographic chromatography and the dissociation using a mixture of n-hexane-ethyl acetate (1: 3). This paper size applies to Chinese National Standard (CNS) A4 specification (210X 297 mm) 29 丨 ~ „--- ^ ---- ϊ— 装 ----- ^ 丨 Order ------ line (please (Please read the notes on the back before filling this page) V. Description of the invention (28) A7 B7 Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs mp = 167-170¾. IR (CHCl3) cnr1: 3620,2956, 1646, 1435 , 1289, 1240, 1148, 1081. NMR (CDC13) S: 0.97 (6H, d, J = 6.4Hz), (CH3) a), 1.45 (18H, s, 2x BuM, 1.81-2.02 (1H, b, CH), 2.87 (2H, d, J = 7.4Hz, CH8), 3.06-3.18 (2H, m, CHa), 3.22-3.33 (2H, b, CHa), 5.50 (lH, s, 0H), 7.23- 7.27 < 3H, m, 2x aromatic-H, CH). Analysis by CgaHaeNOaS: C, 67.14; H, 8.96; N, 3.56; S, 8_15 Found: C, 66.85; H, 8.99; N, 3.58; S, 8.11. 窨 Example 4 (R3 = cyclopropyl) (E) -2- 顼 propylm-5- (3.5-di-didibutan-4- 锊) benzylidene-1. 2-Li Fa _ -1. 1-Dioxin. (8H) In a similar manner to Example 1, using compound 6 (2_67g, 9.6 ββοΙ) and N-cyclopropyl-1,2-isopropazol- 1,1-dioxide 4d (1.29g, 8.0β · 〇1) was subjected to aldol reaction to obtain 3.09g (88%) of addition compound 7d. 7d (3.0g, 7 «〇1) was co-treated with toluene (50ml) using p-toluenesulfonic acid hydrate (300mg). The reaction product M was purified in a similar manner to Example 3 to obtain 1.03g (40%) mesh. Compound 8d. A. P. = 202-204V. IRiCHClaJcm1: 3620, 2956, 1434, 1297, 1237, 1145. NMR (CDC13) 5: 0.68-0.90 (4H, m, 2X CHe), 1.44 (18H, s, 2x Bu *) 2.28-2.40 (1H, m, CH), 3.08 (2H, dt, J = 2.6,6.7Hz, CH.), 3.36 (2H, t, J = 6.7Hz, CHS), 5.51 (lH, s, OH), 7.2〇-7.25 (3H, (Please read the precautions on the back before filling this page). Packing. Ordering Kang. This paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) 30 Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs A7 _____________ B7 V. Description of the invention (29) m, 2x aromatic-H, CH) · Elemental analysis (CaiH31N〇3S) Calculated value: C, 66.81; H, 8.28; N, 3.71; S, 8.49 Found: C, 66.67; H, 8.29; N, 3.71; S, 8.38. Example 5 (R3 = CH2CH2CH3) (E) -2-TF · Bingmou-5- (3.5- 二- Di Sanding Mou-4-Wu) 昍 竽 Mou -1.2-Isopyridine-1.1-Diargonide (8e) »Its (7J-Li suspected in a similar manner to Example 1, using compound 6 (2. (78g, 10 BBol) and N-n-propyl-1,2-isopropazolidine-1,1-digas 4e (1.35g, 8.27ϋ · ο1) were subjected to aldol reaction to obtain 1.5g (41%) Addition compound 7e. Addition compound 7e was treated in a similar manner as described in Example 1 using p-toluenesulfonic acid hydrate (400 * g). The reaction product was subjected to column chromatography on a silica gel and the target compound 8e (810mg, 26%) and 9e (120mg * 3.8) were obtained from the fractions obtained by dissolving using a mixture of n-hexane-ethyl acetate (1: 4). %) 〇 Compound 8e: m. Ρ · = 181-183ΐ !. IR (CHCl3) cm-1: 3616,2954,1435,1289,1146. NMR (CDC13) δ: 0.98 (3H, t, J = 7.4Hz , CH3), 1.45 (18H, s, 2x BuM, 1.57-1.78 (2H, b, CHs), 2.98-3.20 (4H, b, 2x CHa), 3.22-3.34 (2H, m, 2x CHa), 5. 50 (1H, s, OH), 7.23-7.27 (3H, m, 2x aromatic-H, CH). Elemental analysis (CalH33N03S) * Calculated: C, 66_45; H, 8_76; N, 3.69; S, 8.45 Measured Value: C, 66.25; H, 8.74; N, 3.70; S, 8.33. This paper size applies to China National Standard (CNS) A4 specification (210X 297 mm) -31-1 ^ --- ^ ----- -l · —Installation -----. 丨 Order ------ Line 1 (Please read the notes on the back before filling this page) Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs Β7 Ⅴ. Invention Explanation (3〇) Compound 9e: m · p. = 123-124. 5 ^ 0. IRiCHClaJcm-1: 3622, 2958, 1433, 1289, 1164. NMR (CDCla) 5: 0.96 (3H, t, J-7.4 Hz, CH3), 1.45 (18H, s, 2 x BuM, 1.55-1.72 (2H, m & g t; CHa), 2.95-3.08 (4H, m (2x CHa), 3.20-3.29 (2H, m, 2x CHa), 5.47 (lH, s, OH), 6.74 (lH, t, J = 2.1Hz, CH ), 7.57 (2H, s, 2x aromatic-H). Example 6 (R3 = 0CHa) (E) -2-methylargon-5-m-di-ditributane-4--4-) 1.2-Isoprazole-1.1-Difluorene > f. (8Π ^ qi (7J-Liquid (9f)) According to a similar method to Example 1, compound 6 (5. 56g, 20 Bmol) and N-methoxy-1,2-isoazosin-1,1-dioxide 4f (3.32 g, 22 mmol) were subjected to aldol reaction to obtain 6.89 g (80%) of an addition compound. Addition compound 7f (6.89 g, 16 mmol) in toluene (100 ml) was treated in a similar manner as described in Example 1 with p-toluenesulfonic acid hydrate (lg). The reaction product was subjected to column chromatography on silica gel and the fractions obtained by dissolving from a mixture of n-hexane-ethyl acetate (6: 1) to obtain the compound 8f (2.40g, 41%) and 9f (500mg, 8.5%). Compound 8f: mp = 166-168 ^. IRiCHClaJcm-1: 3616,2952,1639,1436,1340,1240,1158, 1002. NMR (CDC13) 5: 1.45 (18H, s, 2x BuM, 3.11 (2H , dt, J = 2.8, 7.0Hz, CHS), 3.66 (2H, t, J = 7Hz, CHa), 3.81 (3H, s, 0CH3), 5.55 (lH, s, 0H>, 7.25-7.35 (3H, m, 2x aromatic-H, CH). Elemental analysis (C19HasN〇4S) This paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) -32 _ ^ ^ _ ^ ^ --- order ----- -^ —1 (Please read the notes on the back before filling out this page) A7 B7 Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 5. Description of the invention (31) Calculated value: C, 62.10; H, 7.95; N, 3.81; S, 8.72 Found: C, 61.90; H, 7.88; N, 3.91; S, 8.67. Compound 9f: mp = 173-176Ϊ:. IR (CHCla) cn-1: 3616, 2950, 1431, 1341, 1240,1155,1010. NMR (CDC13) 5: 1.45 (18H, s, 2x BuM, 3.12 (2H, dt, J = 2.2, 6.8Hz, CH2), 3.61 (2H, t > J = 6.8Hz, CHa), 3.61 (3H, s, 0CHa), 5.49 (1H, s, 0H), 7.01 (1H, t, J = 2.2Hz, CH), 7.49 (2H, s, 2x aromatic-H). Elemental analysis ( ClsHasNCUSX 〇.4HS0) Calculated value: C, 60.90; H, 8.02; N, 3.74; S, 8.56 Found: C, 61.08; H, 7.76; N, 3.75; S, 8.61. Fen example 7 (R3 = 0CHaC6He) (R) -2-benzylsulfonium-fi- (3.5-di-ditributane-4-fluorene) benzylidene-1.2-lipidin -1.1-Dimethyl compound (8g) According to a similar method to that in Example 1, using compound 6 (15g, 54 mmol) and N-benzyloxy-1,2-isosleepazidine-1, 4 g of dioxane ( 10.23 g (45 iamol) were subjected to aldol reaction to obtain 15.5 U (68%) of the addition compound 7 g. The addition compound 7 g (10.21 g, 20 — 2mnol) in toluene (150 ml) was used in a similar manner as described in Example 1 using p-toluene. Treatment with sulfonic acid hydrate (lg). The reaction product was filtered through a small amount of silica gel, and the filtrate was concentrated in vacuo to obtain 5.32 g (59%) of the target compound 8 g (B.P. = 134-135t :). IR (CHCl3> Cffl *: 3620, 2956, 1639, 1436, 1339, 1241, 1159 · NMR (CDC13) 5: 1.44 (18H, s, 2X BuM, 3.09 (2H, dt, J = 2.6, 6.8 Hz, CH.), 3.58 (2H, t, J = 6.8Hz, CHil), 5.02 (2H, s > 0CHa) > This paper size applies Chinese National Standard (CNS) A4 specification (210X297 mm) 33 I- ^ --- Λ--lL --------------- Order ------ line 1 (Please read the precautions on the back before filling out this page) V. A7 B7 Description of Invention (32) 5. 53 (1 H, s, OH), 7.25-7.45 (8H, m, 7x aromatic-H.CH) Elemental analysis (CaeH33N04S > Calculated value: C, 67.69; H, 7.50; N, 3_16; S, 7.23 Found: C, 67.52; H, 7.59; N, 3.18; S, 7.16. Real J @ LS_ (R3 = 4-methoxybenzyl) -Didibutan-4-fluorene) Benzylidene- 1.2-Li__ 腚 -1.1-Diargonide (8h) 苻 Its (Z) -isomer (9h) Following a procedure similar to Example 1, compound 6 (9g, 32MOL) and N- (4- Methoxybenzyl-1,2-isoprazidine-1, dioxane 4h (7.24g, 30miB0l) was subjected to aldol reaction to obtain 13.61g (84%) of addition compound 7h. Addition compound 7h (12.6g, 24.2β · ο1) in toluene (150ml) in a similar manner to Example 1 using p-toluenesulfonic acid hydrate (1.3 g) was processed to obtain 8.83 g of a mixture of mesh hydrazone compounds 8h and 9h.

奮例9 (113=3,4-二甲氧苄基) ( .V/1-二田氩 ¥ 某)-5- ( H -笛三丁某-4-筠 (請先閲讀背面之注意事項再填寫本頁) 裝· 訂. -泉_ 經濟部中央標隼局員工消費合作社印製 )西午某-1.?-埋臃睥啶-K1-二氣仆.物(8i)及其(Z)-異 嫌物(9i) 依據實例1之類似方法,使用化合物6 (5.6g,20 mmol)及N- (3,4-二甲氧苄基)-1,2-異埵唑啶-1,1-二 氧化物4i (5.85g,21.6mmol)進行醛醇反應而得9.25g ( 78%)加成化合物7i。加成化合物7i (4g,7.3mmol) Μ 實例1所述之類似方式進行脫水及脫去保護反應獲得目棲 化合物8i與9i (2.5g)。 34 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇Χ297公釐) A7 B7 經濟部中央標率局員工消費合作社印製 五、發明説明(33 )例10 (R3 = CeH») 芏某-5- (3.5-二-第三丁某-4-镡1亞免基 ny _腚-1 · 1 -二氲仆物(8.i)及其(Z)-里嫌物(9」lI 依據實例1之類似方法,使用化合物6 (2.47g,8· 88 mmol)及N-苯基-1,2-異噻唑啶-1,1-二氧化物4j (2.19g ,ll.lOmmol )進行醛醇反應而得3_184g (75%)加成化 合物7j。加成化合物Ή ( 3. 184g,6.69mmol)於甲苯(1〇〇 ml)使用對-甲苯磺酸水合物( 750ml)處理而得目標化合 物 8j ( 667ng,24%)及 (llOmg,4%)。化合物8_]:1^?.= 195-196<0· IR(KBr)cm-1 : 3560,3520,2960,1636,1593,1492,1430, 1295, 1268,1105,1092. NMR(CDC13)(5 : 1. 47 (18H , s , 2 x Bu*) , 3.31 (2H , dt, J = 2.6 , 6.6Hz,CH.),B.80(2H,t,J-6.6Hz,CHa),5.54(lH,s,0H), 7.17-7.26(111,111,芳香-11,(^〉,7.29(2[1,3,2父芳香-}〇,7.38 -7.42(4H,m,4x 芳香-Η).元素分析(C»«H3iN〇4SX 0 1H20>計算值:C,69.39;H,7.61;N,3.37;S,7.72 實測值:(:,69.27;11,7.60;13_39;5,7.61· ^(KBrJcm-1 : 3540,2960,1629,1598,1503,1435,1305, 1255,1140,1118. NMR(CDC13)5 : 1.44(18H,s,2X BuM,3. 17(2H,dt,J-2.0, 6.2Hz,CHa),3.77(2H,t,J = 6.2Hz,CHs),5.49( lH(s,OH), 6.84(lH,t, J = 2.0Hz,CH)7· 18-7.40(5H,m,5x 芳香-H) ,7.59 (請先閲讀背面之注意事項再填寫本頁) 裝 訂- .泉 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 35 五、發明説明(34Example 9 (113 = 3,4-Dimethoxybenzyl) (.V / 1-Nitrogen Argon ¥ Sodium) -5- (H -Disanbutane-4- 筠 (Please read the precautions on the back first (Fill in this page again) Binding and binding. -Quan _ Printed by the Staff Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. Z) -Isomer (9i) According to a similar method to Example 1, using compound 6 (5.6 g, 20 mmol) and N- (3,4-dimethoxybenzyl) -1,2-isoxazolidine- 1,1-dioxide 4i (5.85 g, 21.6 mmol) was subjected to aldol reaction to obtain 9.25 g (78%) of addition compound 7i. Addition compound 7i (4 g, 7.3 mmol) M was subjected to dehydration and deprotection in a similar manner as described in Example 1 to obtain the eye-dwelling compounds 8i and 9i (2.5 g). 34 This paper size applies Chinese National Standard (CNS) A4 specification (21 × 297 mm) A7 B7 Printed by the Staff Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (33) Example 10 (R3 = CeH ») -5- (3.5-Second-Third Ding-Mou-4- 亚 1 Alkyl ny _ 腚 -1 · 1-Second-Serve (8.i) and Its (Z) -Li Suspect (9 "lI According to a similar method to Example 1, using compound 6 (2.47 g, 8.88 mmol) and N-phenyl-1,2-isothiazolidine-1,1-dioxide 4j (2.19 g, 11.10 mmol) Aldol reaction gave 3-184 g (75%) of addition compound 7j. Addition compound Ή (3.184 g, 6.69 mmol) in toluene (100 ml) was treated with p-toluenesulfonic acid hydrate (750 ml) to obtain the target. Compound 8j (667ng, 24%) and (110mg, 4%). Compound 8 _]: 1 ^?. = 195-196 < · IR (KBr) cm-1: 3560,3520, 2960,1636,1593,1492 , 1430, 1295, 1268,1105,1092. NMR (CDC13) (5: 1. 47 (18H, s, 2 x Bu *), 3.31 (2H, dt, J = 2.6, 6.6Hz, CH.), B .80 (2H, t, J-6.6Hz, CHa), 5.54 (lH, s, 0H), 7.17-7.26 (111,111, aromatic-11, (^>, 7.29 (2 [1,3,2 parent Aromatic-} 〇, 7.38 -7.42 (4H, m, 4x aromatic-fluorene). Elemental analysis C »« H3iN〇4SX 0 1H20 > Calculated value: C, 69.39; H, 7.61; N, 3.37; S, 7.72 Found: (:, 69.27; 11, 7.60; 13_39; 5, 7.61 · ^ (KBrJcm-1 : 3540, 2960, 1629, 1598, 1503, 1435, 1305, 1255, 1140, 1118. NMR (CDC13) 5: 1.44 (18H, s, 2X BuM, 3.17 (2H, dt, J-2.0, 6.2Hz , CHa), 3.77 (2H, t, J = 6.2Hz, CHs), 5.49 (lH (s, OH), 6.84 (lH, t, J = 2.0Hz, CH) 7.18-7.40 (5H, m, 5x Aromatic-H), 7.59 (Please read the notes on the back before filling this page) Binding-. The size of the original paper is applicable to the Chinese National Standard (CNS) A4 (210X 297 mm) 35 5. Description of the invention (34

A7 B7 (2 Η ’ s,2 X 芳香〜μ) 元素分析((^4ΐι3ιΝ〇35Χ〇>1Η8〇) 計算值:C,69.39;H,7.61;N,3.37;S,7.72 實測值:C,69.28;H,7.56;N,3.39;S,7.69. 蓳^丄(Ra=4~氯苯基) U二( 3.5_二-笛三 丁某-r痺)砟午某-U2-異唾唑_^二1.卜二氛仆.物(8k)好其(z)_里嫌物(9k) 依據實例1之類似方法,使用化合物6 (2.25g,8.09 mmol)及N- (4-氯苯基)-1,2-異睡唑啶-1,1-二氧化物 4k (2.34g,l〇.lmmol)進行醛醇反應而得 2.54g (62%) 加成化合物7k。加成化合物7k (2.53g,4.96πηη〇1)於甲 苯(70ml)使用對-甲苯磺酸水合物( 250mg)處理而得目 檫化合物 8k (859mg,39%)及 9k (263mg,12%)。 化合物 8k : m. p. = 245-246C . IRiKBricm-1 : 3560,3960,1644,1592,1491,1430,1280, 1105,1090. NMR(CDC13)§ : 1.46(18H,s,2x BuM,3.30(2H,dt,J=2.6, 6.6Hz,CHa),3.76(2H,t,J=6.6Hz,CHa),5.55(lH,s,0H), 7.28(213,芳香-1〇,7.26-7.40(511,〇1,4父芳香-{1,(:}1)· 元素分析(Ca4H3DN〇3SCl > 計算值:C,64.34;H,6_75;N,3.13;S,7.16;C1,7.91 實測值:C,6459;H,6·78;N,3·28;S,7·17;Cl,7.87· 化合物91<:ffl.P·=207-209cC. IRiKBricm-1 : 3540,2955,1635,1595,1494,1432,1300, - ---------—裝------丨訂------泉{ (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印策 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -36 - 36A7 B7 (2 Η 's, 2 X aromatic ~ μ) Elemental analysis ((^ 4ΐι3ιΝ〇35Χ〇 > 1Η80)) Calculated value: C, 69.39; H, 7.61; N, 3.37; S, 7.72 Found: C , 69.28; H, 7.56; N, 3.39; S, 7.69. 蓳 ^ 丄 (Ra = 4 ~ chlorophenyl) U di (3.5_di-ditributyrate-r bi) Wuwu-U2-isosia Azole ^ 1. 1. erbium (8k) is good (z) _ susceptible (9k) According to a similar method to Example 1, using compound 6 (2.25g, 8.09 mmol) and N- (4- Chlorophenyl) -1,2-isoprazidine-1,1-dioxide 4k (2.34 g, 10.1 mmol) was subjected to aldol reaction to obtain 2.54 g (62%) of addition compound 7k. Addition Compound 7k (2.53g, 4.96πηη〇1) was treated in toluene (70ml) with p-toluenesulfonic acid hydrate (250mg) to obtain the compound 8k (859mg, 39%) and 9k (263mg, 12%). 8k: mp = 245-246C. IRiKBricm-1: 3560,3960,1644,1592,1491,1430,1280, 1105,1090. NMR (CDC13) §: 1.46 (18H, s, 2x BuM, 3.30 (2H, dt , J = 2.6, 6.6Hz, CHa), 3.76 (2H, t, J = 6.6Hz, CHa), 5.55 (lH, s, 0H), 7.28 (213, aromatic-10, 7.26-7.40 (511, 〇 1,4 parent aroma- {1, (:} 1) · Elemental analysis (Ca4H3DN〇3SCl > Calculated value: C, 6 4.34; H, 6_75; N, 3.13; S, 7.16; C1,7.91 Found: C, 6459; H, 6 · 78; N, 3 · 28; S, 7 · 17; Cl, 7.87 · Compound 91 <: ffl.P · = 207-209cC. IRiKBricm-1: 3540, 2955, 1635, 1595, 1494, 1432, 1300,------------------------ Order-- --- Quan {(Please read the notes on the back before filling out this page) Printing policy of Employees' Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs This paper size applies Chinese National Standard (CNS) A4 (210X 297 mm) -36-36

經濟部中央標準局員工消費合作社印I A7 _B7 _ 五、發明説明(35 ) 1270,1130. NMR(CDC13)5 : 1. 44 (18H, s, 2X Bu*) , 3. 17(2H, dt, J = 2.0, 6.4Hz, CHa),3.73(2H,t,J = 6.4Hz,CH*),5.51 (1H,s,OH), 6.86(lH,t, J = 2.0Hz,CH>,7.34(4H,s,4x 芳香-H) ,7.57( 2H,s,2x 芳香-H). 元素分析(Ca4H3DN03SCl) 計算值:C,64.34;H,6.75:N,3.13;S,7.16;CI,7.91 實測值:C,6414;H,6_80;N,3.23;S,706;C1,7.95 宣J@L1^ (R3= 2-吡啶基) ^)-2-(2-卅啶甚)-5-(3.5-二-第三丁某-4-筠)西竽甚-1.2-里噱邮啶-1.1-二氪化物(8Π好其(7.)-蛊嫌物(Q Π 依據實例1之類似方法,使用化合物6 ( 208mg,0.75 mmol)及N- (2-Ptt啶基)-1,2-異睡唑啶-1,卜二氧化物 (41) (149mg,〇_75mmol)進行醛醇反應獲得 233iog (65% )加成化合物71。加成化合物71 ( 231g,0.485nunol>於 甲苯(5ml)係使用對-甲苯磺酸水合物(60ng)處理而得 目檫化合物81 (96mg,48%)及 91 (19mg, 9%)。 化合物 81 : m. p. = 177-179^0 . IMKBrUnr1 : 3570,2960,1646,1600,1587,1472,1431, 1300,1105,1085. NMR(CDC13)5 : 1.47(18H,s,2x BuM,3.31(2H,dt,J=2.4, 6.8Hz,CHa),4.08(2H,t,J = 6.8Hz,CHa),5.55(1H,s,OH), 6.99-7.05(lH,m,CH>,7.28(2H,s,2x 芳香-H),7.38(lH,t, J=2.4Hz,Py-H),7.55-7.74(2H,m,2x Py-H),8.33-8.36(1H, 1J---J----l·I裝-----.——訂.------泉 (請先閲讀背面之注意事項再填寫本頁) 五、發明説明(36 ) A7 B7 經濟部中央標準局員工消費合作社印製 m,Py-H). 元素分析(Ca3H3eNa〇3S) 計算值:C,66.63;H,7.29;N,6.76;S,7.73 實測值:C, 66.31; H,7.30;N,6.72;S,7.66. 化合物 91 : m. p. = 198-199C . IRiKBrJcm-1 : 3550,2960,1626,1594,1570,1470,1429, 1312,1302,1272,1140,1115. NMR(CDC13)5 : 1.46(18H,s,2x BuM,3.16(2H,dt,J=2.0, 6.6Hz,CHa),4.〇6(2H,t,J-6.6Hz,CHa),5.51(lH,s,0H), 6.87(1H,t,J=2.0Hz,CH),6.96-7.04(1H,m,Py-H),7.58( 2H,s,2x 芳香-H) ,7.54-7.73 <2H,b,2x Py-H) ,8.32-8.37 (1H,m,Py-H). 兀素分析(Ca3H3DN*〇3S) 計算值:C,66.63;H,7.29;N,6.76;S,7.73 實測值:C,66.40;H,7.23;N,6.71;S,7.53. 奮例13 (R3= 3-吡啶基) “)-2-(34吐啶基)-5-(3.5-二-筮三丁某-4-筠)55¥甚-1.2-異睡睐啶-1.1-二氛仆.物fRm、 依據實例1之類似方法,使用化合物6 ( 1.474g, 5_30mmol)及N-(3_吡啶基)-1,2-異鳴唑啶-1,1 氧 化物4m (l.〇51g,5·30βι»〇1)進行醛醇反應而得1.522g ( 60%)加成化合物7m。加成化合物7m( 1.522g,3.19Bmol )於甲苯(40ml)使用對-甲苯磺酸水合物( 400mg)處理 而得358Bg (27%)目檫化合物8·。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公瘦) 38 (請先閲讀背面之注意事項再填寫本頁) t[ A7Printed by the Consumers' Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs I A7 _B7 _ V. Description of Invention (35) 1270,1130. NMR (CDC13) 5: 1. 44 (18H, s, 2X Bu *), 3. 17 (2H, dt , J = 2.0, 6.4Hz, CHa), 3.73 (2H, t, J = 6.4Hz, CH *), 5.51 (1H, s, OH), 6.86 (lH, t, J = 2.0Hz, CH >, 7.34 (4H, s, 4x aromatic-H), 7.57 (2H, s, 2x aromatic-H). Elemental analysis (Ca4H3DN03SCl) Calculated value: C, 64.34; H, 6.75: N, 3.13; S, 7.16; CI, 7.91 Found: C, 6414; H, 6_80; N, 3.23; S, 706; C1, 7.95 XJ @ L1 ^ (R3 = 2-pyridyl) ^)-2- (2-pyridine and even) -5- (3.5-Second-Third Ding-Mou-4- 筠) Xishenxi-1.2-Lizhi Postidine-1.1-Difluoride (8Π 好 其 (7.)-蛊 suspect (Q Π similar to Example 1 Method: Compound 6 (208 mg, 0.75 mmol) and N- (2-Pttimidinyl) -1,2-isosleepazolidine-1, butadioxide (41) (149 mg, 0-75 mmol) were used for aldol The reaction yielded 233iog (65%) of addition compound 71. Addition compound 71 (231g, 0.485nunol) was treated with p-toluenesulfonic acid hydrate (60ng) in toluene (5ml) to obtain the head compound 81 (96mg, 48 %) And 91 (19 mg, 9%). Compound 81: mp = 177-179 ^ 0. I MKBrUnr1: 3570,2960,1646,1600,1587,1472,1431, 1300,1105,1085. NMR (CDC13) 5: 1.47 (18H, s, 2x BuM, 3.31 (2H, dt, J = 2.4, 6.8Hz, CHa), 4.08 (2H, t, J = 6.8Hz, CHa), 5.55 (1H, s, OH), 6.99-7.05 (lH, m, CH >, 7.28 (2H, s, 2x aromatic-H), 7.38 (lH, t, J = 2.4Hz, Py-H), 7.55-7.74 (2H, m, 2x Py-H), 8.33-8.36 (1H, 1J --- J ---- l · I-- ---.—— Order .------ Quan (Please read the notes on the back before filling out this page) V. Description of invention (36) A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs m, Py -H). Elemental analysis (Ca3H3eNa〇3S) Calculated: C, 66.63; H, 7.29; N, 6.76; S, 7.73 Found: C, 66.31; H, 7.30; N, 6.72; S, 7.66. Compound 91 : mp = 198-199C. IRiKBrJcm-1: 3550,2960,1626,1594,1570,1470,1429, 1312,1302,1272,1140,1115. NMR (CDC13) 5: 1.46 (18H, s, 2x BuM, 3.16 (2H, dt, J = 2.0, 6.6Hz, CHa), 4.06 (2H, t, J-6.6Hz, CHa), 5.51 (lH, s, 0H), 6.87 (1H, t, J = 2.0Hz, CH), 6.96-7.04 (1H, m, Py-H), 7.58 (2H, s, 2x aromatic-H), 7.54-7.73 < 2H, b, 2x Py-H), 8.32-8.37 ( 1H, m, Py-H). Calculated analysis (Ca3H3DN * 〇3S) Calculated value: C, 66.63; H, 7.29; N, 6.76; S, 7.73 Found: C, 66.40; H, 7.23; N, 6.71; S, 7.53. Example 13 (R3 = 3-pyridyl) ") -2- (34-pyridinyl) -5- (3.5-bis-fluorene" Sandingmo-4- 某) 55 ¥ -1.2-Isophoridine-1.1-Diphenanthrene. The compound fRm was used in a similar manner to Example 1 using compound 6 (1.474g, 5_30mmol) and N- (3_ Pyridyl) -1,2-isonazosin-1,1 oxide 4m (1.051g, 5.30β »» 1) was subjected to an aldol reaction to obtain 1.522g (60%) of an addition compound 7m. Addition of 7m (1.522g, 3.19Bmol) of compound in toluene (40ml) was treated with p-toluenesulfonic acid hydrate (400mg) to give 358Bg (27%) of mesh VIII compound 8 .. This paper size applies to China National Standard (CNS) A4 specifications (210X297 male thin) 38 (Please read the precautions on the back before filling this page) t [A7

經濟部中央橾隼局員工消費合作社印製 五、發明説明(37 ) a. P. = 207-209Ϊ:. IRiKBrJcffl'1 : 3625,3040,2960,1640,1590,1480,1431, 1305,1152. NMR(CDC13)5 : 1.47(18H,s,2x BuM,3.36(2H,dt(J=2.4. 6.4Hz,CHa),3.84(2H,t,J=6.4Hz,CHa),5.59(lH,s,0H), 7.29(2H,s,2x 芳香-1〇,7.29-7.40(211,徹,(:}1沖>^}〇,7.84-7.93(lH,m,Py-H),8.37-8.64(2H,m,2x Py-H). 兀素分析(CaaHjjuNsOaS〉 計算值:C,66.63;H,7.29;N,6.76;S,7.73 實測值:C,66.31;H,7.27;N,6.69;S,7.47 aL@LLl (R3 = 4-吡啶基) (E)-2-(4_11任啶某卜S-(入 二-笛二.丁甚-4-揮)¢5 ¥某-1.2-異睐_啶-1 .1-二氩化物(8η) 依據實例1之類似方法,使用化合物6 (2. 59g,9.36 mmol)及N- (4-吡啶基)-1,2-異睡唑啶-1,1-二氧化物 4n (2.05g,10.4iBmol )進行醛醇反應而得 2.721g (61% )加成化合物7n。加成化合物7n (1.65g,3.46πμηο1)於 甲苯(80ml)使用對-甲苯磺酸水合物( 433mg)處理而得 658i»g (46%)目檫化合物8n。 b. p. = 213-214.5TC . IRiKBrJcm-1 : 3400,2955,1643,1591,1502,1437,1316, 1153. NMR(CDC13)5 : 1.47(18H,s,2x BuM ,3.37(2H,dt, J = 2.2, 6.8Hz,CHa),3.82(2H,t,J = 6.8Hz,CHa),5.61( lH.s,OH), 本紙張尺度適用中國國家標準(CNS ) A4規格(210X29*7公釐) 39 (請先閲讀背面之注意事項再填寫本頁) •髮. 五、發明説明(38 A7 B7 7.2卜7.25(411,靈,2\芳香-11,2/?丫-1〇,7.42(111,1:,<1 = 2.2 Hz,CH)I8.50-8.58(2H,«,Py-H). 兀素分析(CaaHaeNaOaS) 計算值:C,66.63;H,7.29;N,6.76;S,7.73 賁測值:C,66.46;H,7.18;N,6.66;S,7.49. m〇m〇( t-Bu、/t-BuPrinted by the Consumer Cooperatives of the Central Government Bureau of the Ministry of Economic Affairs. 5. Description of Invention (37) a. P. = 207-209Ϊ:. IRiKBrJcffl'1: 3625, 3040, 2960, 1640, 1590, 1480, 1431, 1305, 1152. NMR (CDC13) 5: 1.47 (18H, s, 2x BuM, 3.36 (2H, dt (J = 2.4.6.4Hz, CHa), 3.84 (2H, t, J = 6.4Hz, CHa), 5.59 (lH, s , 0H), 7.29 (2H, s, 2x aromatic-10, 7.29-7.40 (211, To, (:) 1 rush > ^) 〇, 7.84-7.93 (lH, m, Py-H), 8.37- 8.64 (2H, m, 2x Py-H). Element analysis (CaaHjjuNsOaS> Calculated value: C, 66.63; H, 7.29; N, 6.76; S, 7.73 Found: C, 66.31; H, 7.27; N, 6.69 ; S, 7.47 aL @ LLl (R3 = 4-pyridyl) (E) -2- (4_11Rinidine, S- (into di-di, ding shi-4-)) ¢ 5 ¥ -1.2- Isopyridine-1.1-diargonide (8η) Following a procedure similar to that described in Example 1, using compound 6 (2.59 g, 9.36 mmol) and N- (4-pyridyl) -1,2-isosleepazole Pyridine-1,1-dioxide 4n (2.05g, 10.4iBmol) was subjected to aldol reaction to obtain 2.721g (61%) of addition compound 7n. Addition compound 7n (1.65g, 3.46πμηο1) in toluene (80ml) Treatment with p-toluenesulfonic acid hydrate (433 mg) gave 658i »g (46%) of the mesh compound 8n. Bp = 213-214.5TC IRiKBrJcm-1: 3400,2955,1643,1591,1502,1437,1316, 1153. NMR (CDC13) 5: 1.47 (18H, s, 2x BuM, 3.37 (2H, dt, J = 2.2, 6.8Hz, CHa ), 3.82 (2H, t, J = 6.8Hz, CHa), 5.61 (lH.s, OH), this paper size applies to China National Standard (CNS) A4 specification (210X29 * 7 mm) 39 (Please read the back first Please fill in this page for the matters needing attention) • Send. V. Description of the invention (38 A7 B7 7.2, Bu 7.25 (411, Ling, 2 \ Aroma-11, 2 ??-1-10, 7.42 (111,1:, < 1 = 2.2 Hz, CH) I8.50-8.58 (2H, «, Py-H). CaaHaeNaOaS Calculated value: C, 66.63; H, 7.29; N, 6.76; S, 7.73 Test value: C, 66.46; H, 7.18; N, 6.66; S, 7.49. M〇m〇 (t-Bu, / t-Bu

,0 S: 'N、〇 I Y0 S: 'N, 〇 I Y

77

(E/Z混合物) 脫去保iii (丫=脫去保瑰 基) I 11 I n I n 訂 線 (請先聞讀背面之注意事項再填穿,r頁) 經濟部中央樣準局負工消費合作社印製(E / Z mixture) Take off guarantee iii (Ya = take off Bao Jiji) I 11 I n I n Thread (please read the precautions on the back before filling in, page r) Printed by Industrial and Consumer Cooperatives

(E-異構物) 10a(E-isomer) 10a

(Z-異搰物) 10b (R3= Η) (Υ= C0.C(CH3),) (Κ)-Η- ( 二-笛三丁某-4-筠V西午某.2-里臃ΡΦ腚 1 .1-二氬仆.物now 本紙張尺度通用中國國家標準(CNS ) A4規格(210X297公釐) -40 - 經濟部中央標隼局員工消費合作社印製 A7 B7 五、發明説明(39 ) 依據實例1之類似方法,使用化合物6及N-(第三丁 氧羰基)-1,2-異睡唑啶_1,:1 -二氧化物4〇 (其係由起姶物 料,3-氯丙基磺醯氣及碳酸第三丁酯根據反應圖1製備) 進行醛醇反應獲得粗加成化合物7〇。於粗加成化合物7〇於 甲苯之溶液內加入對-甲苯磺酸水合物及所得混合物加熱 至回流經歴45分鐘,然後於氧化矽凝膠上接受柱式層析。 由使用正己烷/乙酸乙酯(2: 1)之混合物溶離之溶離分 中獲得目標化合物10a (產率8.5%)。 Μ·ρ. = 233-234Ϊ: · IR(CHCl3)cm-1 : 3618,2952,1435,1366,1311,1240,1155, 1070. NMR(CDC13)5 : 1.45(18H,s,2X Bu*),3.18(2H,dt,J=2.6, 6.8Hz,CHa),3.42-3.60(2H,m,CHs),4.05-4.25(1H,寬,NH), 5. 52(1H,s,0H〉,7· 22-7_ 27(3H,m, 2X 芳香-H,CH) 元素分析(CieHa7N03Sx〇.35HsO) 計算值:C,62.89;H,8.12;N,4.07;S,9.38 實測值:C,63·10;H,7.90;N,417;S,9_ll ;j£_®lJ^ (R3=H〉(Y=4-甲氧苄基〉 (Z)-fi- f 二-笛三丁甚-4-镩)亞午某-1 .2-異瞎唑啶-L·:!-二氫仆.物 Π Oh) 於加成化合物7h ( 13. 16g,25.3nnol) (Μ類似實例 8之方式由醛醇反應獲得)於甲苯(150ml)之溶液内加 入對-甲苯磺酸水合物(1.3g)。所生成之混合物加熱至 回流經歴30分鐘且通過小量氧化矽凝膠過濾。濾液經蒸餾 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 41 (請先閲讀背面之注意事項再填寫本頁) .裝. 訂 五、發明説明(4〇 ) A7 B7 經濟部中央標準局員工消費合作社印製 去除溶雨獲得粗(E>-與(Z>-2- (4-甲氧苄基)-5_ (3,5-二-三级丁基-4-羥)亞苄基-1,2-異唾唑啶-1,1-二氧化物 8h與9h之混合物(8.93g)。於混合物於二氣甲烷(150ml )之溶液內加入四氣化鈦(4.1ml)。所生成之混合物於〇 υ攪拌30分鐘,然後於氧化矽凝膠上接受柱式層析。由使 用正己烷/乙酸乙酯(1: 1)之混合物溶離之溶離分中獲 得化合物 10a (3.35g,41%)及 10b (120mg,1.5%)。 化合物10a之物理化學資料係與實例15所得之真實樣品資 料符合。 化合物 10b : m.p.= 161_164t!. IRCCHClaicm-1 : 3620,2954,1432,1371,1312,1241,1157. NMR(CDC13)5 : 1.45(18H,s,2X BuM,3.ll(2H,dt,J=2.1, 6.71^,(:^,3.39-3.51(211,11,(:11,),4.26-4.40(111,寬,1^), 5.49(lH,s,0H),6.80(lH,t,J=2.lHz.CH),7.55(2H,s,2x 芳香-H). 元素分析(CieHS7N〇3S) 計算值:C,63.72;H,8.08;N,4.13;S,9.45 實測值:C,63.64;H,8.14;N,4.06;S,9.36. 奮例17 ( R3 = Η) (Y= 3,4-二甲氧苄基) 於加成化合物7i ( 4_0g,7.3nmol )(於實例9之醛 醇反應中獲得)於二甲苯(50b1)之溶液内加入等其耳量 之2,6_二-第三丁酚,茴香醚及對-甲苯磺酸水合物。所生 成之混合物加熱至回流經歷45分鐘及於氧化矽凝膠上接受 柱式層析而得化合物l〇a ( 580mg,24%)及10b (85®g, (請先閲讀背面之注意事項再填寫本f) -裝. 、-·* -泉i- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 42 五、發明説明(41 ) A7 B7 3.5%)。化合物10a及10b之物理資料分別符合實例15及 16所得之真實樣品資料。(Z-isocyanate) 10b (R3 = Η) (Υ = C0.C (CH3),) (Κ) -Η- (Di-Di San Ding Mou-4- 筠 V Xiwu Mou. 2-Li 臃ΡΦ 腚 1.1-Diargon servant. 物 now This paper size is in accordance with the Chinese National Standard (CNS) A4 specification (210X297 mm) -40-Printed by the Consumer Cooperatives of the Central Standardization Bureau of the Ministry of Economic Affairs A7 B7 V. Description of the invention ( 39) According to a similar method to Example 1, using compound 6 and N- (third butoxycarbonyl) -1,2-isopropazolidine_1 :: 1-dioxide 4O (which is composed of starting materials, 3-Chloropropylsulfonium and tertiary butyl carbonate are prepared according to Reaction Scheme 1) Aldol reaction is performed to obtain a crude addition compound 70. To the solution of the crude addition compound 70 in toluene, p-toluenesulfonic acid is added. The hydrate and the resulting mixture were heated to reflux for 45 minutes, and then subjected to column chromatography on a silica gel. The target compound 10a was obtained from the fractions using a mixture of n-hexane / ethyl acetate (2: 1). Yield 8.5%). M · ρ. = 233-234Ϊ: · IR (CHCl3) cm-1: 3618,2952,1435,1366,1311,1240,1155, 1070. NMR (CDC13) 5: 1.45 (18H, s, 2X Bu *), 3.18 (2H, dt, J = 2.6, 6.8Hz, CHa), 3.42 -3.60 (2H, m, CHs), 4.05-4.25 (1H, wide, NH), 5.52 (1H, s, 0H>, 7.22-7_ 27 (3H, m, 2X aromatic-H, CH) Elemental analysis (CieHa7N03Sx 0.35HsO) Calculated value: C, 62.89; H, 8.12; N, 4.07; S, 9.38 Found: C, 63 · 10; H, 7.90; N, 417; S, 9_ll; j £ _ ®lJ ^ (R3 = H〉 (Y = 4-methoxybenzyl group> (Z) -fi-f di-ditributane-4--4-)) ·:!-Dihydrogenate. Π Oh) To the addition compound 7h (13.16g, 25.3nnol) (M obtained by the aldol reaction in a manner similar to Example 8) p-toluene was added to a solution of toluene (150ml). Sulfonic acid hydrate (1.3g). The resulting mixture was heated to reflux for 30 minutes and filtered through a small amount of silica gel. The filtrate was distilled. This paper is sized to the Chinese National Standard (CNS) A4 (210X297 mm) 41 (Please read the precautions on the back before filling this page). Binding. Order five. Invention Description (4〇) A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs to remove dissolved rain to obtain rough (E > -and (Z > -2- (4-methoxybenzyl) -5_ (3,5-di-tert-butyl-4-hydroxy) benzylidene-1,2-isosiazolidine-1,1-dioxide 8h and 9h mixture (8.93g). To a solution of digas methane (150 ml) was added titanium tetragas (4.1 ml). The resulting mixture was stirred at 0 for 30 minutes, and then subjected to column chromatography on a silica gel. Compounds 10a (3.35 g, 41%) and 10b (120 mg, 1.5%) were obtained from the fractions eluted with a mixture of n-hexane / ethyl acetate (1: 1). The physical and chemical data of Compound 10a corresponded to the actual sample data obtained in Example 15. Compound 10b: mp = 161_164t !. IRCCHClaicm-1: 3620, 2954, 1432, 1371, 1312, 1241, 1157. NMR (CDC13) 5: 1.45 (18H, s, 2X BuM, 3.ll (2H, dt, J = 2.1, 6.71 ^, (: ^, 3.39-3.51 (211,11, (: 11,), 4.26-4.40 (111, width, 1 ^), 5.49 (lH, s, 0H), 6.80 (lH, t , J = 2.lHz.CH), 7.55 (2H, s, 2x aromatic-H). Elemental analysis (CieHS7N〇3S) Calculated value: C, 63.72; H, 8.08; N, 4.13; S, 9.45 Found: C, 63.64; H, 8.14; N, 4.06; S, 9.36. Example 17 (R3 = Η) (Y = 3,4-dimethoxybenzyl) in addition compound 7i (4_0g, 7.3nmol) (in Obtained from the aldol reaction of Example 9) To a solution of xylene (50b1) was added an equivalent amount of 2,6-di-tert-butylphenol, anisole and p-toluenesulfonic acid hydrate. The resulting mixture Heat to reflux for 45 minutes and undergo column chromatography on silica gel to obtain compounds 10a (580mg, 24%) and 10b (85®g, (please read the precautions on the back before filling in this f) -Pack.,-· *-泉 i- This paper size applies to Chinese National Standard (CNS) A4 (210X 297 mm) 42 5. Description of the invention (41) A7 B7 3.5%). Physical data of compounds 10a and 10b Minute Examples 15 and 16 in line with real income of the sample data.

t-巳u 烷化 醯化 胺甲醯化 垸氧羰化 〇、,〇 鹼(D)t- 巳 u alkylation hydrazine amine methylation oxocarbonylation 〇 、, 〇 Base (D)

(E/Z) 8J 10 經濟部中央標準局員工消費合作社印製 奮例 18 ( R3 = CUCD (R)-2-Z.氣镅甚申甚-5- (3.5-二-笛三丁甚-4-揮)西罕 某-1 里膝睞啶-1 .1-二氲化物(8d) (E)-5_ (3,5-二-第三丁基-4-羥)亞苄基-1,2-異睡 唑啶-1,1-二氧化物l〇a ( 500mg,1.48dmbo1),碘乙酸乙 醋(240til,2mm〇l) ,2N 氫氧化納(1·5β1,3ιββο1)水溶 液及小童氯化Ν-苄基三甲基銨依序加入氯仿(20ml)舆水 (ΙΟβΙ)之混合物內。所得混合物於室溫攪拌24小時然後 Μ習知方式處理。產物於氧化矽凝膠上藉柱式層析純化而 得300mg(49%)目橒化合物8Ρ。 IR(CHC13)cib-1 : 3620,2956,1747,1435,1298,1229,1160. NMR(CDC13)5 : 1.29(3H,t,J = 7.2Hz,CH3), 1.45(18H,s,2 x BuM,3.19(2H,dt,J=2.6,6.6Hz,CHa),3.51(2H,t,J=6.6 Hz,CH«),3.87(2H,s,CHaC0),4.23(2H,q,J=7.2Hz,CHa), 5.5_2(lH,s,0H〉,7.22-7.30 (3H,ra,2x 芳香-H,CH) (請先閲讀背面之注意事項再填寫本頁) 裝. 訂 娘 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 43 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(42 ) 奮例 19 ( R3 = CHaCOOH) (fp-9-雜申某-5- (3·5-二-第三丁某-4-揮)亞午某-U-声啤呻η$-1·1-二氬仆.物(8α) 化合物8p ( 610mg,1 44mmol)(如藉類似實例18之 方式獲得)及2N-氫氧化納(1.5ml)加入THF(IObI)及 甲醇(4nl)之混合物内。所得混合物於01攪拌30分鐘。 加入乙酸乙酯(50ml)後,反應混合物Μ1Ν鹽酸水溶液( 20b1)及飽和鹽水(20ml)洗滌,Μ無水硫酸鈉乾燥及真 空蒸餾去除溶劑而得445mg (78%)目檫化合物8q (m.p. = 175-1781)。 IRiCHCUjca-1 : 3620,2954,1735,1435,1297,1240,1149. NMR(CDC13)5 : 1.45(18H,s,2x Bu*),3.20(2H,dt,J=2.6, 6.6Hz,CHa),3_51(2H,t,J=6.6Hz,CH*),3.95<2H,s,CHaC0), 5.54(lH,s,0H),7.25(3H,s,2x 芳香-H). 元素分析(CaDHasN0eS> 計算值:C,60.46;H,7.41;N,3.53;S,8.07 實測值:C,60.34;H,7.40;N,3.56;S,8.04. 窗例 20 ( R3 = CHaCHa〇H) (E)-2- ( 2-羥乙基)-5- ( ·υ-二-笛=丁甚-4-镩)亞 ¥ 基-1.2-¾嗛唑啶-1.1-二氬仆.物(8rO 化合物 10a ( 675mg,2anaol) ,2-碘乙醇(624<il,8 mmol) ,2N-氫氧化納水溶液(2ml)及小量氯化N-苄基三 甲基銨加入二氯甲烷(20ml)與水(1〇»1)之混合物内。 所得混合物加熱至回流經歴3日及Μ習知方式處理,產物 ___ 喊:厶 j 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -44—*1 (請先閱讀背面之注意事項再填寫本頁) •裝· 訂 -泉· 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明(43 ) 於氧化矽凝膠上接受柱式層析。由使用正己烷/乙酸乙酯 (7: 3 )之混合物溶離之溶離分中獲得190iag (25%)目 檷化合物 8r(m.p.= 156-1570 。 IR(CHC13)ci-1 : 3620,2950,1434,1290,1240,1151,1066. NMR(CDC13)S : 1.45(18H,s,2x BuM,3.16(2H,dt,J=2.4, 6.5Hz, CH«) , 3.30(2H,m,CHa),3.41(2H,t,J = 6.5Hz,CHa), 3.87(2H,t,J=5.2Hz),5.53(lH,s,OH),7.23-7.29(3H,m,2 X 芳香-H,CH〉. 元素分析(CsdH31N04S> 計算值:C,62.96;H,8_19;N,3.67;S,8.40 實測值:C, 62.72 ;H,8.27;N,3.69; S ,8.21. 奮例 21 ( R3= CH*CH,N(CH3)e) (FJ-2- ( 2-二甲某胺甚 Z 某)-5- Π.5-二-笛二丁某-4-猙)亞苄某-1.2-馬睐睥啶-1.卜二氳化物(8s) 化合物 10a ( 843mg,2_5mB〇l) ,Ν,Ν-二甲基-2-漠乙 胺(750mg,5minol) ,2Ν-氫氧化納水溶液(3nl,6hbo1) 及小量氯化N-苄基三甲基銨加入氯仿(30ml)與水(10ml )之混合物内。所得混合物於加冰冷卻下攪拌2小時。氣 仿層Μ水洗(20mix2 )及Μ無水硫酸鈉脫水。溶液經真 空蒸梅而去除氣仿,獲得950mg ( 93% )目榡化合物呈結 晶狀殘渣(m. p. = 160-16510 )。 IR(CHCl3)cm-1 : 3620,2956,1435,1290,1148. NMR(CDC13)5 : 1.45(18H,s,2x BuM,2.29(6H,s,N(CH3)a) 2.60(2H, t,J = 6.6Hz,CHa),3.12(2H,dt,J = 2.2,6.6Hz,CH*), (請先閲讀背面之注意事項再填寫本頁) .裝 訂· -泉 本紙掁尺度適用中國國家標準(CNS ) A4規格(2】OX297公釐)(E / Z) 8J 10 Example 18 printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs (R3 = CUCD (R) -2-Z. Qi Di Shen Shen -5- (3.5-II-Di San Ding Shi- 4-Vacuum) Xihanmou -1 Li Xing Pyridine-1.1-Difluoride (8d) (E) -5_ (3,5-Di-tertiary-butyl-4-hydroxy) benzylidene-1 , 2-Isoprazole-1,1-dioxide 10a (500mg, 1.48dmbo1), ethyl iodoacetate (240til, 2mm0l), 2N sodium hydroxide (1.5β1, 3ιββο1) aqueous solution and Children's N-benzyltrimethylammonium chloride was sequentially added to a mixture of chloroform (20ml) and water (10βΙ). The resulting mixture was stirred at room temperature for 24 hours and then treated in a conventional manner. The product was borrowed on silica gel Purified by column chromatography to obtain 300 mg (49%) mesh compound 8P. IR (CHC13) cib-1: 3620,2956,1747,1435,1298,1229,1160. NMR (CDC13) 5: 1.29 (3H, t , J = 7.2Hz, CH3), 1.45 (18H, s, 2 x BuM, 3.19 (2H, dt, J = 2.6,6.6Hz, CHa), 3.51 (2H, t, J = 6.6 Hz, CH «), 3.87 (2H, s, CHaC0), 4.23 (2H, q, J = 7.2Hz, CHa), 5.5_2 (lH, s, 0H〉, 7.22-7.30 (3H, ra, 2x aromatic-H, CH) (Please (Please read the notes on the back before filling this page) Standard (CNS) A4 (210X 297 mm) 43 A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (42) Example 19 (R3 = CHaCOOH) (fp-9- 杂 申 某- 5- (3 · 5-Di-Third Ding Mou-4-Wu) Yawu Mou-U-Sound Beer η $ -1 · 1-Diargon. Compound (8α) Compound 8p (610mg, 1 44mmol) (As obtained in a manner similar to Example 18) and 2N-sodium hydroxide (1.5 ml) was added to a mixture of THF (IObI) and methanol (4 nl). The resulting mixture was stirred at 01 for 30 minutes. After adding ethyl acetate (50 ml) The reaction mixture was washed with HCl aqueous solution (20b1) and saturated brine (20ml), dried over MgSO4, and the solvent was removed by vacuum distillation to obtain 445mg (78%) of the compound 8q (mp = 175-1781). IRiCHCUjca-1: 3620,2954,1735,1435,1297,1240,1149. NMR (CDC13) 5: 1.45 (18H, s, 2x Bu *), 3.20 (2H, dt, J = 2.6, 6.6Hz, CHa), 3_51 (2H , T, J = 6.6Hz, CH *), 3.95 < 2H, s, CHaC0), 5.54 (lH, s, 0H), 7.25 (3H, s, 2x aromatic-H). Elemental analysis (CaDHasN0eS > calculated value : C, 60.46; H, 7.41; N, 3.53; S, 8.07 Found: C, 60.34; H, 7.40; N, 3.56; S, 8.04. Example 20 (R3 = CHaCHa〇H) (E) -2- (2-hydroxyethyl) -5- (· υ-di-di = dibutrazol-4- 镩) -1.1-Diargon (8rO compound 10a (675mg, 2anaol), 2-iodoethanol (624 < il, 8 mmol), 2N-sodium hydroxide aqueous solution (2ml) and a small amount of N-benzyl chloride Methyl ammonium was added to a mixture of dichloromethane (20 ml) and water (10 »1). The resulting mixture was heated to reflux for 3 days and treated in a conventional manner. The product ___ shouted: 厶 j This paper size is applicable to China National Standard (CNS) A4 specifications (210X297 mm) -44— * 1 (Please read the back Note: Please fill in this page again.) • Binding, binding, spring, and printing of A7 B7 by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs. 5. Description of the invention (43) Column chromatography was performed on silica gel. From the fractions eluted with a mixture of n-hexane / ethyl acetate (7: 3), 190iag (25%) of the mesh compound 8r (mp = 156-1570. IR (CHC13) ci-1: 3620, 2950, 1434 , 1290,1240,1151,1066. NMR (CDC13) S: 1.45 (18H, s, 2x BuM, 3.16 (2H, dt, J = 2.4, 6.5Hz, CH «), 3.30 (2H, m, CHa), 3.41 (2H, t, J = 6.5Hz, CHa), 3.87 (2H, t, J = 5.2Hz), 5.53 (lH, s, OH), 7.23-7.29 (3H, m, 2 X aromatic-H, CH 〉. Elemental analysis (CsdH31N04S > Calculated value: C, 62.96; H, 8_19; N, 3.67; S, 8.40 Found: C, 62.72; H, 8.27; N, 3.69; S, 8.21. Example 21 (R3 = CH * CH, N (CH3) e) (FJ-2- (2-dimethylamine, even Z, etc.)-5- Π.5-di-didibutane-4- 狰) benzylidene-1.2- Pyridoxine-1. Dipyridine (8s) Compound 10a (843mg, 2-5mBol), N, N-dimethyl-2-moethylamine (750mg, 5minol), 2N-sodium hydroxide aqueous solution ( 3nl, 6hbo1) and a small amount of N-benzyltrimethylammonium chloride were added to a mixture of chloroform (30ml) and water (10ml). The resulting mixture was stirred under ice-cooling for 2 hours. The aerated layer was washed with water (20mix2) And M anhydrous sodium sulfate. The solution was vacuum steamed to remove aerosol, 950 mg (93%) of the compound of eye mesh was a crystalline residue (mp = 160-16510). IR (CHCl3) cm-1: 3620, 2956, 1435, 1290, 1148. NMR (CDC13) 5: 1.45 (18H, s, 2x BuM, 2.29 (6H, s, N (CH3) a) 2.60 (2H, t, J = 6.6Hz, CHa), 3.12 (2H, dt, J = 2.2,6.6Hz, CH *), (Please read first Note on the back side, please fill in this page again). Binding · -The size of spring paper is applicable to China National Standard (CNS) A4 (2) OX297 mm

A7 B7 五、發明説明(44 經濟部中央標準局員工消費合作社印裝 3.20(2H,t,J = 6.6Hz,CHa),3.38(2H,t,J = 6.6Hz,CHa),5.51 (111,3,01〇,7.2卜7.28(別,111,2><芳香4,(:}〇· 元素分析(CaeH36Na03SX 〇.2CHaCla> 計算值:C,62.65;H,8.62;N,6.58;S,7.53;C1,3.33 實測值:C,62.32;H,8.60;N,6.71;S,7.56;C1,3.24. 竇例 22 ( R3= COCH3) (E)-2-乙轆基-5- m-二-笛三丁某-4-筠)亞苄某-1 .2-里嗛睞啶-l.l-二氩仆.物fXt、 於化合物 10a ( 585mg,1.74iomol)於吡啶(10ml)及 小量4-N, N-二甲基胺基毗啶之溶液内於加冰冷卻下逐滴加 入乙酐(6ml)。所得混合物於室溫攪拌1小時及真空濃 縮。殘渣溶解於乙酸乙酯及溶液通過小量氧化矽凝膠過濾 2。濾液經真空濃縮而得360mg( 55%)目檫化合物呈結晶 狀殘渣(m_P. = 177-179C )。 IMCHCMcnr 1 : 3618,2958,1695,1435,1379,1297,1153, 1117. NMR(CDC13)5 : 1.46(18H,s,2x BuM^^BOH.s.COCHa), 3.20(2H,dt,J=2.2,7.0Hz,CHa),3.86(2H,t,J=7.0Hz,CHa), 5.60(1H,s,0H),7.52(2H,s,2x 芳香-H〉,7.39(lH,t,J = 2.2 Hz,CH). 元素分析(CaDHa9NCUS) 計算值:C,63.30;H,7.70;N,3.69;S,8.45 實測值:C,63.27:H,7.83;N,3.64;S,8.22. 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) (請先閲讀背面之注意事項再填寫本頁) 裝.A7 B7 V. Description of the invention (44 Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 3.20 (2H, t, J = 6.6Hz, CHa), 3.38 (2H, t, J = 6.6Hz, CHa), 5.51 (111, 3,01〇, 7.2, 7.28 (Beijing, 111, 2) < Aromatic 4, (:) 〇 Elemental analysis (CaeH36Na03SX 〇2CHaCla) Calculated value: C, 62.65; H, 8.62; N, 6.58; S, 7.53; C1, 3.33 found: C, 62.32; H, 8.60; N, 6.71; S, 7.56; C1, 3.24. Sinus example 22 (R3 = COCH3) (E) -2-ethenyl-5- m- Bis-ditributane-4- 筠) Benzene-1.2-trimethylpyridine-ll-diargon. FXt, compound 10a (585mg, 1.74iomol) in pyridine (10ml) and a small amount To the solution of 4-N, N-dimethylaminopyridine was added dropwise acetic anhydride (6ml) under ice cooling. The resulting mixture was stirred at room temperature for 1 hour and concentrated in vacuo. The residue was dissolved in ethyl acetate and the solution Filtered through a small amount of silica gel 2. The filtrate was concentrated in vacuo to give 360 mg (55%) of the mesh compound as a crystalline residue (m_P. = 177-179C). IMCHCMcnr 1: 3618, 2958, 1695, 1435, 1379, 1297,1153, 1117. NMR (CDC13) 5: 1.46 (18H, s, 2x BuM ^ BOH.s.COCHa), 3.20 (2H, dt, J = 2.2,7.0Hz, CHa), 3.86 (2H, t , J = 7.0Hz, CHa), 5.60 (1H, s, 0H), 7.52 (2H, s, 2x aromatic-H>, 7.39 (lH, t, J = 2.2 Hz, CH). Elemental analysis (CaDHa9NCUS) Calculated value: C, 63.30; H, 7.70; N, 3.69; S, 8.45 Measured values: C, 63.27: H, 7.83; N, 3.64; S, 8.22. This paper size applies to the Chinese National Standard (CNS) A4 specification (210X 297) PCT) (Please read the precautions on the back before filling this page).

、1T -泉 A7 B7 經濟部中央榡隼局員工消費合作杜印製 五、發明説明(45 ) 奮俐23 (R3 = N-甲基-N-甲氧基) fPU- ( 甲某申氩甚)胺申醸甚-5- 二-笛= 丁葚-4-锊)亞¥某-1.2-思諫_啶-1.1-二氲化物(8υ) 化合物10a ( 450mg,1.33βμπο1)及N-甲基-N-甲氧基-0-苯基胺甲酸酯( 300mg,1.66mmol)溶解於THF (10田1) 與HMPA(lOml)之混合物内。於溶液内伴以攪拌及冷卻至 -40Ό逐滴加入六甲基二矽胺烷(LiHMDS)於THF (1M,3.2 1)之溶液内。反應溶液溫熱至室溫後倒入1N鹽酸水溶液 内(20ml)。然後Μ乙酸乙酯(30nl)抽取混合物。乙酸 乙酯層Μ水(30ml)及飽和鹽水(30nl)洗濉,Μ無水硫 酸納乾燥及真空蒸餾去除溶劑。殘渣於氧化矽凝膠上接受 柱式層析。由使用正己烷/乙酸乙酯(7:3)之混合物溶 離出之溶離分中獲得目檫化合物8u( 230mg,41%)。 IR(CHC13)cid-1 : 3620,2958,1673,1435,1388,1330,1240, 1207,1155,1092. NMR(CDC13)5 : 1.45(18H,s,2x Bu*),3.21(2H,dt,J=2.2, 6.8Hz,CHa),3.31(3H,s,0CH3),3.78(3H,s,0CH3),3.89(2H, t, J = 6.8Hz>,5.54(lH,s,0H),7.23(2H,s,2x 芳香-H),7.31 (1H,t,J = 2.2Hz,CH). 奮例24 ( R3 = N-苄氧-N_甲氧甲基) (R)-2- ( N-苄氩-N-甲氬申甚)胺申酿甚-5- (3.5-二-第 三丁基-4-锊)亞午某-1.2-里睐_啶-1.1-二氣仆.物(8v) 化合物10a ( 424mg,1.26minol)及N-节氧甲氧甲 基-0-苯基胺甲酸酯( 722mg,2.52mmol)於 THF(90ml) 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) -47 :-----------L--裝-----^--訂------旅 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(46 ) 及HMPA ( 300ml)之混合物Μ類似實例23所述之方式使用 LiHMDS於THF (1Μ,4.0·1)之溶液處理。反應產物於氧化 矽凝膠上接受柱式層析。由使用正己烷/乙酸乙酯(3: 1) 之混合物溶離出之溶離分獲得目棲化合物8v ( 600mg,90 %)。 NMR(CDC13)5 : 1.45(18H,s,2x BuM,3.18(2H,dt,J=2.0, 6.8Hz,CHa),3.45(3H(s,NCH3),3.79(2H,t,J=6.8Hz,CH.), 4.94(2H,s,0CHa),5.02(2H,s,0CH#),5.54(lH,s,OH),7.22 (2H,s,2x 芳香-H) ,7.30 (lH,t,J = 2.0Hz, CH> ,7.30-7.55( 5H,n,5X 芳香-m. 宭例 25 ( R3= C0NH0H) (e)-2-(禪胺甲醅某)-s- (3.5-二-笛-丁某-4-镡 i ro 苄某-1.2-里__腚-1.1-二Μ化物(8W) 於實例24所得化合物10v ( 600mg,1.13mmol)於二氯 甲烷(8ml)之溶液内於加冰冷卻下加入四氯化鈦( 500W1 ,4·56ββο1)及所生成之混合物攪拌1.5小時。加入2Ν鹽 酸水溶液(10ml)後,反應混合物於室溫攪拌30分鐘然後 以二氯甲烷(20ml)抽取。有機層Μ飽和鹽水(20ml)洗 滌,以無水硫酸鈉乾燥及真空蒸餾去除溶劑。殘渣於氧化 矽凝膠上接受柱式層析。由使用正己烷/乙酸乙酯(1: D 之混合物溶離出之溶離分中獲得目檫化合物8w (150mg, 33% )。 IR(CHCl3)cm-1 : 3618,2956,1707,1434,1320,1151,1100. NMR(CDCla)5 : 1.45(18H,s,2x BuM,3.23(2H,dt,J=2.2, 本纸張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 鉍戒»烟 48 --1T-Quan A7 B7 Consumption Cooperation by Employees of the Central Government Bureau of the Ministry of Economic Affairs 5. Printing of the Invention (45) Fen Li 23 (R3 = N-methyl-N-methoxy) fPU- ( ) Amine application -5--5- di-di = Ding -4- 锊) sub- ¥ -1.2-si-pyridine-1.1-dihydrazone (8υ) compound 10a (450mg, 1.33βμπο1) and N-formyl -N-methoxy-0-phenylcarbamate (300 mg, 1.66 mmol) was dissolved in a mixture of THF (10 fields 1) and HMPA (10 ml). Add hexamethyldisilazane (LiHMDS) in THF (1M, 3.2 1) dropwise into the solution with stirring and cooling to -40 ° C. The reaction solution was warmed to room temperature and poured into a 1N aqueous hydrochloric acid solution (20 ml). The mixture was then extracted with ethyl acetate (30 nl). The ethyl acetate layer was washed with water (30 ml) and saturated brine (30 nl), dried over anhydrous sodium sulfate, and the solvent was removed by vacuum distillation. The residue was subjected to column chromatography on a silica gel. The title compound 8u (230 mg, 41%) was obtained from the eluted fraction using a mixture of n-hexane / ethyl acetate (7: 3). IR (CHC13) cid-1: 3620,2958,1673,1435,1388,1330,1240, 1207,1155,1092. NMR (CDC13) 5: 1.45 (18H, s, 2x Bu *), 3.21 (2H, dt , J = 2.2, 6.8Hz, CHa), 3.31 (3H, s, 0CH3), 3.78 (3H, s, 0CH3), 3.89 (2H, t, J = 6.8Hz >, 5.54 (lH, s, 0H), 7.23 (2H, s, 2x aromatic-H), 7.31 (1H, t, J = 2.2Hz, CH). Fen example 24 (R3 = N-benzyloxy-N_methoxymethyl) (R) -2- (N-benzyl argon-N-methyl argon phenoxide) amine sterilization -5- (3.5-di-tertiary butyl-4-fluorene) yamou-1.2-Lifa_pyridine-1.1-diqi (8v) Compound 10a (424mg, 1.26minol) and N-Betyloxymethyl-0-phenylcarbamate (722mg, 2.52mmol) in THF (90ml) This paper is in accordance with Chinese national standards ( CNS) Α4 specification (210 × 297 mm) -47: ----------- L--loading ----- ^-order ------ Travel (Please read the note on the back first Please fill in this page again) Printed by A7 B7 of the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Mixture of Invention Description (46) and HMPA (300ml) M. Similar to the method described in Example 23, LiHMDS was used in THF (1M, 4.0 · 1). ) Solution treatment. The reaction product was subjected to column chromatography on silica gel. By using n-hexane / acetic acid The eluted fraction of the mixture of ethyl esters (3: 1) yielded 8v (600mg, 90%) of ocular habitat compound. NMR (CDC13) 5: 1.45 (18H, s, 2x BuM, 3.18 (2H, dt, J = 2.0) , 6.8Hz, CHa), 3.45 (3H (s, NCH3), 3.79 (2H, t, J = 6.8Hz, CH.), 4.94 (2H, s, 0CHa), 5.02 (2H, s, 0CH #), 5.54 (lH, s, OH), 7.22 (2H, s, 2x aromatic-H), 7.30 (lH, t, J = 2.0Hz, CH >, 7.30-7.55 (5H, n, 5X aromatic-m. 25 (R3 = C0NH0H) (e) -2- (Zenamine formamidine) -s- (3.5-di-di-dine-4- 镡 i ro benzyl-1.2-li__ 腚 -1.1-two Compound M (8W). In a solution of compound 10v (600mg, 1.13mmol) obtained in Example 24 in dichloromethane (8ml) was added titanium tetrachloride (500W1, 4.56ββο1) under ice cooling, and the resulting mixture was stirred. 1.5 hours. After adding 2N hydrochloric acid aqueous solution (10 ml), the reaction mixture was stirred at room temperature for 30 minutes and then extracted with dichloromethane (20 ml). The organic layer was washed with saturated brine (20 ml), dried over anhydrous sodium sulfate, and the solvent was removed by vacuum distillation. The residue was subjected to column chromatography on silica gel. 8w (150mg, 33%) was obtained from the fractions eluted with a mixture of n-hexane / ethyl acetate (1: D mixture). IR (CHCl3) cm-1: 3618, 2956, 1707, 1434, 1320, 1151,1100. NMR (CDCla) 5: 1.45 (18H, s, 2x BuM, 3.23 (2H, dt, J = 2.2, this paper size applies Chinese National Standard (CNS) A4 specification (210 X 297 mm) bismuth Quit »Smoke 48-

Ia--------L--裝------訂------娘 (請先閲讀背面之注意事項再填寫本頁) i、發明説明(47 A7 B7 7.0Hz,CHa),3.94 (2H,t,J = 7.〇Hz,CHa),5.61(lH,s,OH), 6.85-6.95(11寬,01〇,7.24(2{],3,2><芳香-}〇,7.30(111, t, J = 2.2Hz,CH),8.61 (1H,s,NH). 啻例26 π、—?-镩-5-门.5-二-第三丁某-4-揮)苄某-1 .2-里臃 _啼-1二氦化物(11a)及其(Z)-里饞物Mlh)Ia -------- L--install ------ order ------ mother (please read the notes on the back before filling this page) i. Description of invention (47 A7 B7 7.0Hz , CHa), 3.94 (2H, t, J = 7.〇Hz, CHa), 5.61 (lH, s, OH), 6.85-6.95 (11 wide, 01〇, 7.24 (2 {], 3, 2 > < Aromatic-} 〇, 7.30 (111, t, J = 2.2Hz, CH), 8.61 (1H, s, NH). Example 26 π,-?-镩 -5-gate. 5-Di-Third A certain 4-volume) benzyl-1. 2-Li _ _ -1 dihelium (11a) and its (Z) -Li 馋 Mlh)

(請先閱讀背面之注意事項再填寫本頁) -棄· 欹 Μ 脫去保護(Please read the precautions on the back before filling out this page)-Discard · 欹 M Take off protection

11a ,11b 、vs_ 經濟部中央標準局員工消費合作社印製 根據實例1使用化合物6a及N-苄氧-1,2-異睡唑啶-1, 1-二氧化物進行醛醇反應。藉醛醇反應所得之加成化合物 使用對甲苯磺酸水合物處理而得粗2-苄氧-5- (3,5-二-第 三丁基-4-羥)亞苄基-1,2-異睡唑啶-1,卜二氧化物。於 粗二氧化物(4_44g,lOmoiol)於二氯甲烷(80ml)之溶 液内伴Μ攪拌及加冰冷卻逐滴加入四氯化钛(4 . 4ml,40 。於同溫又攪拌2小時後,將IN鹽酸水溶液(50ml )加入反應混合物内。分離二氯甲烷_,Μ水(50ml)及 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標隼局員工消費合作社印製 A7 __ 1 '發明説明(48 ) 飽和鹽水(50ml)洗滌,以無水硫酸鈉乾燥及真空蒸餾去 除溶劑。殘渣於氧化矽凝膠上接受柱式層析。由使用正己 烷/乙酸乙酯(3: 1)之混合物溶離出之溶離分中依次獲 得目檷化合物 lib (178mg,5%)及 11a (1.6g,45%)。 化合物 11a: m.p.= 177-18210 (分解) IRiKBrJcm-1 : 3560,3430,1425,1330,1240,1155,1130, 1115. NMR(CDC13)5 : 1.45(18H,s,2X BuM,3. 18(2H,dt,J = 2.6, 6.8Hz,CHa),3.89(2H,t,J=6.8Hz,CHa),5.56(lH,s,0H), 6. 18-6.30(1H,寬,OH) ,7.26-7.35<3H,m,2x 芳香-H,CH> . 元素分析(Ct eH8TN04S〉 計算值:C,61.16;H,7.70;N,3.96;S,9.07 實測值:C,6086;H,7.68;N,3.93;S,8·90· 化合物llb:m.p.=190-198cC(分解) IR(CHCl3)cin-1 : 3622,3540,3020,2954,1632,1431,1340, 1241,1157. NMR(CDC13)5 : 1.45(18H,s,2X BuM,3.17(2H,dt,J=2.2, 6.8Hz,CHB),3.62(2H,m,CH8),5.51(lH,s,OH),6.22(lH,s, 〇H),7.04(lH,t, J = 2.2Hz,CH) ,7_49(2H,s,2x 芳香-H) 元素分析(Q eHa7N0«S> 計算值:C,60.16;H,7.70;N,3.96;S,9.07 實測值:C,60.67;H,7.58;N,3.96;S,8.87. 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -50 - IJ---^--- JL--裝------訂------旅 (請先閱讀背面之注意事項再填寫本頁) A7 B7 五、發明説明(49 啻俐27 (R)-2-異丙某-5- ( 3 · 5-二-第三丁某-4-掷、亞千甚-1 · 2_ 里曈邮啶-Ι.Ί-二氩仆.物(8x)11a, 11b, vs_ Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs According to Example 1, compound 6a and N-benzyloxy-1,2-isosleepazolidine-1, 1-dioxide were used for the aldol reaction. The addition compound obtained by the aldol reaction was treated with p-toluenesulfonic acid hydrate to obtain crude 2-benzyloxy-5- (3,5-di-third-butyl-4-hydroxy) benzylidene-1,2 -Isoprazole-1, dioxane. In a solution of crude dioxide (4-44 g, 10 moiol) in dichloromethane (80 ml), titanium tetrachloride (4.4 ml, 40 ° C. was added dropwise with ice-cooling and stirring. After stirring for 2 hours at the same temperature, Add IN aqueous hydrochloric acid solution (50ml) to the reaction mixture. Dichloromethane, M water (50ml) and this paper size are applicable to China National Standard (CNS) A4 specifications (210X297 mm). Consumer Cooperatives, Central Bureau of Standards, Ministry of Economic Affairs Print A7 __ 1 'Explanation of the invention (48) Wash with saturated brine (50ml), dry with anhydrous sodium sulfate and remove the solvent by vacuum distillation. The residue was subjected to column chromatography on silica gel. By using n-hexane / ethyl acetate (3: 1) The eluted compound lib (178mg, 5%) and 11a (1.6g, 45%) were obtained in the dissolving fraction of the mixture. Compound 11a: mp = 177-18210 (decomposed) IRiKBrJcm-1: 3560,3430,1425,1330,1240,1155,1130, 1115. NMR (CDC13) 5: 1.45 (18H, s, 2X BuM, 3. 18 (2H, dt, J = 2.6, 6.8Hz, CHa), 3.89 (2H, t, J = 6.8Hz, CHa), 5.56 (lH, s, 0H), 6. 18-6.30 (1H, wide, OH), 7.26-7.35 < 3H, m, 2x aromatic-H, CH >. Elemental Analysis (Ct eH8TN04S Calculated: C, 61.16; H, 7.70; N, 3.96; S, 9.07 Found: C, 6086; H, 7.68; N, 3.93; S, 8.90 · Compound llb: mp = 190-198cC (decomposition) IR (CHCl3) cin-1: 3622,3540,3020,2954,1632,1431,1340, 1241,1157. NMR (CDC13) 5: 1.45 (18H, s, 2X BuM, 3.17 (2H, dt, J = 2.2 , 6.8Hz, CHB), 3.62 (2H, m, CH8), 5.51 (lH, s, OH), 6.22 (lH, s, 〇H), 7.04 (lH, t, J = 2.2Hz, CH), 7_49 (2H, s, 2x aromatic-H) Elemental analysis (Q eHa7N0 «S > Calculated: C, 60.16; H, 7.70; N, 3.96; S, 9.07 Found: C, 60.67; H, 7.58; N, 3.96 ; S, 8.87. This paper size is applicable to China National Standard (CNS) A4 specification (210X 297mm) -50-IJ --- ^ --- JL--installation ------ order ----- -Brigade (please read the precautions on the back before filling this page) A7 B7 V. Description of the invention (49 啻 27 (R) -2-Isopropyl-5- (3 · 5- 二-三 丁丁- 4-throw, Yaqian-1-2_ 里 曈 Postidine-Ι.Ί- 二 argon servant. 8x

CHO 〇χγ〇 +CHO 〇χγ〇 +

LDALDA

OHOH

p-TsOH 〇、/〇p-TsOH 〇, / 〇

-----^-----L--裝------訂------Af (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標_局員工消費合作社印製 依據實例1之類似方法使用N-異丙基-1,2-異睡唑啶-1,卜二氧化物 <4p> (3.65g,22.4mmol)及 3,5-二-第三丁 基-4-甲氧基甲氧苯甲醛(6a) (5.28g,19.0mniol)進行醛 醇反應而得6.27g (74.7%)加成化合物<7p)呈白色粉末 。於加成化合物7p (6.27g)於甲苯(120b1)之溶液内加 入對-甲苯磺酸水合物( 600mg)。混合物加熱至回流經歴 本紙張尺度適用中國國家操準(CNS ) A4規格(210X 297公釐)----- ^ ----- L--install ------ order ------ Af (Please read the notes on the back before filling this page) Ministry of Economic Affairs Central Standard _ Bureau employee consumption Cooperative prints a similar method according to Example 1 using N-isopropyl-1,2-isoisoprazole-1, dioxane < 4p > (3.65g, 22.4mmol) and 3,5-di- Tributyl-4-methoxymethoxybenzaldehyde (6a) (5.28g, 19.0mniol) was subjected to an aldol reaction to obtain 6.27g (74.7%) of the addition compound < 7p) as a white powder. To a solution of the addition compound 7p (6.27 g) in toluene (120b1) was added p-toluenesulfonic acid hydrate (600 mg). The mixture is heated to reflux. This paper is sized for China National Standards (CNS) A4 (210X 297 mm).

MiFET -51 經濟部中央榡準局員Η消費合作社印製 A7 B7 —~-—----------- 五、發明説明(50 ) 30分鐘,冷卻,以水(100ml)洗兩次,以無水硫酸鈉乾 燥及真空蒸皤去除溶剤。結晶狀殘渣由甲醇中再結晶而得 2.16g (30%)目檷化合物呈無色結晶。 化合物8\:1».?.= 148-15〇·^· IRiKBrJcm'1 : 3550,2960,1645,1600,1432,1273,1173. NMR(CDC13)5 ·· 1.29(6H,d, J = 6.6Hz,2x CH3), 1.45(18H, s,2X BuM ,3.07-3. 14 (2H, m, CHa) , 3.29~3.35(2H, m, CH8), 3.94<1H,族,CH),5.48(lH,s,OH),7.22(lH,t,J=2.8Hz,CH), 7.23(2H,s,Ar-H). 元素分析<CaiH33N03S) 計算值:C, 66.45 ;H, 8.76; N, 3.69; S,8.45 實測值:C, 66.37 ;H,9.01; N, 3.67; S, 8.28. 奮例28 (1^-9-7.甚-5-(3.5-二申某-4-锊)亞苄甚-1.2-里睐脾 逾-l.l-二氣化物(8y)MiFET -51 Printed by A7 B7, a member of the Central Bureau of Associate Bureau of the Ministry of Economic Affairs, and Consumer Cooperatives — ~ -—------------ V. Description of the invention (50) 30 minutes, cool, wash with water (100ml) for two Then, it was dried over anhydrous sodium sulfate and evaporated under vacuum to remove solvent. The crystalline residue was recrystallized from methanol to obtain 2.16 g (30%) of the mesh compound as colorless crystals. Compound 8 \: 1 ».?. = 148-15〇 · ^ IRiKBrJcm'1: 3550, 2960, 1645, 1600, 1432, 1273, 1173. NMR (CDC13) 5 ·· 1.29 (6H, d, J = 6.6Hz, 2x CH3), 1.45 (18H, s, 2X BuM, 3.07-3. 14 (2H, m, CHa), 3.29 ~ 3.35 (2H, m, CH8), 3.94 < 1H, family, CH), 5.48 (lH, s, OH), 7.22 (lH, t, J = 2.8Hz, CH), 7.23 (2H, s, Ar-H). Elemental analysis < CaiH33N03S) Calculated value: C, 66.45; H, 8.76 N, 3.69; S, 8.45 Found: C, 66.37; H, 9.01; N, 3.67; S, 8.28. Fen Example 28 (1 ^ -9-7. -锊) subbenzyl-1.2-Li favors spleen-ll-digas (8y)

本紙張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐) --------—-L--裝------訂------Λ. (請先閲讀背面之注意事項再填寫本頁) A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(51The size of this paper applies to China National Standard (CNS) Α4 specification (210 X 297 mm) ----------- L--packing ------ order ------ Λ. (Please (Please read the notes on the back before filling out this page) A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs

依據實例1之類似方法使用N-乙基-1,2-異睡唑啶-1, 卜二氧化物(4a) (2.5g,16·8ππηο1)及 3,5-二甲基-4-甲 氧甲氧苯甲醛(6b) (2.92g,15mmol )進行醛醇反應而得 4. Olg (77.8%)加成化合物(7q)呈白色粉末。於醛酵加 成化合物7q (3.75g,1〇·9ιιβο1)於甲苯(100·1)之溶液內 加入對-甲苯磺酸水合物( 200mg)。混合物加熱至回流經 歴30分鐘。反應混合物經冷卻,Μ水(100ml)洗兩次, 以無水硫酸鈉乾燥及真空蒸皤去除溶劑。結晶狀殘渣由甲 醇中再結晶而得1.63g( 53%)目檁化合物呈無色結晶。 化合物 8y: m.p.= 167-168t!. IR(Nujol)cm-1 : 3399,1641,1593,1489,1461,1272,1217, 1170, 1145,1128. NMR(CDCla)5 : 1.29(3H,t,J=7.4Hz,CH3),2.26(6H,s,2x CH3) ,3.05-3.36 (6H,m,2x CHs,NCHa> ,5.00 (1H,寬,OH), 7.04(2H,s,Ar-H),7.15(lH,t,J-2.8Hz,CH). 元素分析(C14H13N03S) 計算值:C,59.76;H,6.81;N,4.98;S,11.39 實測值:C,59.56;H,6.85;N,4.99;S,11.38. 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -----^---—-L--裝------訂------康 (請先閱讀背面之注意事項再填寫本頁) 瞻補,::.' 斗月曰Ί >88. 8. 25 補无1 A7 B7A similar method according to Example 1 was used with N-ethyl-1,2-isopropazolidine-1, dioxane (4a) (2.5g, 16.8ππηο1) and 3,5-dimethyl-4-formaldehyde. Olg (77.8%) addition compound (7q) was a white powder. The oxymethoxybenzaldehyde (6b) (2.92 g, 15 mmol) was subjected to an aldol reaction. To a solution of the aldehyde fermentation compound 7q (3.75 g, 10.9 μm βο1) in toluene (100 · 1) was added p-toluenesulfonic acid hydrate (200 mg). The mixture was heated to reflux for 30 minutes. The reaction mixture was cooled, washed twice with M water (100 ml), dried over anhydrous sodium sulfate and evaporated under vacuum to remove the solvent. The crystalline residue was recrystallized from methanol to obtain 1.63 g (53%) of the mesh hydrazone compound as colorless crystals. Compound 8y: mp = 167-168t !. IR (Nujol) cm-1: 3399,1641,1593,1489,1461,1272,1217, 1170, 1145,1128. NMR (CDCla) 5: 1.29 (3H, t, J = 7.4Hz, CH3), 2.26 (6H, s, 2x CH3), 3.05-3.36 (6H, m, 2x CHs, NCHa >, 5.00 (1H, width, OH), 7.04 (2H, s, Ar-H ), 7.15 (lH, t, J-2.8Hz, CH). Elemental analysis (C14H13N03S) Calculated value: C, 59.76; H, 6.81; N, 4.98; S, 11.39 Found: C, 59.56; H, 6.85; N, 4.99; S, 11.38. This paper size is applicable to China National Standard (CNS) A4 specification (210X 297mm) ----- ^ ---------------- ---- Kang (Please read the precautions on the back before filling this page) Zhan Bu, ::. 'Dou Yue Yue Ί > 88. 8. 25 Bu Wu 1 A7 B7

CHO 〇、々〇 + ^N-EtCHO 〇, 々〇 + ^ N-Et

OHOH

五、發明説明(52 啻俐29 (|^-9-7.甚-5-(3.5--二異丙基--4-瘅)亞¥某-1.2-里噱睥 if -1 . 1 -二氩化物(87) 4a. p-TsOH ^ ——Μ-----裝— (請先閲讀背面之注意事項再填^4苋)V. Description of the invention (52 啻 29 (| ^ -9-7. Even-5- (3.5--diisopropyl--4- 瘅)) ¥ -1.2-Li 噱 睥 if -1. 1- Diargon (87) 4a. P-TsOH ^ ——M ----- pack— (Please read the precautions on the back before filling ^ 4 苋)

線 經濟部中央橾準局貝工消费合作社印装 根據實例1之類似方法,使用N-乙基-1,2-異唾唑啶-1,1-二氧化物(4a) (4.9g,32·8·βο1)及 3,5-二異丙基-4-甲氧甲氧苯甲醛<6c) (7.51g,30aa〇l )進行_醇反應 而得6.07g (50.6%)加成化合物(7r)呈白色粉末。於_ 辞加成化合物7r(5.0g,2〇M〇l-)於甲苯(lOOul)之溶 液内加入對-甲苯磺酸水合物( 200ng)。混合物加熱至回 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) -5 4 - A7 B7 五、發明説明(53 ) 流經歴30分鐘。反應混合物經冷卻,Μ水(100ml)洗兩 次,Μ無水硫酸納乾燥及真空蒸皤去除溶劑。結晶狀殘渣 由甲醇中再結晶而得3.24g (48%)目檷化合物8ζ呈無色 結晶。 化合物 8ζ : ηι·ρ. = 167-168t:. IR(Nujol)cm-1 : 3413,1644,1600,1472,1276,1194,1153, 1115. NMR(CDCla)5 : 1.27(12H,d,J=6.6Hz.2X CH(CH3)a),3.06 -3.36(8H,ib,3x CH..2X CH),5.13(lH,s,0H),7.12(2H,s, Ar-H),7.24(1H,t,J=2.8Hz,CH). 兀素分析(CieHa7N〇3S〉 計算值:C,64.06;H,8.07;N,4.15;S,9.50 實測值:C, 64.03 ;H, 8.02; N, 4.11; S,9.46. 奮例如 IE)-2-7.甚-R- ( 二申氲-il-镩)55 苄某-1 . 2-里睐 ΡΦ ^LJ二二氬化物fRTd —ί----;—,—_--裝------訂------Λ (請先閲讀背面之注意事項再填寫本頁)Printed by Shellfish Consumer Cooperative of Central Bureau of Quasi-Economics of the Ministry of Online Economics According to a similar method as in Example 1, N-ethyl-1,2-isosiazolidine-1,1-dioxide (4a) (4.9g, 32 8.β? 1) and 3,5-diisopropyl-4-methoxymethoxybenzaldehyde < 6c) (7.51g, 30aaOl) were subjected to an alcohol reaction to obtain 6.07g (50.6%) of an addition compound (7r) White powder. To a solution of the addition compound 7r (5.0 g, 200 mol-) in toluene (100 ul) was added p-toluenesulfonic acid hydrate (200 ng). The mixture is heated to the back. The paper size is in accordance with Chinese National Standard (CNS) A4 (210 X 297 mm) -5 4-A7 B7. 5. Description of the invention (53) Flow through for 30 minutes. The reaction mixture was cooled, washed twice with M water (100 ml), dried over anhydrous sodium sulfate and evaporated under vacuum to remove the solvent. The crystalline residue was recrystallized from methanol to obtain 3.24 g (48%) of the mesh compound 8ζ as colorless crystals. Compound 8ζ: η · ρ. = 167-168t :. IR (Nujol) cm-1: 3413,1644,1600,1472,1276,1194,1153, 1115. NMR (CDCla) 5: 1.27 (12H, d, J = 6.6Hz. 2X CH (CH3) a), 3.06 -3.36 (8H, ib, 3x CH..2X CH), 5.13 (lH, s, 0H), 7.12 (2H, s, Ar-H), 7.24 ( 1H, t, J = 2.8Hz, CH). Element analysis (CieHa7N03S> Calculated value: C, 64.06; H, 8.07; N, 4.15; S, 9.50 Found: C, 64.03; H, 8.02; N , 4.11; S, 9.46. Fen example IE) -2-7. Even-R- (二 申 氲 -il- 镩) 55 benzyl-1. 2-Li favored PΦ ^ LJ di-diargide fRTd —ί- ---; —, —_-- install ------ order ------ Λ (Please read the notes on the back before filling this page)

MeO 經濟部中央標準局員工消費合作社印製Printed by MeO Consumer Cooperatives, Central Bureau of Standards, Ministry of Economic Affairs

.CH〇 ΜΟΜΟ^γ 〇Me Μ +.CH〇 ΜΟΜΟ ^ γ 〇Me Μ +

N-Et 4a.N-Et 4a.

LDA 本紙張尺度韻中nn家榡準(CNS)八4規格(21Gx 297公羡) A7 B7LDA This paper size rhyme nn house standard (CNS) 8 4 specifications (21Gx 297 public envy) A7 B7

0H0H

ZS_ 五、發明説明(54ZS_ V. Description of the invention (54

p-TsOHp-TsOH

MeOMeO

OMe m 根據實例1之類似方法,使用N-乙基-1,2-異睡唑啶-1,卜二氧化物(4&)(5.22宕,3511111〇1)及3,5-二甲氧-4-甲 氧甲氧笨甲醛(6<0 (6.77g,30mnol )進行醛醇反應而得 8.42g (74.8%)加成化合物(7s)呈白色粉末。於醛醇加 成化合物7s (4.28g,11.4··ο1)於甲苯(l〇〇ml)之溶液 内加入對-甲苯磺酸水合物(20〇Bg)。混合物加熱至回流 經歷30分鐘。反應混合物經冷卻,Μ水洗(100ml)兩次 ,以無水硫酸鈉乾燥及真空蒸餾去除溶劑。所得結晶狀殘 渣由甲醇中再結晶而得1.64g (46%)目檫化合物81 a呈無 色針晶。 化合物 81a ·· m.p.= 164-1661^ . IRCNujoDcm1 : 3434,1643,1607,1593,1517,1454,1321, 1273,1251,1219,1172,1149,1109. 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0'〆297公釐) 丨_„---^---1--裝------訂------成 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(55 ) NMR(CDCla)5 : 1.30(3H,t,J = 7.4Hz,CH3),3. 10-3.37(6H, m, 3X CHa) , 3. 92(6H, s, 2X 0CH3) , 5. 76(1H, s, OH) , 6.65(2H, s, Ar-H),7.20(1H,t,J = 2.8Hz,CH). 元素分析(C14H13NOeS〉 計算值:C,53_66;H,6.11;N,4.47;S,10.23 實測值:C,53.45 ;H,6.06;N,4.44; S, 10.33· 審例.Ή (FJ-2-Z,某-fi- ( 3-申氩-4-揮)菲 ¥ 某-1 .2-¾ 睐 _ 啶-1 . 1 -二氤仆,物(8 Tb) (請先閲讀背面之注意事項再填寫本頁) -裝_OMe m According to a similar method as in Example 1, N-ethyl-1,2-isopropazolidine-1,4-dioxane (4 &) (5.22, 3511111〇1) and 3,5-dimethoxyl were used. -4-methoxymethoxybenzaldehyde (6 < 0 (6.77 g, 30mnol)) was subjected to aldol reaction to obtain 8.42 g (74.8%) of the addition compound (7s) as a white powder. The aldol addition compound 7s (4.28 g, 11.4 ... 1) To a solution of toluene (100 ml) was added p-toluenesulfonic acid hydrate (200 Bg). The mixture was heated to reflux for 30 minutes. The reaction mixture was cooled and washed with water (100 ml). Twice, dry with anhydrous sodium sulfate and remove the solvent by vacuum distillation. The obtained crystalline residue was recrystallized from methanol to obtain 1.64 g (46%) of the compound 81 a as colorless needles. Compound 81a ·· mp = 164-1661 ^. IRCNujoDcm1: 3434,1643,1607,1593,1517,1454,1321, 1273,1251,1219,1172,1149,1109. This paper size applies to China National Standard (CNS) A4 specification (2 丨 0'〆297 public) (Li) 丨 _ 丨 --- ^ --- 1--installation ------ order ------ into (please read the precautions on the back before filling out this page) Employees of the Central Bureau of Standards of the Ministry of Economic Affairs Cooperative printed A7 B7 (55) NMR (CDCla) 5: 1.30 (3H, t, J = 7.4Hz, CH3), 3.10-3.37 (6H, m, 3X CHa), 3.92 (6H, s, 2X 0CH3) , 5. 76 (1H, s, OH), 6.65 (2H, s, Ar-H), 7.20 (1H, t, J = 2.8Hz, CH). Elemental analysis (C14H13NOeS> Calculated value: C, 53_66; H , 6.11; N, 4.47; S, 10.23. Found: C, 53.45; H, 6.06; N, 4.44; S, 10.33. Examination example. Ή (FJ-2-Z, M-fi- ( 4-Wave) Fei ¥ -1-2. 2-¾ Favor _ Pyridine-1. 1-2 氤 servant, thing (8 Tb) (Please read the precautions on the back before filling this page)-equipment_

CHOCHO

VV

LDA + N-Et 4a.LDA + N-Et 4a.

、1T 經潘部中央標準局員工消費合作社印聚, 1T Printed by the Consumers' Cooperative of the Central Standards Bureau of Pan Department

OHOH

p-TsOH 旅p-TsOH trip

57 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐)57 This paper size applies to China National Standard (CNS) A4 (210 X 297 mm)

i '發明説明(56 ) 根據實例1之類似方法,使用N-乙基-1,2-異唾唑啶-1,卜二氧化物4a (5.00g,33.5anol)與3-甲氧-4-甲氧甲 氧苯甲醛(6e) (5.88g,30mmol)進行醛醇反醮而得4.35g (42% )加成化合物7t呈白色粉末。於醛醇加成化合物7t (4.30g,12·4·βο1)於甲苯(lOOal)之溶液内加入對-甲苯磺酸水合物( 200mg)。混合物加熱至回流經歴30分 鐘。反應混合物經冷郤,以水( 200ml)洗兩次,Μ無水 碇酸納乾燥及真空濃縮。殘渣於氧化矽凝膠上接受柱式層 析。分離使用正己烷/乙酸乙酯(2: 1)溶離出之溶離分 及由二氣甲烷/二異丙醚之混合物中再結晶而得2.7g ( 31.8%)目檫化合物呈無色結晶。 化合物 81b : m.p.= 146-14813 . IRCNujoDcm-1 : 3404,2924,1646,1611,1594,1516,1462, 1270,1149,1130. MMR(CDC13)5 : 1.29(3H,t,J=7.4Hz,CH3),3.08-3.18(2H, m,CH») ,3. 17(2H,q, J = 7.4Hz,2x CHa) (3.26-3.34 (2H,ni,CHs), 3.92(3H,s(0CH3),5.88(lH,s,OH),6.86-7.02 (3H,m,Ar-H), 7.21(1H,t,J = 2.8Hz,CH). 元素分析(C13H17N〇4S) 計算值:C,55.11;H,6.05;N,4.94;S,11.32 實测值:C,54·75;H,6·ll;N,4.99;S,ll23· £_@Li2 (E)-2-Z甚-.R- U-镡)亞¥某-1.2-里嫌 _症--1,:1-二氣 化物(8Tr>) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ^------Ί--裝------訂------旅 (請先閲讀背面之注意事項再填寫本頁} 經濟部中央標準局員工消費合作社印製i 'Explanation of the invention (56) According to a similar method to Example 1, N-ethyl-1,2-isosiazolidine-1, dioxane 4a (5.00g, 33.5anol) and 3-methoxy-4 were used. -Methoxymethoxybenzaldehyde (6e) (5.88 g, 30 mmol) was subjected to aldol reaction to obtain 4.35 g (42%) of the addition compound 7t as a white powder. To a solution of the aldol addition compound 7t (4.30g, 12.4 · βο1) in toluene (100al) was added p-toluenesulfonic acid hydrate (200mg). The mixture was heated to reflux for 30 minutes. The reaction mixture was cooled, washed twice with water (200 ml), dried over anhydrous sodium acetate and concentrated in vacuo. The residue was subjected to column chromatography on silica gel. The eluate separated by n-hexane / ethyl acetate (2: 1) was separated and recrystallized from a mixture of methane / diisopropyl ether to obtain 2.7 g (31.8%) of the title compound as colorless crystals. Compound 81b: mp = 146-14813. IRCNujoDcm-1: 3404,2924,1646,1611,1594,1516,1462, 1270,1149,1130. MMR (CDC13) 5: 1.29 (3H, t, J = 7.4Hz, CH3), 3.08-3.18 (2H, m, CH »), 3.17 (2H, q, J = 7.4Hz, 2x CHa) (3.26-3.34 (2H, ni, CHs), 3.92 (3H, s (0CH3 ), 5.88 (lH, s, OH), 6.86-7.02 (3H, m, Ar-H), 7.21 (1H, t, J = 2.8 Hz, CH). Elemental analysis (C13H17N04S) Calculated value: C, 55.11; H, 6.05; N, 4.94; S, 11.32 Found: C, 54 · 75; H, 6.11; N, 4.99; S, ll23 £ _ @ Li2 (E) -2-Z even- .R- U- 镡) ¥¥ -1.2-Li suspected_disease--1,: 1-digas (8Tr >) This paper size is applicable to China National Standard (CNS) A4 (210X297 mm) ^- ----- Ί--Equipment ------ Order ------ Brigade (Please read the notes on the back before filling out this page} Printed by the Staff Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs

A7A7

i '發明説明(57 )i 'Invention note (57)

---„----^--i—--裝-------訂 (請先閲讀背面之注意事項再填寫本頁) 根據實例1之類似方法,使用N-乙基-1,2-異唾唑啶-1,卜二氧化物4a (3.28g,22miB〇l)及4-甲氧甲氧苯甲醛 (6f) (3.32g,20mmol)進行醛醇反應而得 4.10g (65%) 加成化合物7u呈白色粉末。於醛醇加成化合物7u (4.00g ,12.7bbo1)於甲苯(ΙΟΟίΒ〗)之溶液内加入對-甲苯磺酸 水合物(200ng)。混合物加熱至回潦經歷30分鐘。反應 混合物Μ水( 200ml)洗兩次,以無水硫酸納乾燥及真空 濃縮。殘渣於氧化矽凝膠上接受柱式層析。使用正己烷/ 乙酸乙酯(3:2)溶離出之溶離分經分離及由二氯甲烷與 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 旅 經濟部令央襟準局員工消費合作社印製 五、發明説明(58 A7 B7 二異丙«之混合物中再結晶而得l.〇g (31.1%)目檫化合 物呈無色結晶。 化合物 81c: β·ρ·=135-138Τ:. IRiNujoDcm1 : 3346,2914,1646,1605,1584,1513,1453, 1376,1282,1223,1136. NMR(CDC13)§ : 1.29(3H,t,J=7.2Hz,CH3),3.04-3.12(2H, , CHO ,3. 17(2H,q, J = 7.2Hz, CHa) , 3.27-3.33 (2H , m, CH a), 5.59(lH,s,0H),6.85-6.90(2H,m,Ar-H),7. 19(1H,t,J = 2.8 Hz.CH),7.24-7.30(4H,m,Ar-H). 元素分析(ClaHieN〇3S〉 計算值:C,56.90;H,5.97;N,5.53;S,12.66 實測值:C,56.74;H,5.98;N,5.52;S,12.41. 奮例 (丑)-2-(3.5-二-笛三丁某-4-揮1£5午荖頊丁砸(81(^ 經濟部中央標隼局員工消費合作社印製--- „---- ^-i ---- pack ------- order (please read the notes on the back before filling this page) According to the similar method of Example 1, use N-ethyl- 1,2-Isosiazolidine-1, dioxane 4a (3.28g, 22miBOL) and 4-methoxymethoxybenzaldehyde (6f) (3.32g, 20mmol) were subjected to aldol reaction to obtain 4.10g (65%) Addition compound 7u was a white powder. To a solution of the aldol addition compound 7u (4.00g, 12.7bbo1) in toluene (ΙΟΟίΒ) was added p-toluenesulfonic acid hydrate (200ng). The mixture was heated to The reaction was carried out for 30 minutes. The reaction mixture was washed twice with water (200 ml), dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was subjected to column chromatography on silica gel. N-hexane / ethyl acetate (3: 2) was used. ) The dissociated fraction is separated and printed by dichloromethane and the paper size to apply Chinese National Standard (CNS) A4 (210X297 mm). Printed by the Ministry of Tourism Economy, Central Labor Bureau, Consumer Consumption Cooperative. A7 B7 diisopropylene was recrystallized to obtain 1.0 g (31.1%) of the mesh compound as colorless crystals. Compound 81c: β · ρ · = 135-138T :. IRiNujoDcm1 : 3346,2914,1646,1605,1584,1513,1453, 1376,1282,1223,1136. NMR (CDC13) §: 1.29 (3H, t, J = 7.2Hz, CH3), 3.04-3.12 (2H,, CHO, 3.17 (2H, q, J = 7.2Hz, CHa), 3.27-3.33 (2H, m, CH a), 5.59 (lH, s, 0H), 6.85-6.90 (2H, m, Ar-H ), 7.19 (1H, t, J = 2.8 Hz.CH), 7.24-7.30 (4H, m, Ar-H). Elemental analysis (ClaHieN03S> Calculated value: C, 56.90; H, 5.97; N , 5.53; S, 12.66 Found: C, 56.74; H, 5.98; N, 5.52; S, 12.41. Fenyu (ugly) -2- (3.5-di-Di Sanding Mou-4-wave 1 £ 5 noon荖 顼 丁 打 (81 (^ Printed by the Staff Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs

CHO V/°CHO V / °

LDA I . . —-訂 I 旅 (請先閲讀背面之注意事項再填寫本頁) +LDA I.. —-Book I Trip (Please read the notes on the back before filling this page) +

〇H〇H

p-TsOH s 本紙張尺度適用中國國家標準(CNS ) A4規格(210 x 297公釐) 經濟部中央標隼局員工消費合作社印製 A7 〜__B7 五·、發明説明(59 )p-TsOH s This paper size is applicable to China National Standard (CNS) A4 (210 x 297 mm) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs A7 ~ __B7 V. Description of the invention (59)

根據實例1之類似方法使用環丁鲺4q (2.4g,20mi»〇l )及3,5-二-第三丁基-4-甲氧甲氧苯甲醛6a (5.57g,20 ββοΙ)進行醛醇反應而得5_58g (70%)加成化合物7v呈 白色粉末。於醛醇加成化合物7v (4.00g,10.0··〇1 )於 甲苯(100ml)之溶液内加入對-甲苯磺酸水合物(20〇Bg) 。混合物加熱至回流經歴30分鐘。反應混合物Μ水(200 ml)洗兩次,K無水硫酸納乾燥及真空濃縮。所得殘渣 於氧化矽凝膠上接受柱式層析且以正己烷/乙酸乙酯(3 :1 )溶離出之溶離分經收集,真空濃縮及由正己烷/醚 之混合物中再結晶而得1.346g (40%)目檫化合物呈無色 結晶。 化合物 8Id : m.p.= 152-1541C . IRiNujoDcm1 : 3608,2914,1638,1597,1461.1376,1285, 1214, 1133. NMR(CDC13)5 : 1.45(18H,s,2x BuM,2.31(2H,q,J=7Hz, CHa),3.00-3.07(4H,m,2x CHS),5.51(1H,s, OH),7.22(1H, t,J=2.6Hz,CH),7.26(2H,s,Ar-H). 兀素分析(CisHaeOaS〉 計算值:C,67.82;H,8_38;S,9.53 本紙張尺度適用中國國家標準(CNS ) A4規格(210X25)7公楚) . 一 1 -: - - - - - 111 訂 I--.4. (請先閲讀背面之注意事項再填寫本頁) A7 B7 五、發明説明U〇Aldehyde was performed according to a similar method as in Example 1 using cyclamidine 4q (2.4g, 20mi »0l) and 3,5-di-tertiarybutyl-4-methoxymethoxybenzaldehyde 6a (5.57g, 20 ββοΙ). The alcohol reacted to give 5-58 g (70%) of the addition compound 7v as a white powder. To a solution of the aldol addition compound 7v (4.00 g, 10.0 ·· 01) in toluene (100 ml) was added p-toluenesulfonic acid hydrate (20 Bg). The mixture was heated to reflux for 30 minutes. The reaction mixture was washed twice with water (200 ml), dried over anhydrous sodium sulfate, and concentrated in vacuo. The obtained residue was subjected to column chromatography on a silica gel, and the fractions eluted with n-hexane / ethyl acetate (3: 1) were collected, concentrated in vacuo, and recrystallized from a n-hexane / ether mixture to obtain 1.346. g (40%) of the mesh gadolinium compound was colorless crystals. Compound 8Id: mp = 152-1541C. IRiNujoDcm1: 3608,2914,1638,1597,1461.1376,1285, 1214, 1133. NMR (CDC13) 5: 1.45 (18H, s, 2x BuM, 2.31 (2H, q, J = 7Hz, CHa), 3.00-3.07 (4H, m, 2x CHS), 5.51 (1H, s, OH), 7.22 (1H, t, J = 2.6Hz, CH), 7.26 (2H, s, Ar-H) . Element analysis (CisHaeOaS> Calculated value: C, 67.82; H, 8_38; S, 9.53 This paper size applies to China National Standard (CNS) A4 specification (210X25) 7 Gongchu). 1 1-:----- 111 Order I-. 4. (Please read the notes on the back before filling this page) A7 B7 V. Description of the invention U〇

實測值:C,67.90 ;Η,8· 38 ;S,9.34· 審例34 ^丨二-第三丁某-4-鄉1亞苄某-2-申某-HMeasured value: C, 67.90;;, 8.38; S, 9.34. Examination example 34 ^ 丨 Second-third Dingmou-4-Xiang 1 Benzyme-2-Shenmou-H

CHO V0 +CHO V0 +

N-Me - LD-^- O 4jlN-Me-LD-^-O 4jl

OHOH

p-TsOH 經濟部中央標隼局員工消費合作社印裝p-TsOH Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs

根據實例1之類似方法,使用N-甲基-1,3,2-噻噚哄-1,卜二氧化物打(575料,3.80«〇1)及3,5-二-第三丁基 -4-甲氧甲氧苯甲醛6a ( 846ag,304mm〇l)進行醛醇反應 而得1.458g加成化合物7w呈白色粉末。於醛醇加成化合物 7w ( 1.458g)於甲苯(50祖1)之溶液内加入對-甲苯磺酸 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0 X 297公釐) 62 I.„---.;---"L--裝------訂------旅 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標隼局員工消費合作社印裝 A7 B7 五、發明説明(61 ) 水合物(15〇Bg)。混合物加熱至回流經歴30分鐘。反應 產物於氧化矽凝膠上接受柱式層析且使用正己烷/乙酸乙 酯(6: 1)之混合物溶離出溶離分,獲得目檫化合物(511 as,43%)呈無色結晶。 化合物 8Ie: 84, = 215-216.510. IRiKBricm1 : 3599,3438,2960,1637,1599,1437,1326, 1298,1153. NMR(CDC13)5 : 1.44(18H,s,2x BuM.B.OOOH.s.CHa), 3.26-3.32(2H(ni,CHa) ,4. 12-4. 17(2H,n,CHa) ,5.49(lH,s, OH),7. 15(2H,s, Ar-H) ,7.55(1H,寬,CH) · 元素分析(ClsHa9NCUS) 計算值:C,62.10;H,7_95;N,3.81;S,8.72 實測值:C,62_03;H,7·91;N,3_92;S,8_51According to a similar method as in Example 1, N-methyl-1,3,2-thiazepine-co--1,2-dioxolidine (575, 3.80 «〇1) and 3,5-di-third-butyl 4-methoxymethoxybenzaldehyde 6a (846ag, 304 mm) was subjected to an aldol reaction to obtain 1.458 g of the addition compound 7w as a white powder. P-toluenesulfonic acid was added to a solution of aldol addition compound 7w (1.458g) in toluene (50 oz. 1). The paper size is applicable to Chinese National Standard (CNS) A4 (2 丨 0 X 297 mm) 62 I . „--- .; --- " L--installation ------ order ------ brigade (please read the precautions on the back before filling out this page) Staff of Central Bureau of Standards, Ministry of Economic Affairs Printed by Consumer Cooperative A7 B7 V. Description of the invention (61) Hydrate (150Bg). The mixture was heated to reflux for 30 minutes. The reaction product was subjected to column chromatography on silica gel using n-hexane / ethyl acetate. The mixture of (6: 1) was dissolved and the dissolved fraction was obtained, and the obtained compound (511 as, 43%) showed colorless crystals. Compound 8Ie: 84, = 215-216.510. IRiKBricm1: 3599,3438,2960,1637,1599,1437 , 1326, 1298,1153. NMR (CDC13) 5: 1.44 (18H, s, 2x BuM.B.OOOH.s.CHa), 3.26-3.32 (2H (ni, CHa), 4. 12-4. 17 ( 2H, n, CHa), 5.49 (lH, s, OH), 7.15 (2H, s, Ar-H), 7.55 (1H, width, CH) · Elemental analysis (ClsHa9NCUS) Calculated value: C, 62.10; H, 7_95; N, 3.81; S, 8.72 Found: C, 62_03; H, 7 · 91; N, 3_92; S, 8_51

SJ@L1S (FJ-6- ( -笛三 T 某-4-卸)邸 ¥ 某-2-申氩-3.4.5. 6-四氩-1 . 9-瞌 ntt -1 .1 -二氬化物(8ΙΠSJ @ L1S (FJ-6- (-flute three T certain -4- unloading) Di ^ certain -2-shen argon 3.4.5. 6-tetra argon -1. 9- 瞌 ntt -1 .1-di argon物 (8ΙΠ

本紙張尺度適用中國國家標準(CNS ) A4规格(210X 297公釐) - ----------^--—"L--裝------訂------^ -------- (請先閱讀背面之注意事項再填寫本頁) A7 B7This paper size applies to China National Standard (CNS) A4 specification (210X 297 mm)----------- ^ ---- " L--packing ------ order ---- -^ -------- (Please read the notes on the back before filling this page) A7 B7

五、發明説明(62V. Description of the invention (62

0H0H

p-TsOHp-TsOH

根據實例1之類似方法使用N-甲氧-3,4,5,6-四氫-1, 2-睡畊-1,卜二氧化物 4s (2.73g,16_5mmol)及 3,5-二-第三丁基-4-甲氧甲氧苯甲薛6a (5.0mg,18mmol)進行酸 醇反應而得7.3g加成化合物7x。於醛醇加成化合物7x ( 2.1g,4.73mmol)於甲苯(100ml)之溶液内加入對-甲苯 磺酸水合物(20〇Bg)且混合物加熱至回流經歷30分鐘。 反應產物於氧化矽凝膠上接受柱式層析及由Μ正己烷/乙 酸乙酯(4: 1)溶離之溶離分中獲得目檫化合物( 750mg ,42%)呈褐色粉末。 IR(CHC13)cm-1 : 3618,2950,1630,1435,1340,1238,1161. NMR(CDC13)§ : 1.45(18H,s,2x BuM , 1.80-1.95 (2H,in, CHa),3.04(2H,t,J = 6.0Hz,CHs),3.77-3.83(2H,ia>CHa)I 3.80(3H,s,0CH3),5.46(lH.s,OH),7.20(2H,s,Ar-H),7.46 (lH.s,CH). 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) I.„---^--IL--裝------訂------S. (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印裝 ch3s〇2nC【h + 12 A7 B7 五、發明説明(63 ) 奮例36 二-笛芑丁某-4-浑)亞苄基-2-乙基-1.2-里 皤邮腚-酮-1 .1 -二氣化物(8 Ικ) (1) d 5-二-笛三丁某-4-申氣甲氩荣甲醯基)-N-乙某-N-二芏某申某甲烷礒酪胺(14)N-methoxy-3,4,5,6-tetrahydro-1, 2-sleeper-1, dioxane 4s (2.73 g, 16-5 mmol) and 3,5-di- The third butyl-4-methoxymethoxybenzoxe 6a (5.0 mg, 18 mmol) was subjected to acid-alcohol reaction to obtain 7.3 g of addition compound 7x. To a solution of the aldol addition compound 7x (2.1 g, 4.73 mmol) in toluene (100 ml) was added p-toluenesulfonic acid hydrate (20Bg) and the mixture was heated to reflux for 30 minutes. The reaction product was subjected to column chromatography on a silica gel, and the title compound (750 mg, 42%) was obtained as a brown powder from the fraction obtained by dissolving M n-hexane / ethyl acetate (4: 1). IR (CHC13) cm-1: 3618,2950,1630,1435,1340,1238,1161. NMR (CDC13) §: 1.45 (18H, s, 2x BuM, 1.80-1.95 (2H, in, CHa), 3.04 ( 2H, t, J = 6.0Hz, CHs), 3.77-3.83 (2H, ia > CHa) I 3.80 (3H, s, 0CH3), 5.46 (lH.s, OH), 7.20 (2H, s, Ar-H ), 7.46 (lH.s, CH). This paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) I. „--- ^-IL--installation ------ order-- ---- S. (Please read the notes on the back before filling this page) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs ch3s〇2nC [h + 12 A7 B7 V. Description of the Invention (63) Fen Example 36 II- Diazepam-4-hundronyl) benzylidene-2-ethyl-1.2-lipidone-one-1. 1-digas (8 Ικ) (1) d 5-di-diazine -4-Shenqi Methyl Argonyl Methionyl) -N-Ethyl-N-Dioxine Shenshen Methane Tyramine (14)

OMOMOMOM

LiHMDS 丫 /OMeLiHMDS YA / OMe

conCconC

Me 13 11— I n Ml i — J I I -— (請先閲读背面之注意事項再填寫本頁)Me 13 11— I n Ml i — J I I -— (Please read the notes on the back before filling this page)

.?τ 經濟部中央標準局員工消費合作社印製 (bh=ch(c6h5)2 M習知方式合成化合物(II),係經由令甲烷磺醯氯與 二苯基甲基胺於三乙胺存在下反應,接箸使用乙基碘於碳 酸鉀存在下處理所得產物。化合物(11)之製法係經由Μ習 知方式將3,5-二-第三丁基-4-羥苯甲酸轉成醯氯,及令酿 氣與Ν,Ο-二甲基羥胺反醮接著進行酚条羥基之甲氧甲基化 反應。 化合物(12J (16.82g,58··οΙ)於 THF <200ml)之溶 Λ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) A7 B7 五、發明説明(64 ) 液冷卻至低於-50Ό。溶液內緩慢逐滴加入鋰貳三甲基矽 烷醯胺於THF ( 1.0M) (64·1,64··ο1 )之溶液及混合物 於-50t攪拌30分饞。隨後將化合物(LI〉( 17.7g,52.2 Mol)於THF (lOOinl)之溶液緩慢逐滴加入混合物内。反 應溶液溫熱至室溫後,將氯化銨飽和水溶液( 500ml)加 入其中。所得混合物以乙酸乙酯( 400ml)抽取。取出有 機層,以飽和碩酸氫納水溶液( 500ml)及飽和鹽水(500 ml)洗滌,以無水硫酸納乾燥及真空蒸發而去除溶劑。殘 渣於氧化矽凝膠上藉柱式層析純化並Μ正己烷/乙酸乙酯 (9: 1至7: 1)溶離而得27 _2g (92%)化合物U里無色 油。 IR(CHC13)cni-1 : 2960,1673,1339,1188. NMR(CDCU)5 : 0.83(BH,t,J = 7.0Hz,CHa), 1.45(18H,s, 2X fBu),3.56(2H,q,J=7.0Hz,CH*),3.65(3H,s,CH3),4.37 (2H,s, CHS),6.42(1H, s, CH),7.3卜7.38(10H, m, l〇X 芳香-H) ,7.89(2H,s,2X 芳香-Η). I-------r--裝------訂----------t (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 (2)笛孑-丁甚-3- ( 3.5-二-笛三丁甚-4-田督.氩荣甲酿 某、-3- ( N-Z某-N-二茱某田甚脓磋醣某)丙酴酷(1 5).? τ Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (bh = ch (c6h5) 2 M The conventionally synthesized compound (II) is obtained by the presence of methanesulfonyl chloride and diphenylmethylamine in triethylamine The reaction is followed by treatment of the product with ethyl iodide in the presence of potassium carbonate. The method for preparing compound (11) is to convert 3,5-di-third-butyl-4-hydroxybenzoic acid to hydrazone by conventional methods. Chlorine, and the fermentation gas with Ν, Ο-dimethylhydroxylamine, followed by a methoxymethylation reaction of the phenolic strip hydroxyl. Compound (12J (16.82g, 58 ·· Ι) in THF < 200ml) Λ This paper size applies Chinese National Standard (CNS) A4 (210X 297 mm) A7 B7 V. Description of the invention (64) Liquid cooling to less than -50 ° C. Lithium trimethylsilylamine is slowly added dropwise into the solution. The solution and mixture in THF (1.0M) (64 · 1, 64 ·· ο1) were stirred at -50t for 30 minutes. Then the solution of the compound (LI> (17.7g, 52.2 Mol) in THF (100inl) was slowly washed one by one. The mixture was added dropwise. After the reaction solution was warmed to room temperature, a saturated aqueous solution of ammonium chloride (500 ml) was added thereto. The resulting mixture was acetic acid Ester (400ml) was extracted. The organic layer was taken out, washed with a saturated sodium hydrogen persulfate aqueous solution (500ml) and saturated brine (500ml), dried over anhydrous sodium sulfate and evaporated in vacuo to remove the solvent. The residue was borrowed on a silica gel column Purified by chromatography and dissolved in n-hexane / ethyl acetate (9: 1 to 7: 1) to give 27_2g (92%) of compound U as a colorless oil. IR (CHC13) cni-1: 2960,1673,1339, 1188. NMR (CDCU) 5: 0.83 (BH, t, J = 7.0Hz, CHa), 1.45 (18H, s, 2X fBu), 3.56 (2H, q, J = 7.0Hz, CH *), 3.65 (3H , s, CH3), 4.37 (2H, s, CHS), 6.42 (1H, s, CH), 7.3 and 7.38 (10H, m, 10X aromatic-H), 7.89 (2H, s, 2X aromatic-fluorene) ). I ------- r--install ------ order ---------- t (Please read the notes on the back before filling this page) Central Bureau of Standards, Ministry of Economic Affairs Printed by employee consumer cooperatives (2) Di 孑 -Ding Shi-3- (3.5-Second-Di San Dingxi-4-Tian Du. Ar Rong Jia Bing, -3- (NZ-N-N-Erhu, Tian Very pussy sugar) Bing 酴 cool (1 5)

五'、發明説明(65 A7 B7 〇Five ', description of the invention (65 A7 B7 〇

S〇2N: C02'BuS〇2N: C02'Bu

.Et 'BH.Et 'BH

經濟部中央標準局員工消費合作社印裝 (3,5-二-第三丁基-4-甲氧甲氧苯甲醯基)-N-乙基-N-二苯基甲基甲烷磺醸胺(II〉(27.0g,47.7mmol),溴 乙酸第三丁酯(9.25ml,57.3mmol),及碩酸鉀(9.89g ,71.6mmol)於DMF( 300ml)之懸浮液於室溫攪拌18小時 。懸浮液内加水( 600ml)及反應混合物Μ乙酸乙酯(800 ml)抽取。分離有機層,以水(300β1)及飽和鹽水(500 ml)洗滌,Μ無水硫酸納乾燥及真空蒸餾而去除溶劑。所 得淡黃色固體當使用正己烷徹底洗滌及真空濃縮獲得26.75g (82%)化合物15_呈無色粉末(m.p.= l〇4-105t:)。 IR(KBr)cm-1 : 3435,1735,1677,1340,1164,1147. NMR(CDC13)S : 0.77(3H,t,J=7.0Hz,CH3),1.21<9H,s,tBu), 1.44(18H,s,2x Mu),2.83(lH,dd,J = 3.2, 16.8Hz,CHa X 1/2>, 3-29-3.51(3H,m,CHa+CHa x 1/2),3.65(3H,s,CH3),4.90(2H, s,CH2)>5.28(lH,dd,J=3.2,10.4Hz)CH),6.B9(lH>s,CH),7.3l -7.34(1011,|1,10\芳香-1〇,7.96(211,3,2><芳香-1〇. 元素分祈(C3sHa3N0TS) 計算值:C,68.90;H,7.86;N,2.06;S,4.72 實测值:C,68.80,·H,7·93;N,2_16;S,4·55· (3) 第^丁基-4- dR-一-笛=丁苓甲氩申氩笼甚) :苯基甲基胺猶酵某)丁酸酿(1 R) 本纸張尺度適用中國ϋ家標準(CNS) M規格(2 ] 〇 χ 297公楚 ——& -67 ___1 (請先閲讀背面之注意事項再填寫本頁) -裝· 訂 A7 B7 五、 發明説明(66Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (3,5-di-third-butyl-4-methoxymethoxybenzyl) -N-ethyl-N-diphenylmethylmethanesulfonamide (II> (27.0 g, 47.7 mmol), a third butyl bromoacetate (9.25 ml, 57.3 mmol), and a suspension of potassium sulphate (9.89 g, 71.6 mmol) in DMF (300 ml) was stirred at room temperature for 18 hours Water was added to the suspension and the reaction mixture was extracted with ethyl acetate (800 ml). The organic layer was separated, washed with water (300β1) and saturated brine (500 ml), dried over anhydrous sodium sulfate and distilled under vacuum to remove the solvent. The obtained pale yellow solid was thoroughly washed with n-hexane and concentrated in vacuo to obtain 26.75 g (82%) of compound 15 as a colorless powder (mp = 104-105t :). IR (KBr) cm-1: 3435, 1735, 1677,1340,1164,1147. NMR (CDC13) S: 0.77 (3H, t, J = 7.0Hz, CH3), 1.21 < 9H, s, tBu), 1.44 (18H, s, 2x Mu), 2.83 ( lH, dd, J = 3.2, 16.8Hz, CHa X 1/2 >, 3-29-3.51 (3H, m, CHa + CHa x 1/2), 3.65 (3H, s, CH3), 4.90 (2H, s, CH2) > 5.28 (lH, dd, J = 3.2,10.4Hz) CH), 6.B9 (lH &s; s, CH), 7.3l -7.34 (1011, | 1,10 \ aromatic-1〇, 7.96 (211,3,2 > < Aromatic-1〇. Elemental elemental prayer (C3sHa3N0TS) Calculated value: C, 68.90; H, 7.86; N, 2.06; S, 4.72 Found: C, 68.80, · H, 7.93; N, 2_16; S, 4 · 55 · (3) Butyl-4- dR-a-di = Dingling Methane Arsenic cage): Phenylmethylamine still fermented) Butyric acid (1 R) This paper is applicable to China Family Standard (CNS) M Specification (2) 〇χ 297 公 楚 —— & -67 ___1 (Please read the precautions on the back before filling out this page)-Binding and ordering A7 B7 V. Description of the invention (66

S〇2N: C〇21BuS〇2N: C〇21Bu

.Et •BH.Et • BH

NaBH4 CHgC 丨 2_ ΜθΟΗNaBH4 CHgC 丨 2_ ΜθΟΗ

OHOH

C02*BuC02 * Bu

S〇2NS〇2N

BH I, i In n·'- -- · ^^1 - (請先閱讀背面之注意事項再填寫本頁) 於第三-丁基-3- (3,5-二-第三丁基-4-甲氧甲氧苯甲 醢基)-3- (H-乙基-N-二苯基甲基甲烷磺醢基)丙酸酯 (15) (22.6g,33.2inmol)於 MeOH (180nl)及 CH»Cla ( 180ml )之混合物之溶液於加冰冷郤下分成數份加入硼氫 化納(1.89g,49.9aniol )。所生成之混合物溫熱至室溫 且攪拌45分鐘。然後於混合物内依次加入丙酮(5ml)及 飽和氯化銨水溶液( 400ml ),及反應混合物以二氯甲烷 ( 400ml)抽取。分離有機層,Μ水( 400ml)及飽和鹽水 ( 400ml)洗滌,以無水硫酸鈉乾燥及真空蒸餾而去除溶 劑。所得淡粉紅色固體當使用正己烷徹底洗滌時獲得21.8g (96% )化合物〇£_)呈無色粉末。 IRiKBrJcm-1 : 3499,2970,1737,1600,1319,1151. NMR(CDC13)5 : 0.84(3H,t>J=7.0Hz>CH3)>1.21(9H(sItBu), 1.41(18H,s,2xtBu),2.22(lH,dd>J=6.6,17.6Hz,CHexl/2), 2.48(lH,dd,J=4.2,17.6Hz,CH,x 1/2),3.37-3.58(2H,m,CHa), 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐)BH I, i In n · '--· ^^ 1-(Please read the notes on the back before filling out this page) In the third-butyl-3- (3,5-di-third-butyl- 4-methoxymethoxybenzyl) -3- (H-ethyl-N-diphenylmethylmethanesulfonyl) propionate (15) (22.6 g, 33.2 inmol) in MeOH (180nl) The solution of the mixture with CH »Cla (180 ml) was added in several portions under cooling with ice, and sodium borohydride (1.89 g, 49.9 aniol) was added. The resulting mixture was warmed to room temperature and stirred for 45 minutes. Then, acetone (5 ml) and a saturated ammonium chloride aqueous solution (400 ml) were sequentially added to the mixture, and the reaction mixture was extracted with dichloromethane (400 ml). The organic layer was separated, washed with M water (400 ml) and saturated brine (400 ml), dried over anhydrous sodium sulfate and vacuum distilled to remove the solvent. The resulting pale pink solid, when thoroughly washed with n-hexane, gave 21.8 g (96%) of the compound as a colorless powder. IRiKBrJcm-1: 3499, 2970, 1737, 1600, 1319, 1151. NMR (CDC13) 5: 0.84 (3H, t > J = 7.0Hz > CH3) > 1.21 (9H (sItBu), 1.41 (18H, s, 2xtBu), 2.22 (lH, dd > J = 6.6, 17.6Hz, CHexl / 2), 2.48 (lH, dd, J = 4.2,17.6Hz, CH, x 1/2), 3.37-3.58 (2H, m, CHa), This paper size applies to China National Standard (CNS) Α4 specification (210X297 mm)

.1T Λ - 經濟部中央標準局員工消費合作社印製.1T Λ-Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs

A7 B7 五、發明説明(67 3,62(3H> S,CH3),3.92-4.07(1H,m,CH),4.14(1H,d,J = 2.2Hz; OH),4.86(2H,s,CHa),4.97( lH,dd,J = 2.2,9.2Hz,CH),6.47( 1H,S,CH),7. 19(2H,s,2X 芳香-H) ,7.32-7.34(10H,m, l〇x 芳香-H). 元素分析(C33HaeN〇7S · 〇.7H»0> 計算值:C,67.44;H,8.18;N,2.02;S,4.62 實撕值:C,67.50;H,8_06;N,2.15;S,4.51. ⑷第^-~r苓-4- m-二-第三丁某-4-田氩申窗.芏奠)-4-羥.某貯声醃甚)丁酴酷Μ 7)A7 B7 V. Description of the invention (67 3, 62 (3H > S, CH3), 3.92-4.07 (1H, m, CH), 4.14 (1H, d, J = 2.2Hz; OH), 4.86 (2H, s, CHa), 4.97 (lH, dd, J = 2.2, 9.2 Hz, CH), 6.47 (1H, S, CH), 7. 19 (2H, s, 2X aromatic-H), 7.32-7.34 (10H, m, l〇x aromatic-H). Elemental analysis (C33HaeN〇7S · 0.7H »0 > Calculated value: C, 67.44; H, 8.18; N, 2.02; S, 4.62 Real tear value: C, 67.50; H, 8_06 ; N, 2.15; S, 4.51. ⑷ 第 ^-~ r 凌 -4- m- 二-三 丁丁 -4- 田 氩 申 窗. 芏 芏) -4-Hydroxy. Some storage sound pickled even) Ding 酴 ku Μ 7)

C02'BuC02'Bu

OH ^Et S02NOH ^ Et S02N

BHBH

[H2] Pd(〇H)/C THF-MeOH[H2] Pd (〇H) / C THF-MeOH

OHOH

S02NHEt C02'Bu —„---^--ί--裝------訂------Λ. (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標隼局員工消費合作社印製 第三-丁基-4- (3,5-二-第三丁基-4-甲氧甲氧苯基) -4-羥-3- (N-乙基-N-二苯基甲基)-4-羥-3- (N-乙基-N-二苯基甲基胺磺醯基)丁酸酯(L6J (20.8g,30.5mmol) 及氫氧化耙/磺(3.05g)於THF(lOOnl)及甲醇(200道1 )之混合物之懸浮液於室溫於氫下攪拌5小時。經由乙醯 本紙張尺度適用中國國家標準(CNS ) A4規格(210x297公釐) A7 B7 五、發明説明(68 ) 塑料(celite)過濾去除觭媒及將濾液濃縮。殘渣由醚-正 己垸中再結晶而得13.69g (87%)化合物〇!_) (β·ρ· = 96 -9710)。 IR(KBr)cm-1 : 3441,3298,2966,1736,1635,1367,1152. NMR(CDC13)§ : 1.15(3H,t,J=7.4Hz,CH3),1.36<9H,s,*Bu), 1.44(18H,s,2x ^Bu),2.31(lH,dd,J=5.6,17.6Hz,CHax 1/2), 2.80(1H,dd,J = 6.6,17.6Hz,CH* x 1/2),3.00-3.27(2H,m,CH*), 3.40(lH,d,J=4.8Hz,0H),3.64(3H,s,CH3),3.97(lH,ddd,J= 5_6,6.6,8.2Hz,CH),4.19-4.25(lH,m,NH〉,4.89(2H,s,CHa), 4.95(111,(1(1,<1 = 4.8,8_2112,(:1〇,7_27(211,3,2\芳香-1〇· 元素分析(CaeH4eN07S) 計算值:C,60.56;H,8.80;N,2.72;S,6.22 實測值:C,60.37;H,8.72;N,2.69;S,6.17. (5) 5- 二-笛三丁某-4-揮荣甚)-4- f .甚 礎 醅某)-r-丁肉酯(18) I «I Jmmf HL In *^-々 (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局員工消費合作社印製S02NHEt C02'Bu — „--- ^-ί--install -------- order ------ Λ. (Please read the notes on the back before filling this page) Central Bureau of Standards, Ministry of Economic Affairs Tertiary-butyl-4- (3,5-di-tertiarybutyl-4-methoxymethoxyphenyl) printed by employee consumer cooperatives 4-hydroxy-3- (N-ethyl-N-di Phenylmethyl) -4-hydroxy-3- (N-ethyl-N-diphenylmethylaminesulfonyl) butyrate (L6J (20.8g, 30.5mmol) and hydroxide / sulfonate (3.05 g) Suspension in a mixture of THF (100nl) and methanol (200 channels 1) at room temperature under hydrogen for 5 hours. Applicable to Chinese National Standard (CNS) A4 size (210x297 mm) A7 paper size B7 V. Description of the invention (68) Plastic filter (celite) to remove the solvent and concentrate the filtrate. The residue was recrystallized from ether-n-hexane to obtain 13.69 g (87%) of the compound 〇! _) (Β · ρ · = 96 -9710). IR (KBr) cm-1: 3441,3298,2966,1736,1635,1367,1152. NMR (CDC13) §: 1.15 (3H, t, J = 7.4Hz, CH3), 1.36 < 9H , s, * Bu), 1.44 (18H, s, 2x ^ Bu), 2.31 (lH, dd, J = 5.6,17.6Hz, CHax 1/2), 2.80 (1H, dd, J = 6.6,17.6Hz, CH * x 1/2), 3.00-3.27 (2H, m, CH *), 3.40 (lH, d, J = 4.8Hz, 0H), 3.64 (3H, s, C H3), 3.97 (lH, ddd, J = 5-6, 6.6, 8.2 Hz, CH), 4.19-4.25 (lH, m, NH>, 4.89 (2H, s, CHa), 4.95 (111, (1 (1, < 1 = 4.8,8_2112, (: 1〇, 7_27 (211,3,2 \ aromatic-1〇 · elemental analysis (CaeH4eN07S) calculated value: C, 60.56; H, 8.80; N, 2.72; S, 6.22 found Values: C, 60.37; H, 8.72; N, 2.69; S, 6.17. (5) 5-Di-DiSanDingMou-4-WuRongYi) -4-f. Meat Ester (18) I «I Jmmf HL In * ^-々 (Please read the notes on the back before filling out this page) Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs

OHOH

S02NHEt C02lBuS02NHEt C02lBu

TMSI CHCI,TMSI CHCI,

S02NHEt 18S02NHEt 18

- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 經濟部中央標準局員工消費合作社印製 A7 B7 --------------- 五、發明説明(69 ) 於第三-丁基-4- (3,5-二-第三丁基-4-甲氧甲氧苯基 )- 4-羥-3- (N-乙基胺磺酿基)丁酸酯〇!_) (1.10g,2_13 mmol)於氣仿(30ml)之溶液內於加冰冷卻下一次加入碘 三甲基矽烷(TMSI〉(0_91ml,6.39Bm〇l)及所得溶液於同 溫攪拌30分鐘,加入5%碇代碕酸納水溶液(70ml)後, 反應混合物Μ二氣甲烷(60·1)抽取兩次。合併的有機層 Μ飽和鹽水(70ml)洗2次,Κ無水碕酸銷乾燥及真空蒸 餾去除溶劑。殘渣於氧化矽凝膠上藉柱式層析純化以正己 烷/乙酸乙酯(3: 1)溶離而得481mg (57%)化合物(11) 呈無色固體。m.p.= 129-131C。 IR(CHCl3)cm-1 : 3626,3374,3288,2960,1785,1436,1331. NMR(CDC13)5 : 1.08(3H,t,J=7.2Hz,CH3),1.44(18H,s,2 x "Bu)(2.90-3.22(2H,m,CH2),3.07(2H,d,J-7.6Hz,CHs), 3.94(lH,dt, J = 5.0,7.6Hz,CH〉,4.25(1H,寬,t,J = 6.0Hz, NH),5.38(1H)S)0H),5.72(lH,d,J=5.0Hz,CH),7.12(2H,s, 2X芳香-H). 元素分析(CmH^NC^S) 計箕值:C,60.43;H,7_86;N,3.52;S,8.07 實測值:C,60.32;H,7.84;N,3.55;S,7.85. ⑹红丄二1_-(3.5-二-第三丁基-4-粹荣某、-2-〇1-7.甚 ) -丁拢酴 f1Q) 本紙張尺度適『中A4規格 (210X297公釐) ----------裝------訂------.,1 (請先閲讀背面之注意事項再填寫本頁) A7 B7 五、 發明説明(70 )-This paper size applies to Chinese National Standard (CNS) A4 (210 X 297 mm). Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs. A7 B7 --------------- V. Invention Description (69) for tert-butyl-4- (3,5-di-tert-butyl-4-methoxymethoxyphenyl) -4-hydroxy-3- (N-ethylaminesulfonyl ) Butyrate 〇! _) (1.10g, 2_13 mmol) in a gas-form (30ml) solution was added with iodine trimethylsilane (TMSI> (0_91ml, 6.39Bmol)) and the resulting solution under ice cooling in one portion After stirring at the same temperature for 30 minutes, after adding a 5% sodium sulfonate aqueous solution (70 ml), the reaction mixture M digas methane (60 · 1) was extracted twice. The combined organic layers were washed twice with saturated brine (70 ml) K was dried over anhydrous acetic acid and the solvent was removed by vacuum distillation. The residue was purified by column chromatography on silica gel, and the solvent was dissolved in n-hexane / ethyl acetate (3: 1) to obtain 481 mg (57%) of compound (11). Colorless solid. Mp = 129-131C. IR (CHCl3) cm-1: 3626,3374,3288,2960,1785,1436,1331. NMR (CDC13) 5: 1.08 (3H, t, J = 7.2Hz, CH3) , 1.44 (18H, s, 2 x " Bu) (2.90-3.22 (2H, m, CH2), 3.07 (2H, d, J-7.6Hz, CHs), 3.94 (lH dt, J = 5.0, 7.6 Hz, CH>, 4.25 (1H, wide, t, J = 6.0 Hz, NH), 5.38 (1H) S) 0H), 5.72 (lH, d, J = 5.0 Hz, CH) , 7.12 (2H, s, 2X aromatic-H). Elemental analysis (CmH ^ NC ^ S) Calculated value: C, 60.43; H, 7_86; N, 3.52; S, 8.07 Found: C, 60.32; H, 7.84; N, 3.55; S, 7.85. ⑹ 红 丄 二 1 _- (3.5-di-third butyl-4-Ci Rongmou, -2-〇1-7. Even)-Ding Luo 酴 f1Q) paper Standard size "Medium A4 size (210X297 mm) ---------- Installation ------ Order ------., 1 (Please read the precautions on the back before filling this page ) A7 B7 V. Description of the invention (70)

DBU 苯DBU benzene

19 經濟部中央標準局員工消費合作社印製 於5- (3,5-二-第三丁基-4-羥苯基)-4- (N-乙基胺 磺醢基)-r-丁內酯(ISJ (l_516g,3_81β·ο1)於苯(50 ml)之溶液内加入DBU (1.14ml乃7.62mmol )及混合物於 相同條件下攪拌30分鐘,接著加入1NHC1(60b1)。反應 混合物Μ乙酸乙酯(7〇nl)抽取。分離有機層,Μ水(60 Bl)及飽和鹽水(60nl)洗滌及Μ無水碕酸鈉乾燥。溶液 於真空蒸餾而去除溶劑,獲得1.52g (定量)化合物1 9呈 無色固龌。m. P. = 169-172t:。 IR(KBr)cm-1 : 3604,3267,2958,1719,1631,1596,1430, 1326,1158. NMR(CD3〇D)5 : 1. 15(3H,t, J-7.4Hz,CH3),1.43(18H,s,2 x "Bu) ,2.99(2H,q,J = 7.4Hz,CHS),3.63(2H.S.CH,),7.29 (2H,s,2x 芳香-H ),7.58 (lH,s,CH). 元素分析(CaeH31N0eS〉 計算值:C,60.43;H,7.86;N,3.52;S,8.07 實测值:C,60.36;H,7.95;N,3.54;S,7.87. ⑺IE)-5-(入二-笛三丁某-4-羥)亞午某•某-1. 2-異瞇 _ 啶-1 .1 -二氩仆.物(8Ig) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -WWi I.^----------裝------訂------,^*· (請先閲讀背面之注意事項再填寫本頁) 五、 發明説明(Ή ) A7 B719 Printed by 5- (3,5-di-tertiarybutyl-4-hydroxyphenyl) -4- (N-ethylaminesulfonyl) -r-butane Ester (ISJ (l_516g, 3_81β · ο1) was added to a solution of benzene (50 ml) in DBU (1.14 ml was 7.62 mmol) and the mixture was stirred under the same conditions for 30 minutes, and then 1NHC1 (60b1) was added. Reaction mixture M ethyl acetate Ester (70 nl) was extracted. The organic layer was separated, washed with M water (60 Bl) and saturated brine (60nl), and dried with anhydrous sodium sulphate. The solution was distilled under vacuum to remove the solvent to obtain 1.52 g (quantitative) of Compound 1 9 It was colorless and solid. M. P. = 169-172t: IR (KBr) cm-1: 3604, 3267, 2958, 1719, 1631, 1596, 1430, 1326, 1158. NMR (CD3〇D) 5: 1 15 (3H, t, J-7.4Hz, CH3), 1.43 (18H, s, 2 x " Bu), 2.99 (2H, q, J = 7.4Hz, CHS), 3.63 (2H.S.CH, ), 7.29 (2H, s, 2x aromatic-H), 7.58 (lH, s, CH). Elemental analysis (CaeH31N0eS> Calculated value: C, 60.43; H, 7.86; N, 3.52; S, 8.07 Found: C, 60.36; H, 7.95; N, 3.54; S, 7.87. ⑺IE) -5- (into di-ditributane-4-hydroxy) Mouwu · Mou-1. 2-Isopyridine_pyridine-1 .1-Diargon Substance (8Ig) China National Standard (CNS) A4 Specification (210X297 mm) -WWi I. ^ ---------- Installation ------ Order ------, ^ * · (Please read first Note on the back, please fill out this page again) 5. Description of the invention (Ή) A7 B7

CIC〇2Et NEt3 〇CIC〇2Et NEt3 〇

(請先閲讀背面之注意事項再填寫本頁) .裝. 經濟部中央標隼局員工消費合作社印t 81g 於(£)-4-(3,5-二-第三丁基-4-羥苯基)-3-(^乙 基胺基磺酿基)-3-丁烯酸Il_(1.52g,3_81mmol)及三乙 胺( 0.737ml,1·5當量)於二氯甲烷(60ml)之溶液内於 Μ水冷卻下伴Μ攪拌逐滴加入氣磺酸乙酯(〇· 437ml,1.2 當量)及混合物又攪拌50分鐘。加入水(60ml)後,反應混 合物Μ二氯甲烷(50ml)抽取。有機層以飽和鹽水(70ml )洗滌,以無水硫酸鈉乾燥及真空蒸餾而去除溶劑。所得 粗結晶以醚洗而得1.30g (89.9%)目檫化合物呈無色結 晶0 化合物 8Ig : B.p. = 188-19010 . IRCKBrJcm-1 : 3559,2960,1715,1641,1598,1434,1317, 1159. NMR(CDC13)5 : 1.38(3H,t,CH3) , 1.46(18H,s,2x BuM , 3.74(2H,q,J = 7.2Hz,CHa),3.80 (2H,d,J = 2.4Hz,CH«),5.64 (1H,s,0H),7.23(2H,s,Ar-H),7.45(1H,t,J=2.4Hz, CH).(Please read the precautions on the back before filling out this page). Packing. 81 g printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs at (£) -4- (3,5-di-tert-butyl-4-hydroxy Phenyl) -3-(^ ethylaminosulfonyl) -3-butenoic acid Il_ (1.52g, 3-81mmol) and triethylamine (0.737ml, 1.5 equivalents) in dichloromethane (60ml) In the solution, ethyl gas sulfonate (0.437 ml, 1.2 equivalents) was added dropwise with cooling with water and stirring with M, and the mixture was stirred for another 50 minutes. After adding water (60 ml), the reaction mixture was extracted with dichloromethane (50 ml). The organic layer was washed with saturated brine (70 ml), dried over anhydrous sodium sulfate and distilled under vacuum to remove the solvent. The obtained crude crystals were washed with ether to obtain 1.30 g (89.9%) of the mesh gadolinium compound as colorless crystals. Compound 8Ig: Bp = 188-19010. IRCKBrJcm-1: 3559, 2960, 1715, 1641, 1598, 1434, 1317, 1159. NMR (CDC13) 5: 1.38 (3H, t, CH3), 1.46 (18H, s, 2x BuM, 3.74 (2H, q, J = 7.2Hz, CHa), 3.80 (2H, d, J = 2.4Hz, CH ``), 5.64 (1H, s, 0H), 7.23 (2H, s, Ar-H), 7.45 (1H, t, J = 2.4Hz, CH).

、1T -Λ 本紙張尺度適用中國國家標準(CNS ) A4規格(2!OX 297公釐) A7 B7 ◦\v>〇、 1T -Λ This paper size applies to China National Standard (CNS) A4 specification (2! OX 297 mm) A7 B7 ◦ \ v > 〇

五、發明説明(72 ) 元素分析(CsoHusNCUS) 計算值:C, 63.30 ;H,7.70;N,3.69; S, 8.45 實測值:C, 63.07 ;H,7.71;N,3.72; S,8. 30. 奮例37 (£)-5-(3.5-二-笛二.丁某-4-揮)菲¥甚-2-7.某-3-禪 1.2-里瞎唑啶-1.1-二氣化物f8ThlV. Description of the invention (72) Elemental analysis (CsoHusNCUS) Calculated value: C, 63.30; H, 7.70; N, 3.69; S, 8.45 Found: C, 63.07; H, 7.71; N, 3.72; S, 8.30 Example 37 (£) -5- (3.5-Di-Di Er. Ding Mou-4-Hou) Fei ¥ 2-2-7.Mou 3-Zhen 1.2-Liblazidine-1.1-Digas f8Thl

DIBALDIBAL

於化合物 8Ig ( 870mg,2.29mmol)於二氯甲烷(30ml )之溶液內伴K摟拌及冷卻至低於-40Ό逐滴加入氫化二 異丁鋁(DIBAL)於己烷(1_〇Μ,4·22η1)之溶液。約5分 鐘後,將飽和氯化銨水溶液(30ml)加入反應混合物內, 所得淤漿通過乙醯塑料過濾。濾液内加入飽和氯化銨水溶 液(70ml)及混合物Μ乙酸乙酯(100ml)抽取。有機層 Μ飽和鹽水(100ml)洗滌,以無水硫酸納乾燥及真空蒸 餾而去除溶劑。所得粗結晶由正己烷/¾之混合物中再結 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1^------Λ--裝------訂------,Α (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標隼局員工消費合作社印製In a solution of compound 8Ig (870mg, 2.29mmol) in dichloromethane (30ml) was stirred with K 搂 and cooled to below -40Ό. Diisobutylaluminum hydride (DIBAL) in hexane (1-0M, 4 · 22η1). After about 5 minutes, a saturated aqueous ammonium chloride solution (30 ml) was added to the reaction mixture, and the resulting slurry was filtered through acetam plastic. The filtrate was added with a saturated aqueous ammonium chloride solution (70 ml) and the mixture was extracted with ethyl acetate (100 ml). The organic layer was washed with saturated brine (100 ml), dried over anhydrous sodium sulfate, and evaporated under vacuum to remove the solvent. The obtained crude crystals are re-settled from a mixture of n-hexane / ¾. The paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) 1 ^ ------ Λ--packing ------ order- -----, Α (Please read the precautions on the back before filling out this page) Printed by the Staff Consumer Cooperative of the Central Bureau of Standards, Ministry of Economic Affairs

A7 B7 i、發明説明(73 ) 晶而得762mg(87.2%)目檷化合物呈無色結晶。 化合物8111:111.?.= 138-141<0· ^(KBrJcm-1 : 3610,3427,2968,1653,1595,1432,1261, 1214,1147. NMR(d6-丙酮>δ : 1.27(3H,t,J = 7.0Hz,CH3>,1.48(18H, s,2x Bu*),3.01-3.12(IH.b.CH),3.27(2H,q,J = 7.0Hz,CH»), 3.57(lH,n,CH),5.21-5.24(1H,b,CH(OH)>,5.35(1H,寬,OH), 7. 18(1H,t,J = 2.4Hz,CH),7.37(2H,s,Ar-H). 元素分析(CaDH3lN0*S> 計算值:C,62.94;H,8.19;N,3.67;S,8.40 實測值:C,63.05;H,8.26;N,3.67;S,8.33. 奮例38 (R)-5- (3· 5-二-筮三丁某-/t-揮)盱 ¥ 甚-2-7.甚-二 Μ-5Η-1 . 2-里暄 11$ 啶-1 . 1 -二氩化物(8ΤΠ 、々〇 N-Et H+ 'Η —J---Ί11 ----裝-------訂------京 i (請先閲讀背面之注意事項再填寫本頁)A7 B7 i. Description of the invention (73) Crystals were obtained to obtain 762 mg (87.2%) of the mesh hydrazone compound as colorless crystals. Compound 811: 111.?. = 138-141 < 0 · ^ (KBrJcm-1: 3610,3427,2968,1653,1595,1432,1261, 1214,1147. NMR (d6-acetone > δ: 1.27 (3H , T, J = 7.0 Hz, CH3>, 1.48 (18H, s, 2x Bu *), 3.01-3.12 (IH.b.CH), 3.27 (2H, q, J = 7.0Hz, CH »), 3.57 ( lH, n, CH), 5.21-5.24 (1H, b, CH (OH) >, 5.35 (1H, wide, OH), 7.18 (1H, t, J = 2.4Hz, CH), 7.37 (2H , s, Ar-H). Elemental analysis (CaDH3lN0 * S > Calculated value: C, 62.94; H, 8.19; N, 3.67; S, 8.40 Found: C, 63.05; H, 8.26; N, 3.67; S, 8.33. Fen Example 38 (R) -5- (3 · 5-Di- 筮 三 丁某-/ t- 挥) 盱 ¥ -2--2-. Very-di-M-5Η-1. 2-Li 暄 11 $ DING-1. 1-Diargonide (8ΤΠ, 々〇N-Et H + 'Η —J --- Ί11 ---- install ------- order -------- 京 i (please (Read the notes on the back before filling out this page)

經濟部中央標準局員工消費合作社印製Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs

Et 張 -紙 本 準 標 一家 國 國 I中 用 適 釐公 7 9 2Et Zhang-Paper Standard Applicable to a country I China Appropriate centimeter 7 9 2

A7 B7 經濟部中央標準局員工消費合作社印製 i、發明説明(74 ) 於化合物 8Ih ( 342mg,0.896mmol)於 THF (30ml)之 溶液内加入2N-鹽酸(1滴)。混合物於室溫攪拌3小時 及加入飽和碩酸氫鈉水溶液(35ral)。反應混合物Μ乙酸 乙酯(30ml)抽取,有機層以飽和鹽水(35ml)洗滌,以 無水硫酸納乾燥及真空蒸皤而去除溶劑。所得粗結晶由正 己烷/醚之混合物中再結晶而得296mg (90.8%)目檫化 合物呈橙色結晶。 化合物 81 i : b. p. = 135-137¾ . IRiKBrJcm1 : 3608,3472,2961,1593,1560,1435,1392, 1300,1212,1153. NMR(CDCla)5 : 1.40(3H,t,J = 7.2Hz,CH3), 1.43(18H,s,2 x BuM,3.52(2H,q,J = 7.2Hz,CHa),5.50(1H,s,OH) ,6.22( IH.dd,J=〇.8,6.2Hz,CH),6.54(lH,dd,J=1.8,6.2Hz,CH), 6.84(1H,寬,CH),7_30(2H,s, Ar-H). 元素分析(Cs DHa sN03S> 計箕值:C,66.08;H,8.04;N,3.85;S,8.82 實測值:C,6653;H,8·08;N,382;S,8_68 Csf 1)R3NH2 〇〇 2)POCI3 5 ( r3=ch,ch2ch3) 異睡脞啶-1,丄ϋ氩仆物Up)A7 B7 Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs i. Description of Invention (74) To a solution of compound 8Ih (342mg, 0.896mmol) in THF (30ml) was added 2N-hydrochloric acid (1 drop). The mixture was stirred at room temperature for 3 hours and a saturated aqueous sodium hydrogenpersulfate solution (35ral) was added. The reaction mixture was extracted with ethyl acetate (30 ml), and the organic layer was washed with saturated brine (35 ml), dried over anhydrous sodium sulfate and evaporated under vacuum to remove the solvent. The obtained crude crystals were recrystallized from a mixture of n-hexane / ether to obtain 296 mg (90.8%) of the mesh compound as orange crystals. Compound 81 i: bp = 135-137¾. IRiKBrJcm1: 3608,3472,2961,1593,1560,1435,1392, 1300,1212,1153. NMR (CDCla) 5: 1.40 (3H, t, J = 7.2Hz, CH3 ), 1.43 (18H, s, 2 x BuM, 3.52 (2H, q, J = 7.2Hz, CHa), 5.50 (1H, s, OH), 6.22 (IH.dd, J = 0.8,6.2Hz, CH), 6.54 (lH, dd, J = 1.8, 6.2Hz, CH), 6.84 (1H, width, CH), 7_30 (2H, s, Ar-H). Elemental analysis (Cs DHa sN03S > count value: C, 66.08; H, 8.04; N, 3.85; S, 8.82 Found: C, 6653; H, 8.08; N, 382; S, 8_68 Csf 1) R3NH2 〇〇2) POCI3 5 (r3 = ch, ch2ch3) Isopropylpyridine-1, argon servant Up)

(請先閲讀背面之注意事項再填寫本頁) 裝.(Please read the notes on the back before filling this page).

、1T 泉卜 準 標 I /JC 八 麟 釐 公 經濟部中央標準局員工消費合作社印製 A7 _ B7 五、發明説明(75 ) 於環丙《内酯(r-sulton) (12_2g,0.1mol )内伴 Μ 攪拌及加冰冷卻下加入正丙胺(5.9g,0.1mm〇l )。隨著 反醮之進行,內容物固化。於固體產物內加入磷醢氯(10 趣1)。反應混合物加熱至回流經歷2小時然後真空蒸皤去 除其餘磷醢氣。醚(100ml)加入殘渣後,過濾去除不溶 性物質。醚層Μ無水硫酸鈉乾燥及真空蒸餾而去除溶劑獲 得目檫化合物4e( 15.2g,93%)呈無色油。此棰產物與 製備例5所得之真實樣品符合。 參者俐 2 ( R3 = CH2CH(CH3)») N-里丁某-1.2-里嗛0$啶-1.1-二氩仆.物(4c) 根據參考例1之類似方法,瓖丙風内酯(12.2g,0.1 mol),異丁胺(7.3g,O.lmol )及磷醢氯(1〇b1)反應 而得目檷化合物4c (15.9g,93% )。此產物與製備例3 所得之真實樣品符合一致。 如上實例製備之本發明之式I化合物於試管試驗及活 體試驗中評估其作為抗炎蕖物之功效。如下實驗例中所用 對照化合物之一E-5110爲日本特許公開案第257967/ 1986 所述之N-甲氧-3- (3,5-二-第三丁基-4-羥亞苄基)-2-吡 略嗣。 窨驗例1 於大鼠滑膜細胞對?(^8生產之抑制活性 收集LEW/Crj雄大鼠(重300-350g)之滑膜組鏃並於 穩定條件下進行次培養至細胞數足夠供試驗為止。培養後 之細胞M4-103細胞/ 160wl/孔放置於96孔平板內並於C〇a 本紙張尺度適用中國國家榇隼(CNS ) A4規格(210X297公釐)、 1T Spring Standard I / JC Printed by A7 _ B7 of Employees' Cooperatives of Central Standards Bureau of the Ministry of Economic Affairs of Balin Li Kong. 5. Description of Invention (75) In Cyclopropane (r-sulton) (12_2g, 0.1mol) The n-propylamine (5.9 g, 0.1 mm) was added with stirring and cooling with internal M. As the reaction proceeds, the contents solidify. Phosphorus chloride (10) is added to the solid product. The reaction mixture was heated to reflux for 2 hours and then evaporated under vacuum to remove the remaining phosphine gas. After ether (100 ml) was added to the residue, insoluble matter was removed by filtration. The ether layer M was dried over anhydrous sodium sulfate, and the solvent was removed by vacuum distillation to obtain the compound 4e (15.2 g, 93%) as a colorless oil. This osmium product is consistent with a real sample obtained in Preparation Example 5. Participant Li 2 (R3 = CH2CH (CH3) ») N-Ridin-1.2-Ridin0 $ pyridine-1.1-Diargon. (4c) According to a similar method as in Reference Example 1, propanone (12.2 g, 0.1 mol), isobutylamine (7.3 g, 0.1 mol) and phosphonium chloride (10b1) were reacted to obtain the compound 4c (15.9 g, 93%). This product is consistent with the real sample obtained in Preparation Example 3. The compound of formula I of the present invention prepared as the above example was evaluated for its efficacy as an anti-inflammatory substance in test tubes and in vivo tests. One of the reference compounds E-5110 used in the following experimental examples is N-methoxy-3- (3,5-di-third-butyl-4-hydroxybenzylidene) described in Japanese Patent Laid-Open No. 257967/1986 -2-pyloridine.窨 Experiment 1 on rat synovial cell pairs? Inhibitory activity produced by ^ 8 Synovial group of male LEW / Crj rats (weighing 300-350g) were collected and subcultured under stable conditions until the number of cells was sufficient for the test. M4-103 cells / 160wl / Well placed in a 96-well plate and at Coa This paper size applies to China National Standard (CNS) A4 (210X297 mm)

— ^---\------裝------訂------^F (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(76 ) 培育器内培育72小時。各孔內同時加入溶液(20m1),溶 液含有不等濃度之有待試驗之藥物及人IL-1/3 (20W1)( 終濃度:30U/ml),及於COa培育器内進行反應15小時。 上清液保藏於-80C至測量PGE,時為止。將保藏樣品解凍 後使用iaeI-PGE,藉RIA進行PGEa之測量。結果示於下表 1 〇 奮驗例2 於大鼠腹部細胞對LTB4生產之抑制括性— ^ --- \ ------ install ------ order ------ ^ F (Please read the notes on the back before filling out this page) Printed by the Staff Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs System A7 B7 V. Description of the invention (76) Incubator for 72 hours. A solution (20m1) was added to each well at the same time. The solution contained undetermined drugs and human IL-1 / 3 (20W1) (final concentration: 30U / ml), and the reaction was performed in a COa incubator for 15 hours. The supernatant was stored at -80C until PGE was measured. After thawing the preserved samples, iaeI-PGE was used to measure PGEa by RIA. The results are shown in the table below. 〇 Example 2 Inhibition of LTB4 production in rat abdominal cells

Jci-SD雄大鼠(重300_350g)腹内注射漢克氏溶液( l〇ml)其中含有0.1%牛血清白蛋白(BSA)及25U/ml肝素 。牧集腹水及於4υΜ150〇Γρπ離心5分鐘。細胞部分( 沈澱物)懸浮於含0.1%BSA之漢克氏溶液內並將細胞密度 調整為1X10B細胞/ml。調整後之懸浮液( 800&lt;tl ; 8X 1〇β 細胞)移入聚丙烯管内並於371C培育10分鐘。加入含不等 濃度之有待試驗藥物之溶液(1〇〇»1)後,試管又培育10 分鐘,接著加入Ca-離子基園Α23187 (lOOjil ;終濃度,1 ιιΜ)。反應進行15分鐘然後藉加冰冷卻中止。懸浮液以 3000rp·於4¾離心5分鐘而收集上清液,上清液於測量 前保藏於-801C。將保藏樣品解凍後使用3H-LTB4藉RIA進 行LTB*澜量。結果示於下表1。 奮驗例3 於THP-1細胞對接受LPS剌激下之生產IL-1的抑制活性 THP-1細胞勻散於RPMI 1640。26孔平板之各孔內加入 800W1之匀散液(5X106細胞/孔),100ttl溶液及含有不 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0 X 297公釐)Jci-SD male rats (weighing 300-350g) were intraperitoneally injected with Hank's solution (10ml), which contained 0.1% bovine serum albumin (BSA) and 25U / ml heparin. The ascites were collected and centrifuged for 5 minutes at 4 μM 150 Γρπ. The cell fraction (precipitate) was suspended in Hank's solution containing 0.1% BSA and the cell density was adjusted to 1 × 10B cells / ml. The adjusted suspension (800 <8; 8X 10β cells) was transferred into a polypropylene tube and incubated at 371C for 10 minutes. After adding a solution (100 »1) containing the drug to be tested at various concentrations, the tube was incubated for another 10 minutes, and then Ca-ion group A23187 (100 μl; final concentration, 1 μM) was added. The reaction was carried out for 15 minutes and then stopped by adding ice cooling. The suspension was centrifuged at 3000 rp for 5 minutes at 4¾ to collect the supernatant. The supernatant was stored at -801C before measurement. After thawing the preserved samples, 3H-LTB4 was used for RTB * measurement by RIA. The results are shown in Table 1 below. Trial example 3 THP-1 cells were inhibited for IL-1 production under LPS stimulation. THP-1 cells were evenly dispersed in RPMI 1640. 800W1 homogeneous solution (5X106 cells / Hole), 100ttl solution and paper containing non-standard paper applicable to China National Standard (CNS) A4 specification (2 丨 0 X 297 mm)

----Ί ---_--.--扯衣---I n- ------束 L---. (請先閱讀背面之注意事項再填寫本頁) A7 B7 五、發明説明(77 ) 等濃度之有待試驗藥物及l〇〇wl LPS (終濃度lOOiig/ml) 開姶進行反應。令反應混合物於371C放置24小時。收集上 清液及於3000rpm離心10分鐘。使用&quot;oi-IL-l/S藉RIA進 行上清液之IL-1測量。結果示於下表1。 UL·試管試驗結果 請 先 閱 面 之 注---- Ί ---_--.-- pulling clothes --- I n- ------ bundle L ---. (Please read the precautions on the back before filling this page) A7 B7 Five 2. Description of the invention (77) Drugs to be tested at equal concentrations and 100wl LPS (final concentration 100iig / ml) were opened for reaction. The reaction mixture was allowed to stand at 371C for 24 hours. The supernatant was collected and centrifuged at 3000 rpm for 10 minutes. The IL-1 measurement of the supernatant was performed using &quot; oi-IL-l / S by RIA. The results are shown in Table 1 below. UL · test tube test results, please read the note above

化合物编號 R3 PGE2 (大鼠 ic50 (μΜ) LTB4 (大鼠 ΡΡΓΜ IL-1 (ΤΗΡ-1)Compound number R3 PGE2 (rat ic50 (μΜ) LTB4 (rat PPΓΜ IL-1 (ΤΗΡ-1)

I f 裝 經濟部中央標準局員工消費合作社印製 8a Et &lt;0.001 6.0 10 8b Me &lt;0.001 2.8 21 8f OMe 0.001 3.0 &gt;100 0 0 Bu V 8g och2h6h5 0.18 2.5 11 XjT0i^z 81 批啶基 1.0 3.0 19 HO t - Bu 8w CONHOH 0.024 6.0 20 100 8u CON(OMe)M e 0.1 28 10a H 0.03· &gt;100 &gt;ιο〇 11a OH 0.013 9.5 90 8b Me &lt;0.001 1.8 29 八 厂 i 了、' ) 8f OiMe &lt;0.001 1·5 — ηοΎ 〇i~f! t-Bu 0 H3 81 2-吡啶基 &gt;1 1.4 100 90 11b OH 0.012 9.6 E-5110 C.005 6.0 &gt;100 吲哚美沙辛 0.002 &gt;100 &gt;100 __- 奮驗例4· 於大鼠對鹿角菜膠誘生水腫之抑制活性 實驗係根據溫特氏方法(Winter, C.A. et al_, Proe· 本紙張尺度適用中國國家標準(CNS )八4規格(210 X 297公釐) 决 iS[· 訂 經濟部中央標率局員工消費合作社印黎 Α7 Β7 五、發明説明(78 )Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 8a Et &lt; 0.001 6.0 10 8b Me &lt; 0.001 2.8 21 8f OMe 0.001 3.0 &gt; 100 0 0 Bu V 8g och2h6h5 0.18 2.5 11 XjT0i ^ z 81 1.0 3.0 19 HO t-Bu 8w CONHOH 0.024 6.0 20 100 8u CON (OMe) M e 0.1 28 10a H 0.03 &gt; 100 &gt; ιο〇11a OH 0.013 9.5 90 8b Me &lt; 0.001 1.8 29 Eight factories i, ') 8f OiMe &lt; 0.001 1 · 5 — ηοΎ 〇i ~ f! T-Bu 0 H3 81 2-pyridyl &gt; 1 1.4 100 90 11b OH 0.012 9.6 E-5110 C.005 6.0 &gt; 100 indomethacin Xin 0.002 &gt; 100 &gt; 100 __- Endemic example 4 · The experimental study on the inhibitory activity of carrageenan-induced edema in rats is based on the Winter's method (Winter, CA et al_, Proe · This paper is applicable to China Standard (CNS) Eight-four specifications (210 X 297 mm) Decision iS [· Order the Central Consumer Bureau of the Ministry of Economy Staff Consumer Cooperatives Co., Ltd. Yin Li Α7 Β7 V. Description of the invention (78)

Soc. Exp. Biol. Med·, vol.lll: 54 ( 1962〉略作修改而 進行。亦邸LEW/Crj雄大鼠(6周齡,重140-170g)空腹 24小時,分成數組每組含7至8頭大鼠。投予藥物後1小 時,每頭動物皮下注射〇· lml 1% λ -鹿角菜膠(PICININ-A ,Zushikagaku)溶液,注射部位為右後腿足底引發水腫。 注射前及注射後每1小時共計5小時,以水置換方法使用 容積測量儀-測量右後腿容積。根據Dunnett-t試驗,藉著 計算投藥組相對於媒劑投予組之水腫抑制率來評估藥物功 效。藥物之抗水腫功效MEDbd (mg/kg)表示,基於抑制 率作回歸分析,此ED〃可在鹿角菜膠投予後3或4小時獲 得。結果示於下表2。 竇驗例5 於大鼠對胃粘膜病變生成之抑制功效 LEW/Crj雄大鼠(6周齡,重140-160g)根據試驗藥 物剤量分成數組每組6頭大鼠。動物於試驗前空腹24小時 後投藥及於投藥後6小時使用乙醚麻醉動物並以放血殺死 。取出胃裝入生理鹽水(約6ml)。隨後胃浸泡入15%福 馬林溶液中約15分鐘並順著大彎切開。使用立體顯撤鏡觀 察胃病變狀说,算出顯示胃病變之大鼠數目及出血斑塊長 度。病變程度以病變指數(mm)表示,病變指數為各投藥 組織出血斑塊長度的累進值。藥物功效強度MUDee (mg/ kg)表示,UDu係利用Probit方法基於投予特定劑量藥物 組中顯示出病變的病例數目計算而得。結果示於下表2。 本紙張尺度適用中國國家橾準(CNS ) Α4規格(210Χ 297公釐) ml- ►11 m· · n n^l —J HI US (請先閲讀背面之注意事項再填寫本頁) 訂 Λ 五、發明説明79 您涸{Γτπϊ&gt;兹 Ε — 5110 A7 B7 I {bn!&gt;兹Soc. Exp. Biol. Med ·, vol.lll: 54 (1962) with minor modifications. Yidi LEW / Crj male rats (6 weeks old, weighing 140-170g) were fasted for 24 hours, divided into arrays, each group containing 7 To 8 rats. 1 hour after the administration of the drug, 0.1 ml of a 1% λ-carrageenan (PICININ-A, Zushikagaku) solution was injected subcutaneously into each animal, and the injection site was edema caused by the plantar of the right hind leg. And 5 hours every 1 hour after injection, the volume of the right hind leg was measured by a water displacement method using a volumetric meter. According to the Dunnett-t test, the drug was evaluated by calculating the edema suppression rate of the administration group relative to the vehicle administration group. Efficacy. The anti-edema effect of the drug, MEDbd (mg / kg), is based on regression analysis of inhibition rate. This ED can be obtained 3 or 4 hours after carrageenan administration. The results are shown in Table 2 below. LEW / Crj male rats (6 weeks old, weighing 140-160g) were divided into groups of 6 rats per group according to the amount of test drug. Animals were administered on an empty stomach 24 hours before the test and in The animals were anesthetized with ether 6 hours after administration and killed by exsanguination. Normal saline (approximately 6ml). Then the stomach is immersed in 15% formalin solution for about 15 minutes and cut along the large curve. Observe the gastric lesions using a stereoscopic microscope. Calculate the number of rats showing gastric lesions and bleeding plaque Length. The degree of lesion is expressed by the lesion index (mm), and the lesion index is a progressive value of the length of bleeding plaque in each administered tissue. The intensity of drug efficacy MUDee (mg / kg) is expressed. UDu uses the Probit method based on the administration of a specific dose of the drug group. The number of cases showing lesions was calculated. The results are shown in Table 2 below. This paper size applies to China National Standard (CNS) A4 (210 × 297 mm) ml- ►11 m · · nn ^ l —J HI US (Please read the notes on the back before filling out this page) Order Λ V. Invention Description 79 You 涸 {Γτπϊ &gt;; Ε — 5110 A7 B7 I {bn! &Gt;

O O V-〇 &gt;O O V-〇 &gt;

Cs&gt; N&gt; JU· CTv o Η-»»—**—* DO to LO — o 〇-&gt; &lt;J\ CJ\Cs &gt; N &gt; JU · CTv o Η-»» — ** — * DO to LO — o 〇- &gt; &lt; J \ CJ \

-~4 ——J -'J i—» K-* t—1 K&gt; CO Cs&gt;-~ 4 ——J -'J i— »K- * t—1 K &gt; CO Cs &gt;

CTN O 經濟部中央標準局員工消費合作社印裝 &gt;400 \X&gt; 〇〇 — i o o o o o ΟΊ»— OO CTs^O'JHUn VJ1 V&gt;J -«4 OO OO 1+ 1+ 丨 + 丨+ 1+ 1+ 1+ 1+ 1+ 1 + C〇i~»&lt;Z&gt;0 t〇&gt;—*»—*!—*〇0 &gt;—* ΟΊ vO -&lt;J 〇J OJ U1 仏—J — to 00±°00 04Ι+004 00Ι+Ρ 00 17Ι+0. 17 5Ι+Ρ 03 ^ Φ ^ ^ 0 = 毽_ Μ渔娉 涊沖靼您遡筘键31洚许aR苕莖S泠 Π第 ms/kg 踏肝澍漶餑 UD=,31總喆焓 日 g/k'/«(5) 8a 左0&gt;兹 ¾错 E-5110 ss卅CTN O Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs &gt; 400 \ X &gt; 〇〇— iooooo ΟΊ »— OO CTs ^ O'JHUn VJ1 V &gt; J-« 4 OO OO 1+ 1+ 丨 + 丨 + 1+ 1+ 1+ 1+ 1+ 1 + C〇i ~ »&lt; Z &gt; 0 t〇 &gt; — *» — *! — * 〇0 &gt; — * ΟΊ vO-&lt; J 〇J OJ U1 仏 — J — to 00 ± ° 00 04 Ι + 004 00 Ι + Ρ 00 17 Ι + 0. 17 5 Ι + Ρ 03 ^ Φ ^ ^ 0 = 娉 涊 _ M 娉 涊 娉 涊 娉 涊 遡 筘 洚 key 31 洚 a aR 苕 遡 筘 SLINGΠ Ms / kg UD = 3131, total enthalpy day g / k '/ «(5) 8a left 0 &gt; wrong E-5110 ss 卅

〇 UJ OO (請先閲讀背面之注意事項再填寫本頁)〇 UJ OO (Please read the notes on the back before filling this page)

Et (ΕΓ ) % 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) :81 - ^7o2G7 at B7 五、發明説明(80 ) 由實驗結果顯然易知本發明化合物具有可抑制PGEa, IL-1等產生之活性而對胃粘膜並無鼹重副作用,預期可用 作炎症疾病治療上之醫藥配方中的活性成分。 鑿莓調g _ 粒酬 化合物8a 20mg 乳糖 250ag 玉米澱粉 115mg 羥丙基缕維素 115ng Μ上各物料以習知濕法造粒而得粒劑。 m. f I n . I- -- —1 - 1^^ —I— n^i HI ·- I - ^^1 In :——ϊ·^ t請先聞讀背面之注意事項存填寫本Va〇 經濟部中央標準局員工消費合作社印製Et (ΕΓ)% This paper size is in accordance with Chinese National Standard (CNS) A4 specification (210 X 297 mm): 81-^ 7o2G7 at B7 V. Description of the invention (80) It is clear from the experimental results that the compounds of the present invention can be inhibited The activities produced by PGEa, IL-1, etc. have no serious side effects on the gastric mucosa, and are expected to be used as active ingredients in pharmaceutical formulations for the treatment of inflammatory diseases. Chiaberry adjusts g_ granules Compound 8a 20mg Lactose 250ag Corn starch 115mg Hydroxypropylstrylavirin 115ng Μ Each material on the conventional wet granulation method is used to obtain granules. m. f I n. I--—1-1 ^^ —I— n ^ i HI ·-I-^^ 1 In: —— ϊ · ^ t Please read the notes on the back and fill in this Va 〇 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs

本紙張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐)This paper size applies to China National Standard (CNS) A4 (210 X 297 mm)

Claims (1)

^ 年 _ 丨 8&amp;. \六、申請專利範圍 Λ8 B8 C8 D8 第82108811號再審查案申請專利範圍修正本 修正曰期:88年〇9月 1. 一種如式I化合物^ Years _ 丨 8 &amp;. \ 六 、 Scope of patent application Λ8 B8 C8 D8 No. 82108811 reexamination application Patent scope amendments Date of amendment: 1988 September 1. A compound such as formula I 經濟部中央標準局貝工消費合作社印裝 式中A 為-CH2-或-CH2CH2-; B 為.一鍵或-CH2-_, -CHOH- ’ -CO-,-Ο-,或者a與B可共同結合生成 -CH=CH&lt; D為&gt;1或&gt;〇卜;R1及R2各自獨立為氫, Ci-C5烷基或Ci-Ca烷氧基;R3為氫,ς^-Cs烷基,C·»- 〇 C5環烧基’ CfC3烧氧基’ 〇6_芳香基烧氧基,僅含 氮之雜環芳香基烷基氧基,CrCs烷基羰基,芳香基, 羰基,胺甲醯基,經CVC3烷基、CfCs烷氧基、c6-芳香基烷氧基、CrC3烷基Ci-C3烷氧基或羥基所取代 之胺甲醯基或為如下式之基: -(CH2)n-R4 式中R4為風’經基’胺基或烧基取代之胺基, .^基’經CfC3燒氧基或鹵素所單或雙取代之芳基, 含有氮原子作為雜原子之雜芳基,羥羰基或垸 基氧羰基;η為0至3之整數。 2·如申請專利範圍第1項之化合物,其中及R2各別為 第三丁基者。 3.如申請專利範圍第1或2項之化合物,其中Α為-CH2-; B為-CH2-,及0為&gt;N-者》 \ i (fn - Ύ HI I ·!·1 I n I ....... HI I — - 1^1 (請先w讀背面之注意事項再填寫本頁) ^ 年 _ 丨 8&amp;. \六、申請專利範圍 Λ8 B8 C8 D8 第82108811號再審查案申請專利範圍修正本 修正曰期:88年〇9月 1. 一種如式I化合物In the printed form of the Shellfish Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs, A is -CH2- or -CH2CH2-; B is. One-click or -CH2-_, -CHOH- '-CO-, -Ο-, or a and B Can be combined to form -CH = CH &lt; D is &gt; 1 or &gt;B; R1 and R2 are each independently hydrogen, Ci-C5 alkyl or Ci-Ca alkoxy; R3 is hydrogen, and ^ -Cs alkane C · »-〇C5 ring alkyl group 'CfC3 alkyloxy group' 〇6_aryl alkyloxy group, nitrogen-containing heterocyclic aromatic alkyloxy group, CrCs alkylcarbonyl group, aromatic group, carbonyl group, amine Formamyl, amidomethyl substituted by CVC3 alkyl, CfCs alkoxy, c6-arylalkoxy, CrC3 alkyl Ci-C3 alkoxy, or hydroxyl group or a group of the formula:-(CH2 ) n-R4 where R4 is an amine group substituted by amine group or alkynyl group, and ^ group is aryl group which is mono- or di-substituted by CfC3 alkoxy group or halogen, and contains nitrogen atom as hetero atom. Heteroaryl, hydroxycarbonyl or fluorenyloxycarbonyl; n is an integer from 0 to 3. 2. If the compound of the scope of application for item 1, wherein R2 is a third butyl, respectively. 3. A compound as claimed in item 1 or 2, in which A is -CH2-; B is -CH2-, and 0 is &gt; N- ". \ I (fn-Ύ HI I ·! · 1 I n I ....... HI I —-1 ^ 1 (please read the notes on the back before filling this page) ^ Year_ 丨 8 &amp;. \ 六 、 Scope of patent application Λ8 B8 C8 D8 No. 82108811 No. Examination of the application for amendments to the scope of the patent amendment date: September 1988 1. A compound such as formula I 經濟部中央標準局貝工消費合作社印裝 式中A 為-CH2-或-CH2CH2-; B 為.一鍵或-CH2-_, -CHOH- ’ -CO-,-Ο-,或者a與B可共同結合生成 -CH=CH&lt; D為&gt;1或&gt;〇卜;R1及R2各自獨立為氫, Ci-C5烷基或Ci-Ca烷氧基;R3為氫,ς^-Cs烷基,C·»- 〇 C5環烧基’ CfC3烧氧基’ 〇6_芳香基烧氧基,僅含 氮之雜環芳香基烷基氧基,CrCs烷基羰基,芳香基, 羰基,胺甲醯基,經CVC3烷基、CfCs烷氧基、c6-芳香基烷氧基、CrC3烷基Ci-C3烷氧基或羥基所取代 之胺甲醯基或為如下式之基: -(CH2)n-R4 式中R4為風’經基’胺基或烧基取代之胺基, .^基’經CfC3燒氧基或鹵素所單或雙取代之芳基, 含有氮原子作為雜原子之雜芳基,羥羰基或垸 基氧羰基;η為0至3之整數。 2·如申請專利範圍第1項之化合物,其中及R2各別為 第三丁基者。 3.如申請專利範圍第1或2項之化合物,其中Α為-CH2-; B為-CH2-,及0為&gt;N-者》 \ i (fn - Ύ HI I ·!·1 I n I ....... HI I — - 1^1 (請先w讀背面之注意事項再填寫本頁) Α8 Β8 C8 D8 — 、申請專利範圍 4.二申請專利範圍第3項之化合物,其㈣為…貌基 或環烷基者。 5· -種治療骨關節炎之藥學組合物,其十含有 利範圍第1項之化合物作為活性成分者。 6. 一種用以治療風濕症之藥學組合物,其中含有如 專利範圍第1項之化合物作為活性成分者。 眚 (請先聞讀背面之注項再填寫本頁) •訂 經濟部中央榡準局貝工消費合作社印製 -2 - 私紙張尺度通用中國國家標準(CNS ) A4規格(2丨0Χ297公釐)In the printed form of the Shellfish Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs, A is -CH2- or -CH2CH2-; B is. One-click or -CH2-_, -CHOH- '-CO-, -Ο-, or a and B Can be combined to form -CH = CH &lt; D is &gt; 1 or &gt;B; R1 and R2 are each independently hydrogen, Ci-C5 alkyl or Ci-Ca alkoxy; R3 is hydrogen, and ^ -Cs alkane C · »-〇C5 ring alkyl group 'CfC3 alkyloxy group' 〇6_aryl alkyloxy group, nitrogen-containing heterocyclic aromatic alkyloxy group, CrCs alkylcarbonyl group, aromatic group, carbonyl group, amine Formamyl, amidomethyl substituted by CVC3 alkyl, CfCs alkoxy, c6-arylalkoxy, CrC3 alkyl Ci-C3 alkoxy, or hydroxyl group or a group of the formula:-(CH2 ) n-R4 where R4 is an amine group substituted by amine group or alkynyl group, and ^ group is aryl group which is mono- or di-substituted by CfC3 alkoxy group or halogen, and contains nitrogen atom as hetero atom. Heteroaryl, hydroxycarbonyl or fluorenyloxycarbonyl; n is an integer from 0 to 3. 2. If the compound of the scope of application for item 1, wherein R2 is a third butyl, respectively. 3. A compound as claimed in item 1 or 2, in which A is -CH2-; B is -CH2-, and 0 is &gt; N- ". \ I (fn-Ύ HI I ·! · 1 I n I ....... HI I —-1 ^ 1 (please read the precautions on the reverse side before filling out this page) Α8 Β8 C8 D8 — , the scope of patent application 4. The compound of scope 3 of the patent application, Its ㈣ is a morpho group or a cycloalkyl group. 5. A pharmaceutical composition for treating osteoarthritis, which contains the compound of the first range of interest as an active ingredient. 6. A medicament for treating rheumatism The composition contains the compound as the active ingredient in the patent scope item 1. 眚 (Please read the note on the back before filling out this page) • Order printed by the Shellfish Consumer Cooperative of the Central Bureau of the Ministry of Economic Affairs-2- Standard for private paper: Common Chinese National Standard (CNS) A4 specification (2 丨 0 × 297 mm)
TW082108811A 1992-10-28 1993-10-22 Benzylidene derivatives TW378207B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28997292 1992-10-28

Publications (1)

Publication Number Publication Date
TW378207B true TW378207B (en) 2000-01-01

Family

ID=17750115

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082108811A TW378207B (en) 1992-10-28 1993-10-22 Benzylidene derivatives

Country Status (14)

Country Link
US (1) US5418230A (en)
EP (1) EP0595546B1 (en)
KR (1) KR100281490B1 (en)
CN (1) CN1035614C (en)
AT (1) ATE135697T1 (en)
AU (1) AU675078B2 (en)
CA (1) CA2109498A1 (en)
DE (1) DE69301894T2 (en)
DK (1) DK0595546T3 (en)
ES (1) ES2089736T3 (en)
GR (1) GR3019395T3 (en)
HU (1) HU215924B (en)
NO (1) NO303828B1 (en)
TW (1) TW378207B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3507124B2 (en) * 1993-05-26 2004-03-15 塩野義製薬株式会社 Method for producing benzylidene derivative
DE19700061A1 (en) * 1997-01-03 1998-07-09 Hoechst Schering Agrevo Gmbh Production of new or known cyclic amino:sulphonamide derivatives
KR20010031319A (en) 1997-10-24 2001-04-16 요시히코 시오노 Antirheumatic
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
CA2360066A1 (en) * 1999-01-21 2000-07-27 Hidekazu Shodai A pharmaceutical composition containing a compound having a phenolic hydroxyl group with coloring change being controlled
HUP0302068A3 (en) 2000-07-20 2005-05-30 Lauras As Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
WO2002080974A1 (en) * 2001-04-04 2002-10-17 Sankyo Company, Limited Novel medicinal use of cytokine production inhibitor
AR038957A1 (en) 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
ES2341240T3 (en) 2002-12-13 2010-06-17 Warner-Lambert Company Llc BINDING ALFA-2-DELTA TO TREAT SYMPTOMS OF LOWER URINARY TRACT.
HUE029309T2 (en) 2006-03-17 2017-02-28 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
CN101600458A (en) 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 Adopt α 2The therapeutic alliance of the lower urinary tract disorders of 2-delta ligand and NSAID
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066571B2 (en) * 1985-05-09 1994-01-26 エーザイ株式会社 2-pyrrolidone derivative
PT83152B (en) * 1985-08-09 1989-03-30 Lilly Co Eli PROCESS FOR THE PREPARATION OF DI-T-BUTYLPHENOIC COMPOUNDS
EP0334119B1 (en) * 1988-03-21 1993-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Compounds for inhibiting the biosynthesis of lipoxygenase-derived metabolites of arachidonic acid
NZ231534A (en) * 1988-11-29 1992-02-25 Warner Lambert Co 3,5-di-t-butyl-4-hydroxyphenyl-triazoles, oxadiazoles and thiadiazoles; anti-inflammatory compositions
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
IL96654A (en) * 1989-12-21 1995-06-29 Lilly Co Eli Hydroxybenzyl substituted sulfur containing heterocyclic derivatives their preparation and pharmaceutical compositions containing them
US5319099A (en) * 1991-01-21 1994-06-07 Shionogi Seiyaku Kabushiki Kaisha 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents

Also Published As

Publication number Publication date
DE69301894T2 (en) 1996-11-07
CN1035614C (en) 1997-08-13
CN1092414A (en) 1994-09-21
NO933870D0 (en) 1993-10-27
AU675078B2 (en) 1997-01-23
EP0595546A1 (en) 1994-05-04
AU4910793A (en) 1994-05-12
NO303828B1 (en) 1998-09-07
HUT70530A (en) 1995-10-30
US5418230A (en) 1995-05-23
HU9303053D0 (en) 1994-01-28
KR940009163A (en) 1994-05-20
CA2109498A1 (en) 1994-04-29
KR100281490B1 (en) 2001-02-15
DE69301894D1 (en) 1996-04-25
EP0595546B1 (en) 1996-03-20
ES2089736T3 (en) 1996-10-01
HU215924B (en) 1999-03-29
NO933870L (en) 1994-04-29
ATE135697T1 (en) 1996-04-15
GR3019395T3 (en) 1996-06-30
DK0595546T3 (en) 1996-04-15

Similar Documents

Publication Publication Date Title
RU2733741C2 (en) Tetrasubstituted alkene compounds and use thereof
CN102883607B (en) Compounds for treatment of cancer
JP2617546B2 (en) 3- [4 (1-substituted-4-piperazinyl) butyl] -4-thiazolidinone and method for producing the same
ES2559687T3 (en) Composition and methods to modulate a kinase cascade
TW378207B (en) Benzylidene derivatives
AU658194B2 (en) Heterocyclic-cyclic amine derivatives
WO2018006795A1 (en) Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
ES2682108T3 (en) Process for the preparation of compositions to modulate a kinase cascade and methods of use of these
OA10794A (en) Metalloproteinase inhibitors pharmaceutical compositions containing them and their pharmaceutical uses and methods and intermediates useful for their preparation
BRPI0618589A2 (en) oxazole compound, a pharmaceutical composition comprising said oxazole, manufacturing processes and uses thereof
WO2019226991A1 (en) Androgen receptor modulators and methods for their use
SK14642003A3 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as anti-tumour agents
BG61915B1 (en) Herbicides
JP2010529196A (en) Azapeptide derivatives
TW202003495A (en) Benzene and piperidine or heteroaryl group and piperidine derivatives, preparation method thereof and application thereof in medicine
WO2015024448A1 (en) Benzo piperidine ring and benzo morpholine ring compounds, manufacturing method therefor, and medical applications thereof
CA3143334A1 (en) Glycolate oxidase inhibitors for the treatment of disease
CA3230259A1 (en) Indole compounds and methods of use
ES2231439T3 (en) BENZOOXAZOL DERIVATIVES AS TNF AND PDE INHIBITORS IV.
EP1820799A1 (en) 2,3,4,5-tetrahydro-1h-1,5-benzodiazepine derivative and medicinal composition
AU741180B2 (en) Antirheumatic
WO2005090320A2 (en) Triazole derivatives and method of using the same to treat hiv infections
JP3193789B2 (en) Thiadiazinones
US4946963A (en) Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones
JPS6399057A (en) Glycine derivative

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees